document incorporate reference document proxy statement annual meeting shareholder hold file iii security exchange commission day close fiscal year cover reporttable content table content item business item risk factor cautionary factor affect future result item b unresolved staff comment item c cybersecurity item property item legal proceeding item safety disclosure executive officer registrant ii item market registrant common equity relate stockholder matter issuer purchase equity security item reserve item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum afinancial statement note consolidated financial statement report independent register public accounting firm item change disagreement accountant account financial disclosure item control procedure management report item b information item c disclosure foreign jurisdiction prevent inspection iii item director executive officer corporate governance item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction director independence item principal accountant fee service iv item exhibit financial statement schedule item summary signature table content item business merck co inc merck company global health care company deliver innovative health solution prescription medicine include biologic therapy vaccine animal health product company operation principally manage product basis include operate segment pharmaceutical animal health reportable segment pharmaceutical segment include human health pharmaceutical vaccine product human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution human health vaccine product consist preventive pediatric adolescent adult vaccine company sell human health vaccine primarily physicians wholesaler distributor government entity animal health segment discover develop manufacture market wide range veterinary pharmaceutical vaccine product health management solution service prevention treatment control disease major livestock companion animal specie company offer extensive suite digitally connect identification traceability monitoring product company sell product veterinarian distributor animal producer farmer pet owner june merck complete spinoff spinoff product women health biosimilar establish brand business new independent publicly trade company name organon co organon distribution organon publicly trade stock company shareholder establish brand include transaction consist dermatology nonopioid pain management respiratory select cardiovascular product rest merck diversify brand franchise product service mark appear type form different surround text trademark service mark own license promote distribute merck subsidiary affiliate note trademark service mark respective owner product sale total company sale include sale company pharmaceutical product sale animal health product follow million total sale pharmaceutical keytruda gardasilgardasil januviajanumet proquadmmr iivarivax bridion lagevrio alliance revenue lynparza alliance revenue lenvima rotateq vaxneuvance animal health livestock companion animal revenue alliance revenue represent merck share profit product sale net cost sale commercialization cost revenue primarily comprise miscellaneous corporate revenue include revenue hedging activity revenue thirdparty manufacture arrangement table content pharmaceutical pharmaceutical segment include human health pharmaceutical vaccine product human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder human health vaccine product consist preventive pediatric adolescent adult vaccine certain product company franchise follow oncology keytruda antipd program death receptor therapy approve monotherapy treatment certain patient cervical cancer classical hodgkin lymphoma cutaneous squamous cell carcinoma esophageal gastroesophageal junction gej carcinoma head neck squamous cell carcinoma hnscc hepatocellular carcinoma hcc melanoma merkel cell carcinoma microsatellite instabilityhigh msih mismatch repair deficient dmmr solid tumor include msihdmmr colorectal cancer endometrial carcinoma nonsmallcell lung cancer nsclc primary mediastinal large bcell lymphoma pmbcl tumor mutational burdenhigh tmbh solid tumor urothelial cancer include nonmuscle invasive bladder cancer keytruda approve monotherapy adjuvant treatment certain patient melanoma certain patient renal cell carcinoma rcc postsurgery keytruda approve adjuvant treatment follow resection platinumbase chemotherapy certain patient nsclc additionally keytruda approve patient certain type resectable nsclc combination chemotherapy neoadjuvant treatment continue single agent adjuvant treatment surgery keytruda approve patient highrisk early stage triplenegative breast cancer tnbc combination chemotherapy neoadjuvant treatment continue single agent adjuvant treatment surgery addition keytruda approve combination chemotherapy treatment certain patient advance nsclc combination chemotherapy certain type advance biliary tract cancer combination chemotherapy bevacizumab advanced cervical cancer combination chemotherapy advance esophageal cancer combination trastuzumab chemotherapy certain patient advance human epidermal growth factor receptor herpositive gastric gej adenocarcinoma pdl cps combination chemotherapy advance hernegative gastric gej adenocarcinoma combination chemotherapy hnscc combination chemotherapy advance tnbc combination axitinib advance rcc combination lenvima lenvatinib patient advance rcc certain type advance endometrial carcinoma combination enfortumab vedotin adult patient locally advanced metastatic urothelial cancer welireg belzutifan medication treatment adult patient certain von hippellindau diseaseassociate tumor treatment adult patient advance rcc follow pd program deathligand pdl inhibitor vascular endothelial growth factor tyrosine kinase inhibitor addition company recognize alliance revenue relate sale lynparza olaparib oral poly adpribose polymerase parp inhibitor certain type advance recurrent ovarian early metastatic breast metastatic pancreatic metastatic castrationresistant prostate cancer alliance revenue relate sale lenvima oral receptor tyrosine kinase inhibitor certain type thyroid cancer rcc hcc combination everolimus certain patient advance rcc combination keytruda certain patient advance endometrial carcinoma advance rcc alliance revenue relate reblozyl luspatercept aamt treatment certain type anemia vaccine gardasil human papillomavirus quadrivalent type vaccine recombinantgardasil human papillomavirus valent vaccine recombinant vaccine help prevent certain cancer disease cause certain type human papillomavirus hpv proquad measle mump rubella varicella virus vaccine live pediatric combination vaccine help protect measle mump rubella varicella mmr ii measles mumps rubella virus vaccine live vaccine help prevent measle mump rubella varivax varicella virus vaccine live vaccine help prevent chickenpox varicella rotateq rotavirus vaccine live oral pentavalent vaccine help protect rotavirus gastroenteritis infant child vaxneuvance pneumococcal valent conjugate vaccine vaccine help prevent invasive pneumococcal disease individual week age old pneumovax pneumococcal vaccine polyvalent vaccine help prevent pneumococcal disease vaqta hepatitis vaccine inactivated indicate prevention disease cause hepatitis virus person month age old hospital acute care bridion sugammadex medication reversal type neuromuscular block agent surgery prevymis letermovir prophylaxis cytomegalovirus cmv infection disease cmv disease certain high risk adult recipient allogeneic hematopoietic stem cell transplant kidney transplant respectively dificid fidaxomicin treatment c difficileassociate diarrhea zerbaxa ceftolozane tazobactam injection combination antibacterial betalactamase inhibitor treatment certain table content bacterial infection noxafil posaconazole antifungal agent prevention certain invasive fungal infection primaxin imipenem cilastatin injection antibiotic treatment certain bacterial infection cardiovascular adempas riociguat cardiovascular drug treatment chronic thromboembolic pulmonary hypertension pulmonary arterial hypertension certain patient verquvo vericiguat medicine reduce risk cardiovascular death heart failure hospitalization follow hospitalization heart failure need outpatient intravenous diuretic certain adult symptomatic chronic heart failure reduce ejection fraction virology lagevrio investigational oral antiviral covid medicine available emergency use authorization eua isentressisentress hd raltegravir hiv integrase inhibitor use combination antiretroviral agent treatment hiv infection neuroscience belsomra suvorexant orexin receptor antagonist indicate treatment insomnia characterize difficulty sleep onset andor sleep maintenance immunology simponi golimumab oncemonthly subcutaneous treatment certain inflammatory disease remicade infliximab treatment inflammatory disease company market europe russia trkiye diabete januvia sitagliptin janumet sitagliptinmetformin hcl treatment type diabete animal health animal health segment discover develop manufacture market wide range veterinary pharmaceutical vaccine health management solution service extensive suite digitally connect identification traceability monitoring product principal product segment include livestock product nuflor florfenicol antibiotic range use cattle swine bovilisvista vaccine line infectious disease cattle banamine flunixin meglumine bovine swine antiinflammatory estrumate cloprostenol sodium treatment fertility disorder cattle matrix altrenogest fertility management swine resflor florfenicol flunixin meglumine combination broadspectrum antibiotic nonsteroidal antiinflammatory drug bovine respiratory disease zuprevo tildipirosin bovine respiratory disease revalor trenbolone acetate estradiol improve production efficiency beef cattle safeguard fenbendazole dewormer cattle mpac mycoplasma hyopneumoniae bacterin swine pneumonia vaccine porcilis lawsonia intracellularis baterin circumvent porcine circovirus vaccine type kill baculovirus vector vaccine line infectious disease swine nobilisinnovax live marek disease vector vaccine line poultry paracox coccivac coccidiosis vaccine exzolt systemic treatment poultry red mite infestation slice emamectin benzoate parasiticide sea lice salmon aquavac avirulent live culturenorvax vaccine bacterial viral disease fish aquaflor florfenicol antibiotic farmraise fish flexolt fluralaner lice sheep allflex livestock intelligence solution animal identification monitor traceability companion animal product bravecto line oral topical parasitic control product include original bravecto fluralaner product dog cat week bravecto fluralaner onemonth monthly product dog bravecto plus fluralanermoxidectin twomonth product cat sentinel line oral parasitic product dog include sentinel spectrum milbemycin oxime lufenuron praziquantel sentinel flavor tab milbemycin oxime lufenuron optimmune cyclosporine ophthalmic ointment nobivac vaccine line flexible dog cat vaccination gilvetmab immune checkpoint inhibitor monoclonal antibody conditionally license melanoma mastocytoma tumor otomax gentamicin sulfate usp betamethasone valerate usp clotrimazole usp ointmentmometamax gentamicin sulfate usp mometasone furoate monohydrate clotrimazole usp otic suspensionmometamax ultra gentamicin sulfate mometasone furoate monohydrate posaconazole suspensionposatex orbifloxacin mometasone furoate monohydrate posaconazole suspension ear ointments acute chronic otitis caninsulinvetsulin porcine insulin zinc suspension diabete mellitus treatment dog cat panacur fenbendazolesafeguard fenbendazole broadspectrum anthelmintic dewormer use animal regumate altrenogest fertility management horse prestige vaccine line table content horse scalibor deltamethrinexspot protect bite flea tick mosquitoe sandfly sure petcare product companion animal identification wellbee include microchip pet recovery system home discussion sale company product item management discussion analysis financial condition result operation product approval set forth summary significant product approval receive company date product date approval food drug administration fda approval single agent adjuvant treatment follow surgical resection platinumbase chemotherapy adult patient stage ib ta cm ii january iiia nsclc base keynote trial fda approval treatment adult pediatric patient unresectable metastatic msi h dmmr solid tumor progress follow prior treatment satisfactory alternative treatment option conversion accelerate regular approval base march keynote keynote keynote trial fda accelerate approval combination padcev enfortumab vedotinejfv treatment adult patient locally advanced metastatic urothelial carcinoma eligible cisplatincontaine chemotherapy base keynote trial dose escalation cohort cohort april cohort k conduct collaboration seagen pfizer inc pfizer astellas japans ministry health labor welfare mhlw approval treatment patient june relapse refractory pmbcl base keynote keynotea trials european commission ec approval combination trastuzumab fluoropyrimidine platinumcontaine chemotherapy firstline treatment locally advanced unresectable august metastatic herpositive gastric gej adenocarcinoma adult tumor express pdl base keynote trial keytruda china national medical products administration nmpa approval monotherapy treatment adult patient advance unresectable metastatic msih dmmr solid tumor include patient colorectal cancer progress follow treatment fluoropyrimidine oxaliplatin irinotecan solid tumor progress follow prior therapy september satisfactory alternative treatment option base keynote keynote trial october ec approval monotherapy adjuvant treatment adult nsclc high risk recurrence follow complete resection platinumbase chemotherapy base keynote trial fda approval treatment patient resectable tumor cm node positive nsclc october combination platinumcontaine chemotherapy neoadjuvant treatment continue single agent adjuvant treatment surgery base keynote trial fda approval treatment adult pediatric patient recurrent locally advanced metastatic merkel cell carcinoma conversion accelerate regular approval october base keynote keynote trial october fda approval combination gemcitabine cisplatin treatment patient locally advance unresectable metastatic biliary tract cancer base keynote trial table content fda approval combination fluoropyrimidine platinumcontaine chemotherapy firstline treatment adult locally advanced unresectable metastatic hernegative gastric november gej adenocarcinoma base keynote trial fda approval combination padcev enfortumab vedotinejfv antibodydrug conjugate treatment adult patient locally advanced metastatic urothelial cancer conversion december accelerate regular approval base keynotea trial conduct collaboration seagen pfizer astella ec approval combination fluoropyrimidine platinumcontaine chemotherapy line treatment locally advanced unresectable metastatic hernegative gastric gej december adenocarcinoma adult tumor express pdl base keynote trial ec approval combination gemcitabine cisplatin firstline treatment locally december advance unresectable metastatic biliary tract carcinoma adult base keynote keytruda trial chinas nmpa approval combination fluoropyrimidine platinumcontaine chemotherapy firstline treatment patient locally advance unresectable metastatic hernegative december gastric gej adenocarcinoma base keynote trial fda approval combination chemoradiotherapy treatment patient figo january international federation gynecology obstetric stage iiiiva cervical cancer base keynotea trial fda approval treatment patient hcc secondary hepatitis b receive january prior systemic therapy pdpdl contain regimen conversion accelerate regular approval base keynote trial chinas nmpa approval combination gemcitabine cisplatin firstline treatment february patient locally advanced metastatic biliary tract carcinoma base keynote trial fda approval combination abiraterone prednisone prednisolone treatment adult patient deleterious suspect deleterious brcamutate brcam metastatic castrationresistant prostate cancer mcrpc base propel trial lynparza japans mhlw approval combination abiraterone prednisolone treatment adult august patient brcam mcrpc distant metastasis base propel trial fda approval cmv prophylaxis donor cmvseropositiverecipient cmvseronegative adult kidney june transplant recipients base p trial prevymis ec approval cmv prophylaxis donor cmvseropositiverecipient cmvseronegative adult kidney november transplant recipient base p trial fda approval expand indication prevention disease cause zaire ebolavirus individual month age old vaccine previously approve use individual august year age old ervebo ec approval expand indication active immunization individual year age old protect ebola virus disease cause zaire ebolavirus vaccine previously approve september use eu individual year age old fda approval treatment adult patient advance rcc follow pd pdl welireg december inhibitor vascular endothelial growth factor tyrosine kinase inhibitor base litespark trial ec approval injectable formulation dog persistent killing flea tick month bravecto january treatment jointly develop commercialize worldwide collaboration astrazeneca table content competition health care environment competition market company conduct business pharmaceutical industry general highly competitive highly regulate company competitor include worldwide researchbase pharmaceutical company small research company limit therapeutic focus generic drug manufacturer animal health care company companys operation adversely affect generic biosimilar competition company product mature technological advance competitor industry consolidation patent grant competitor competitive combination product new product competitor generic availability competitor brand product new information clinical trial market product postmarkete surveillance addition patent right increasingly challenge competitor outcome highly uncertain adverse result patent dispute preclude commercialization product negatively affect sale exist product result payment royalty recognition impairment charge respect intangible asset associate certain product pharmaceutical competition involve rigorous search technological innovation ability market innovation effectively longstanding emphasis research development company wellpositione compete search technological innovation company active acquire marketing product external alliance license arrangement collaboration refine sale marketing effort address change industry condition introduction new product process competitor result price reduction product displacement product protect patent example number compound available treat particular disease typically increase time result slow sale growth reduce sale company product therapeutic category highly competitive animal health business affect factor include regulatory legislative issue scientific technological advance product innovation quality price company product competitor product effective promotional effort frequent introduction generic product competitor health care environment government regulation global effort health care cost containment continue exert pressure product pricing market access change health care system health care reform enact prior year increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary contribute pricing pressure international market governmentmandate pricing action reduce price generic patent drug addition company sale performance negatively affect costreduction measure take government party low health care cost biden administration congress continue discuss legislation design control health care cost include cost drug company anticipate action additional action future continue negatively affect sale profit united states company face increase pricing pressure manage care organization government agency program negatively affect company sale profit margin include practice manage care organization federal state exchange institutional governmental purchasers ii federal law regulation relate medicare medicaid include medicare prescription drug improvement modernization act patient protection affordable care act aca american rescue plan act american rescue plan act inflation reduction act ira federal state government year pursue method reduce cost drug vaccine pay example federal state law require company pay specify rebate medicine reimburse medicaid provide discount medicine purchase certain state federal entity department defense veteran affairs public health service entity hospital serve disproportionate share low income uninsured patient additionally consolidation integration health care provider major factor competitive marketplace pharmaceutical product health plan pharmacy benefit manager pbms consolidate few large entity enhance purchasing strength importance private thirdparty insurer government employ formulary control cost negotiate discount price exchange formulary inclusion failure obtain timely adequate pricing formulary placement merck product obtain placement unfavorable pricing adversely affect revenue addition formulary table content tier copay differential private health insurance company selfinsure employer increase costshare require beneficiary particularly brand pharmaceutical biotechnology product private health insurance company increasingly impose utilization management tool clinical protocol require prior authorization brand product require patient fail generic product permit access brand medicine management tool treatment area payor take position multiple brand product therapeutically comparable payor market concentrate company face great pricing pressure private thirdparty payor order provide information company pricing practice company annually post website pricing transparency report report provide company average annual list price net price increase average discount company portfolio date company gross sale reduce result rebate discount return legislative change congress pass ira make significant change drug cover pay medicare program include creation financial penalty drug price rise fast rate inflation redesign medicare program require manufacturers bear liability certain drug benefit government pricesette certain medicare drug start medicare b drug start august department health human service hhs center medicare medicaid services cms announced januvia include year iras drug price negotiation program program pursuant iras program discussion government occur continue government price setting effective january company sue government iras program item financial statement supplementary datum note contingency environmental liability furthermore biden administration congress continue discuss legislation design control health care cost include cost drug longterm implication ira remain uncertain subject factor include manner department health human service decides implement statute expert analyst industry outside predict law harm innovation pharmaceutical industry result few new treatment develop approve time merck work mitigate potentially harmful effect law include detrimental impact innovation addition congress pass american rescue plan act include provision eliminate statutory cap rebate drug manufacturer pay medicaid begin january rebates act discount list price eliminate cap mean manufacturer discount pay medicaid increase prior change manufacturer require pay average manufacturer price amp rebate state medicaid program medicaidcovere drug result provision begin manufacturer pay state medicaid programs rebate receive sale particular product change present risk merck drug high medicaid utilization rebate exposure amp company face increase pricing pressure state look exert great influence price prescription drug number state pass pharmaceutical price cost transparency law law typically require manufacturer report certain product price information financial datum state law require manufacturer provide advance notification price increase company expect state continue focus pharmaceutical pricing increasingly shift aggressive price control tool prescription drug affordability board authority conduct affordability review establish upper payment limit addition recently fda authorize year period florida application import prescription drug canada table content regulatory change pharmaceutical industry consider potential source saving legislative administrative proposal debate enact type revenue generating cost saving proposal include additional direct price control european union effort health care cost containment remain intense european union eu company face competitive pricing pressure result generic biosimilar drug addition majority country eu attempt contain drug cost engage reference pricing authority examine predetermine market publish price drug reference pricing compare product price market external reference pricing compare product price product national class internal reference pricing authority use price datum set new local price brandname drug include company drug guideline examine reference pricing usually set local market change pursuant local regulation eu member states establish freeprice system regulate pricing drug profit control plan seek negotiate set price base costeffectiveness product assessment offer therapeutic benefit product relevant class downward pressure health care cost general particularly prescription drug intense result increasingly high barrier erect entry new product eu member states crossborder import lowprice market exert competitive pressure reduce pricing eu member state additionally eu member states power restrict range pharmaceutical product national health insurance system provide reimbursement eu pricing reimbursement plan vary widely member state member state eu member state provide drug product marketed reimbursement price agree eu member states require completion additional study compare costeffectiveness particular product candidate available therapy socalle health technology assessment hta order obtain reimbursement pricing approval hta pharmaceutical product increasingly common price reimbursement procedure eu member states hta process govern national law country involve assessment cost effectiveness public health impact therapeutic impact andor economic social impact use give pharmaceutical product national health care system individual country conduct ultimately hta measure add value new health technology compare exist one outcome hta specific pharmaceutical product influence pricing reimbursement status grant pharmaceutical product regulatory authority individual eu member states negative hta company product mean product reimbursable force company reduce reimbursement price offer discount rebate negative hta leading recognize hta body undermine company ability obtain reimbursement relevant product outside jurisdiction example eu member states develop hta mechanism rely extent hta perform country develop hta framework inform pricing reimbursement decision hta procedure require additional data review administrative process increase complexity timing cost obtain product reimbursement exert downward pressure available reimbursement obtain reimbursement pricing approval eu member states company require conduct study compare cost effectiveness company product candidate therapy consider local standard care assurance eu member state allow favorable pricing reimbursement market access condition company product feasible conduct additional costeffectiveness study require japan japan pharmaceutical industry subject governmentmandate annual price reduction pharmaceutical product certain vaccine furthermore government order repricing specific product determine use product exceed certain threshold define applicable repricing rule addition merck product medical action composition product subject market expansion pricing merck product subject repricing meet exception criterion governmentmandate price reduction occur april table content china company business china grow rapidly past year importance china company overall pharmaceutical vaccine business increase accordingly continue growth company business china dependent ongoing development favorable environment innovative pharmaceutical product vaccine sustain access company currently market product absence trade impediment adverse pricing control recent year chinese government introduce implement number structural reform accelerate shift innovative product reduce cost multiple new policy introduce government improve access new innovation reduce complexity regulatory filing accelerate review approval process lead significant increase number new product approve year mechanism drug add government national reimbursement drug list nrdl evolve inclusion require price negotiation impact outlook market select brand new nrdl recently complete new entry average price reduction pricing pressure exist china health care reform increase pressure acceleration generic substitution volume base procurement vbp government implement vbp program tendering process mature product generic substitute generic quality consistency evaluation approval mature product enter round vbp average price reduction company expect vbp semiannual process significant impact mature product move forward emerge market company focus emerge market addition china continue government emerge market focus constrain health care cost enact price control measure impact intellectual property include exceptional case threat compulsory license aim pressure price innovative pharmaceutical result constrain market access innovative medicine company anticipate pricing pressure market access challenge continue future vary degree emerge market price market access challenge condition emerge market country affect company effort continue grow market include potential political instability change trade sanction embargo significant currency fluctuation control financial crisis limit change availability funding health care credit worthiness health care partner hospital development adversely impact business environment company company engage thirdparty agent assist operate emerge market country affect ability realize continued growth increase company risk exposure address global cost containment pressure company engage public policy advocacy policymaker continue work demonstrate medicine provide value patient pay health care company advocate government policymaker encourage longterm approach sustainable health care financing ensure access innovative medicine disproportionately target pharmaceutical source budget saving market historically low rate health care spending company encourage government increase investment adopt market reform order improve citizen access appropriate health care include medicine operating condition challenge global pressure competition industry regulation cost containment effort predict effect factor company business company continually take measure evaluate adapt improve organization business practice well meet customer need believe wellpositione respond evolve health care environment market force regulation pharmaceutical industry subject regulation regional country state local agency world focus standard process determine drug safety effectiveness condition sale reimbursement particular importance fda administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceutical case fda requirement practice increase time resource necessary develop new product bring market time fda commit expedite development review product bear breakthrough therapy designation accelerate table content regulatory review process medicine designation fda undertake effort bring generic competition market efficiently timely manner eu adopt directive legislation concern classification approval marketing labeling advertising manufacture wholesale distribution integrity supply chain pharmacovigilance safety monitor medicinal product human use provide mandatory standard eu supplemented implement additional regulation eu member states particular eu regulator approve product subject number postauthorization condition example typical postauthorization commitment include additional pharmacovigilance conduct clinical trial establishment patient registry physician patient education control distribution prescribing arrangement noncompliance postauthorization condition pharmacovigilance obligation lead regulatory action include variation suspension withdrawal marketing authorization enforcement regulatory action include imposition financial penalty company policy procedure consistent substance directive consequently believe material effect company business company believe continue able conduct operation include launch new drug regulatory environment research development discussion regulatory approval process access medicine global health care company merck primary role discover develop innovative medicine vaccine company recognize collaboration key stakeholder role play help ensure science advance health care product accessible affordable company commit ensure reliable safe global supply quality medicine vaccine develop testing implement innovative solution address barrier access affordability medicine vaccine company approach design enable serve great number patient today meeting need patient future company wideranging effort expand access health encompass set principle embed business strategy operation principle guide company global approach address significant public health burden unmet medical need company systematically evaluate pipeline candidate assess potential lowresource setting life cycle product company seeks continually evaluate potential adapt change external environment collaborate stakeholder include private governmental multilateral nonprofit organization company seek design deliver sustainable solution address access challenge payer provider patient level furthermore company incorporate access health metric scorecard make component calculate annual incentive pay majority global employee addition social investment include philanthropic program impact investing merck help strengthen health system build capacity particularly underresourced community merck patient assistance program provide certain medicine adult vaccine free people prescription drug health insurance coverage company assistance afford merck medicine vaccine globally merck substantial contribution access health key initiative include product donation humanitarian assistance lowincome country medical outreach program mectizan donation program long run diseasespecific drug donation program kind support elimination neglect tropical disease onchocerciasis lymphatic filariasis additionally merck mother company provide fund scientific business acuman help global health partner end preventable death complication pregnancy childbirth merck provide fund merck foundation independent grantmaking organization support variety organization dedicate address systemic barrier health equity privacy data protection company subject significant number privacy datum protection law regulation globally place restriction company ability transfer access use personal datum business legislative regulatory landscape privacy datum protection continue evolve increase attention privacy datum protection issue develop emerge market potential affect directly company business include eu general data protection regulation gdpr impose penalty global revenue gdpr related implement law individual eu member states govern collection use personal health datum personal datum eu gdpr increase responsibility liability relation personal datum company process impose number strict obligation restriction table content ability process include collection analysis transfer personal datum include health datum clinical trial adverse event report gdpr include requirement relate consent individual personal data relate information provide individual prior process personal datum personal health datum notification datum processing obligation national datum protection authority security confidentiality personal datum gdpr prohibits transfer personal data country outside eu consider ec provide adequate level data protection include datum controller meet specific requirement follow schrems ii decision court justice eu considerable uncertainty permissibility international data transfer gdpr light implication decision company face difficulty transfer personal datum eu country company enter euapproved standard contractual clause vendor supplier collaboration partner clinical trial site order facilitate lawful transfer personal datum eu addition president biden issue executive order october address datum privacy concern raise schrems ii decision introduce measure safeguard oversight personal data collection signal intelligence activity provide individual redress mechanism data protection concern certainty international transfer personal datum eu euus datum privacy framework successor invalidated euus privacy shield come way new eu adequacy decision issue ec july new adequacy decision contest privacy advocate subject legal review failure comply requirement gdpr related national datum protection law eu member states result significant monetary fine administrative penalty civil liability claim individual personal datum process datum protection authority different eu member state implement certain variation enforce gdpr national datum protection law differently introduce additional national regulation guideline add complexity process personal datum eu guidance develop eu level national level individual eu member state concern implementation compliance practice update revise grow trend require public disclosure clinical trial datum eu add complexity obligation relate processing health datum clinical trial fail comply obligation lead government enforcement action significant penalty company harm reputation adversely impact business operating result uncertainty interplay different regulatory framework add complexity company face regard datum protection regulation august china pass personal information protection law pipl aim standardize handle personal information china effective november pipl currently apply process personal information natural person china process personal information outside china purpose provide product service china analyze activity individual china similar gdpr pipl contain unique requirement find gdpr company develop implement comprehensive plan ensure compliance pipl plan relate data localization crossborder transfer pende forthcoming guidance cyberspace administration china additional law regulation enact certain state canada europe asia latin america increase enforcement litigation activity develop market increase regulatory cooperation privacy authority globally company adopt comprehensive global privacy program manage evolving requirement risk facilitate transfer personal information international border distribution company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pbms institution human health vaccine sell primarily physician wholesaler distributor government entity company professional representative communicate effectiveness safety value company pharmaceutical vaccine product health care professional private practice group practice hospital manage care organization company sell animal health product veterinarian distributor animal producer farmer pet owner table content raw material company obtain raw material essential business numerous supplier worldwide principal material company use manufacture operation available source company obtain certain raw intermediate material primarily source company attempt possible mitigate potential risk associate raw material component supply inventory appropriate supplier management patent trademark license patent protection consider aggregate material importance company marketing product major foreign market patent cover product se pharmaceutical formulation process intermediate useful manufacture product use product patent protection individual product extend vary period accordance legal life patent country protection afford vary country country depend type patent scope coverage patent portfolio develop product introduce company normally provide market exclusivity key patent subject patent term restoration know patent term extension pte year japan certain jurisdiction europe year extended term available form supplementary protection certificate spc pte spc award offset portion patent term lose clinical testing regulatory review process product prior approval food drug administration modernization act include pediatric exclusivity provision provide additional month market exclusivity add patent term orange bookliste patent regulatory datum exclusivity term small molecule biologic product indication new currently market drug certain agree pediatric study complete applicant eu provide additional month pediatric market exclusivity attach product spc term japan attach additional term pediatric study market exclusivity extension unrelated patent term regulatory data exclusivity tie protection clinical data complementary patent protection case provide effective long last marketing exclusivity product patent portfolio regulatory datum protection term generally run year marketing approval new chemical entity extend seven year orphan drug indication year marketing approval biological product table content table provide list expiration date include pende pte spc period indicate key patent protection eu japan china follow market product product year expiration year expiration eu year expiration japan year expiration china januvia expire expire janumet expire na expire janumet xr na na expired isentress expire expire simponi na na na lenvima expire bridion expire expire expire bravecto pende pte gardasil expire expire expire gardasil keytruda lynparza pending pte zerbaxa na adempas na expire belsomra na na prevymis pende pte vaxneuvance patent patent na delstrigo pende pte na pifeltro pende pte welireg pende pte na na na note compound patent note certain product list subject patent litigation item financial statement supplementary datum note contingency environmental liability na currently market approval eu date represent expiration date follow country france germany italy spain major eu market spc application file grant major eu markets patent expiry date spc expiry date list pte system japan allow patent extend provide later approval direct different indication previous approval result multiple pte approval give patent expiration date result settlement agreement relate patent direct specific sitagliptin salt form product exclusivity extend januvia janumet july janumet xr generic entry anticipate expiry date reflects grant pte mg tablet japan company marketing right japan china distribution agreement johnson johnson innovative medicine expire october global strategic oncology collaboration eisai co ltd eligible month pediatric market exclusivity global strategic oncology collaboration astrazeneca commercialize worldwide collaboration bayer ag company marketing right pte pende include list patent expiry date datum exclusivity grant expire july datum exclusivity grant eu japan expire december september respectively table content company follow key patent protection drug candidate review fda currently anticipate review year expiration mk gefapixant mk sotatercept mk patritumab deruxtecan v pneumococcal vaccine receive complete response letter fda december biologic product mk sotatercept eligible year datum exclusivity approval grant patent cover method treat pulmonary arterial hypertension mk sotatercept expire absent pte provide additional exclusivity company follow key patent protection drug candidate phase development currently anticipate phase drug candidate year expiration mka doravirine islatravir pende pte doravirine patent mka quavonlimab pembrolizumab mk nemtabrutinib mka vibostolimab pembrolizumab mka favezelimab pembrolizumab v mk clesrovimab mk bomedemstat mk mk lagevrio mk mka pembrolizumab hyaluronidase subcutaneous mk mk tulisokibart develop collaboration receive emergency use authorization fda treatment highrisk adult mild moderate covid note patent table compound patent drug candidate review development key patent subject future pte year andor month pediatric market exclusivity addition depend circumstance surround final regulatory approval product grant patent pende patent application relevance product finally approve expiration compound patent generally result loss market exclusivity cover pharmaceutical product commercial benefit continue derive laterexpire patent process intermediate relate economical method manufacture active ingredient product ii patent relate use product iii patent relate novel composition formulation iv certain country market exclusivity available relevant law effect product patent expiration pharmaceutical product sale depend factor nature market position product growth market complexity economic process manufacture active ingredient product requirement new drug provision federal food drug cosmetic act similar law regulation country addition market exclusivity seek country relevant law include law increase patent life benefit increase patent life partially offset increase number incentive use generic product additionally improvement intellectual property law seek country reform patent relevant law implementation international treaty table content information respect company patent item risk factor item financial statement supplementary datum note contingency environmental liability worldwide company important product sell trademark consider aggregate material importance trademark protection continue country long country long register registration fix term renew indefinitely royalty income patent knowhow license right amount million merck incur royalty expense amount billion patent knowhow license hold research development company business characterize introduction new product new use exist product strong research development program december approximately people employ company research activity company prioritize research development effort focus candidate believe represent breakthrough science unmet medical need difference patient payer company maintain number longterm exploratory fundamental research program biology chemistry research program direct product development company research development model design increase productivity improve probability success prioritize company research development resource candidate company believe capable provide unambiguous promotable advantage patient payer deliver maximum value approve medicine vaccine new indication new formulation merck pursue emerge product opportunity independent therapeutic area modality company commit ensure externally source program remain important component pipeline strategy focus supplement internal research acquisition license external alliance strategy focus entire spectrum collaboration early research latestage compound access new technology company clinical pipeline include candidate multiple disease area include cancer cardiovascular disease metabolic disease infectious disease neuroscience immunology respiratory disease vaccine development human health product industry practice government regulation foreign country provide determination effectiveness safety new chemical compound preclinical test control clinical evaluation new drug vaccine marketed record datum preclinical clinical experience include new drug application nda drug biologic license application bla vaccine biologic submit fda require approval company scientist discover new small molecule compound biologic believe promise treat medical condition company commence preclinical testing compound preclinical testing include laboratory testing animal safety study gather data chemistry pharmacology immunogenicity toxicology pende acceptable preclinical datum company initiate clinical testing accordance establish regulatory requirement clinical testing begin phase study design assess safety tolerability pharmacokinetic preliminary pharmacodynamic activity compound human favorable additional large phase study initiate determine efficacy compound affect population define appropriate dosing compound identify adverse effect limit compound usefulness situation clinical program incorporate adaptive design methodology use accumulate datum decide modify aspect ongoing clinical study continue undermine validity integrity trial type adaptive clinical trial adaptive phase ab trial design twostage trial design consist phase proofofconcept stage phase b doseoptimization finding stage datum phase trial satisfactory company commence largescale phase trial confirm compound efficacy safety type adaptive clinical trial adaptive phase trial design study include interim analysis adaptation change trial feature common phase study eg multiple dose group design similar phase trial adaptive phase trial design reduce timeline eliminate activity require start separate study completion phase trial satisfactory company submit regulatory filing appropriate regulatory agency world product candidate approve marketing assurance compound result particular program obtain regulatory approval necessary market vaccine development follow general pathway drug preclinical testing focus vaccine safety ability elicit protective immune response immunogenicity premarkete vaccine clinical trial typically phase initial phase clinical study conduct normal subject evaluate table content safety tolerability immunogenicity vaccine candidate phase study doserange study provide additional data safety immunogenicity andor effectiveness finally phase trial conduct intended population licensure provide datum immunogenicity andor effectiveness safety support application regulatory approval successful company submit regulatory filing appropriate regulatory agency united state fda review process begin complete nda bla submit receive accept review agency day receipt fda determine application sufficiently complete permit substantive review fda assess time application grant priority review standard review pursuant prescription drug user fee act vii pdufa fda review period target nda original bla month priority review month standard review time application deem sufficiently complete original efficacy supplement nda bla fda review period target month priority review month standard review time supplemental application receive review timeline determine fda generally act application timeline goal major amendment submit company initiative fda request pende application occur fda extend review period allow review new information month extension review period communicate company fda act application issue approval letter issue complete response letter crl state application approve present form describe deficiency fda identify company wish pursue application receive crl resubmit application information address question issue identify fda order support approval resubmission subject review period target vary depend underlie submission type content resubmission fda program designation fast track breakthrough therapy accelerate approval priority review facilitate expedite development review new drug address unmet medical need treatment lifethreatening condition fast track designation provide pharmaceutical manufacturer opportunitie frequent interaction fda reviewer product development ability manufacturer roll submission ndabla rolling submission allow complete portion application submit review fda ongoing basis breakthrough therapy designation provide manufacturer feature fast track designation intensive guidance implement efficient development program product commitment fda involve senior manager experience staff review accelerate approval designation allow fda approve product base effect surrogate intermediate endpoint reasonably likely predict product clinical benefit generally require manufacturer conduct require postapproval confirmatory trial verify clinical benefit priority review designation mean fda goal action ndabla month compare month standard review special designation grant give application ie product designate breakthrough therapy eligible priority review covid public health crisis secretary health human service secretary exercise statutory authority determine public health emergency exist declare circumstance justify emergency use drug biological product authorize fda secretary issue amend determination public health emergency significant potential public health emergency exist declare circumstance continue justify authorization emergency use product effect declaration amend enable fda issue emergency use authorization euas permit distribution use specific medical product absent ndabla submission approval include product treat prevent disease condition cause sarscov virus subject term euas fda certain finding grant eua include reasonable believe base totality evidence drug biologic effective know potential benefit term eua outweigh know potential risk additionally fda find adequate approve available alternative emergency use authorize drug biologic fda revise revoke eua circumstance justify issuance long exist criterion issuance long meet circumstance revision revocation appropriate protect public health safety european union primary method company use obtain marketing authorization pharmaceutical product eu centralized procedure procedure compulsory certain pharmaceutical product particular biotechnological process available certain new chemical compound table content product company seek market innovative pharmaceutical product centralized procedure file complete set safety datum efficacy datum marketing authorization application maa european medicine agency ema ema evaluate maa provide recommendation ec ec approve deny maa possible new chemical product obtain marketing authorization eu mutual recognition procedure application single member state member state approve pharmaceutical product national procedure applicant submit approval mutual recognition procedure eu member states market outside eu company submit marketing application national regulatory authority example ministry health labour welfare japan national medical products administration china health canada agncia nacional de vigilncia sanatria brazil korea food drug administration south korea therapeutic goods administration australia country separate independent review process timeline market approval time long regulatory authority require approval major market eu issuance certificate pharmaceutical product market initiate local review process research development update company currently candidate regulatory review internationally latestage clinical development mk patritumab deruxtecan potential firstinclass direct dxd antibody drug conjugate adc priority review fda treatment adult patient locally advanced metastatic egfrmutate nsclc previously treat systemic therapy bla base primary result herthenalung pivotal phase trial datum result present iaslc world conference lung cancer simultaneously publish journal clinical oncology fda set pdufa date june bla priority review follow receipt breakthrough therapy designation grant fda december bla review realtime oncology review program patritumab deruxtecan herdxd discover daiichi sankyo jointly develop daiichi sankyo merck mk sotatercept mercks novel investigational activin signal inhibitor priority review fda treatment adult patient pulmonary arterial hypertension world health organization group application base result phase stellar trial fda set pdufa date march sotatercept review ema sotatercept grant breakthrough therapy designation orphan drug designation fda priority medicine prime scheme orphan drug designation ema treatment pulmonary arterial hypertension sotatercept subject licensing agreement bristolmyer squibb company bms v company investigational valent pneumococcal conjugate vaccine specifically design help prevent invasive pneumococcal disease pneumococcal pneumonia adult priority review fda bla v support result multiple phase clinical study evaluate v vaccinenave vaccineexperience adult patient population include stride stride stride stride fda set pdufa date june v grant breakthrough therapy designation fda prevention invasive pneumococcal disease pneumococcal pneumonia cause streptococcus pneumoniae serotype ac f n f bc f f f b f f b adult year age old mk gefapixant nonnarcotic oral selective px receptor antagonist treatment refractory unexplained chronic cough adult december fda issue second crl resubmission merck nda gefapixant crl fda conclude merck application meet substantial evidence effectiveness treat refractory chronic cough unexplained chronic cough crl relate safety gefapixant merck review fdas feedback determine step mk keytruda antipd therapy approve treatment cancer clinical development expand indication study encompass cancer type include biliary estrogen receptor positive breast cancer cervical colorectal cutaneous squamous cell endometrial esophageal gastric glioblastoma head neck hepatocellular hodgkin lymphoma nonhodgkin lymphoma nonsmallcell lung smallcell lung melanoma mesothelioma ovarian prostate renal triplenegative breast urothelial currently phase clinical development trial plan cancer keytruda priority review fda combination standard care chemotherapy carboplatin paclitaxel follow keytruda single agent treatment patient primary table content advance recurrent endometrial carcinoma base keynote trial fda set pdufa date june supplemental bla keytruda review eu japan perioperative treatment regimen patient resectable stage ii iiia iiib nsclc base keynote study perioperative treatment regimen include treatment surgery neoadjuvant continue surgery adjuvant february emas committee medicinal product human use chmp adopt positive opinion recommend approval keytruda combination platinumcontaine chemotherapy neoadjuvant treatment continue monotherapy adjuvant treatment treatment resectable nsclc high risk recurrence adult base keynote trial chmp recommendation review ec marketing authorization eu final decision expect half addition keytruda review eu japan combination padcev enfortumab vedotinejfv adc treatment adult patient locally advanced metastatic urothelial carcinoma base keynotea trial conduct collaboration seagen pfizer astellas keytruda review eu combination chemoradiotherapy treatment patient highrisk locally advanced cervical cancer base keynotea trial additionally keytruda review japan combination fluoropyrimidine platinumcontaine chemotherapy firstline treatment patient locally advance unresectable metastatic gastric gej adenocarcinoma base keynote trial keytruda review japan combination standard care chemotherapy gemcitabine cisplatin treatment patient locally advance unresectable metastatic biliary tract cancer base keynote trial welireg review eu treatment previously treat advanced renal cell carcinoma base lightspark clinical trial treatment von hippellindau disease base lightspark clinical trial company diversify oncology portfolio execute strategy broadly base strategic pillar immunooncology precision molecular target tissue target merck numerous phase oncology program pillar immunooncology keytruda therapeutic area cutaneous squamous cell hepatocellular mesothelioma ovarian smallcell lung cancer mka coformulation quavonlimab merck novel investigational antictla antibody pembrolizumab evaluate treatment rcc subcutaneous mka coformulation pembrolizumab hyaluronidase evaluate comparability intravenous formulation pembrolizumab certain type nsclc mka coformulation favezelimab merck novel investigational antilag therapy pembrolizumab evaluate treatment colorectal cancer hematological malignancy mka coformulation vibostolimab antitigit therapy pembrolizumab evaluate treatment certain type melanoma nsclc sclc v mrna investigational individualized neoantigen therapy evaluate combination keytruda adjuvant treatment patient certain type melanoma interpath clinical trial fda ema grant breakthrough therapy designation prime scheme respectively v mrna combination keytruda adjuvant treatment patient certain stage highrisk melanoma follow complete resection v mrna evaluate phase interpath clinical trial adjuvant treatment certain patient nsclc v develop collaboration moderna precision molecular target mk lynparza oral parp inhibitor develop collaboration astrazeneca plc company currently evaluate lynparza combination pembrolizumab expand indication therapeutic area nsclc sclc mk lenvima oral receptor tyrosine kinase inhibitor evaluate combination keytruda expand indication therapeutic area esophageal gastric cancer lenvima develop collaboration eisai co ltd table content mk nemtabrutinib oral reversible noncovalent bruton tyrosine kinase btk inhibitor evaluate treatment hematological malignancy include chronic lymphocytic leukemia small lymphocytic lymphoma mk bomedemstat investigational orally available lysinespecific demethylase inhibitor evaluate treatment certain patient essential thrombocythemia bomedemstat fda orphan drug fast track designation treatment essential thrombocythemia myelofibrosis orphan drug designation treatment acute myeloid leukemia priority medicine prime scheme designation ema treatment myelofibrosis mk investigational cytochrome p cypa inhibitor evaluate treatment certain patient metastatic castration resistant prostate cancer mk develop collaboration orion corporation tissue target mk investigational trophoblast cellsurface antigen tropdirecte adc evaluate certain patient nsclc certain patient previously treat endometrial carcinoma mk develop collaboration kelunbiotech company terminate certain phase oncology development program company discontinue development ladiratuzumab vedotin adc targeting liv develop collaboration seagen inc pfizer additionally december company pfizer terminate license codevelopment agreement tukysa tucatinib december merck announce stopping phase keylynk trial evaluate keytruda combination maintenance lynparza treatment patient metastatic squamous nsclc merck discontinue study base recommendation independent datum monitoring committee review datum plan interim analysis interim analysis keytruda combination chemotherapy follow keytruda plus lynparza demonstrate improvement overall survival studys dual primary endpoint compare keytruda combination chemotherapy follow keytruda plus placebo december merck eisai announce phase leap trial evaluate keytruda plus lenvima meet dual primary endpoint overall survival progressionfree survival firstline treatment patient advance recurrent endometrial carcinoma disease mismatch repair proficient pmmrnot microsatellite instabilityhigh msih mismatch repair deficient dmmrmsih final analysis keytruda plus lenvima improve overall survival progressionfree survival sufficiently meet studys prespecifie statistical criterion versus standard care platinumbase chemotherapy doublet carboplatin plus paclitaxel company work investigator share result scientific community additionally company currently candidate phase clinical development therapeutic area mk investigational oral proprotein convertase subtilisinkexin type pcsk inhibitor evaluate hypercholesterolemia participant enrol registrational phase study evaluate lowdensity lipoprotein ldl cholesterol reduction phase cardiovascular outcome study mk clesrovimab respiratory syncytial virus rsv monoclonal antibody evaluate prevention rsv medically attend low respiratory tract infection infant certain child year age mk tulisokibart humanize monoclonal antibody direct tumor necrosis factorlike ligand target associate intestinal inflammation fibrosis evaluate treatment ulcerative colitis mka new doravirineislatravir oncedaily oral combination doravirine mg lower dose islatravir evaluate beginning phase program previously untreated adult switch antiretroviral therapy virologically suppress adult mk islatravir investigational nucleoside reverse transcriptase translocation inhibitor nrtti evaluate treatment hiv infection december fda place clinical hold islatravir investigational new drug application base observation decrease total lymphocyte cd tcell count participant receive islatravir clinical study phase clinical trial evaluate oral onceweekly combination low dose islatravir gilead science lenacapavir virologically suppress adult complete enrollment investigational nda doravirineislatravir islatravir table content lenacapavir onceweekly treatment regimen remain partial clinical hold study use islatravir dose high dose consider revise clinical program mk lagevrio investigational oral antiviral medicine treatment mild moderate covid adult risk progress severe disease merck develop lagevrio collaboration ridgeback biotherapeutic lp ridgeback fda grant emergency use authorization lagevrio december reissue october lagevrio authorize treatment adult current diagnosis mild moderate covid high risk progression severe covid include hospitalization death alternative covid treatment option approve authorize fda accessible clinically appropriate authorization base phase moveout trial lagevrio approve use authorize duration declaration circumstance exist justify authorization emergency use food drug cosmetic act authorization terminate revoke soon november ema issue positive scientific opinion lagevrio intend support national decisionmake possible use lagevrio prior marketing authorization october ema initiate rolling review lagevrio treatment covid adult february merck ridgeback announce committee medicinal product human use chmp ema recommend refusal marketing authorization application maa lagevrio merck ridgeback appeal decision request reexamination maa june merck ridgeback announce withdraw eu application marketing authorization lagevrio base chmp view datum submit sufficient satisfy eu regulatory requirement marketing authorization lagevrio application regulatory body review chart reflect company research pipeline february candidate show phase include date candidate enter phase development candidate show phase include advanced compound specific mechanism list compound mechanism currently intend commercialization give therapeutic area small molecule biologic give mknumber designation vaccine candidate give vnumber designation note candidate phase additional indication therapeutic area respect cancer additional claim line extension formulation inline product show phase cancer cancer cancer mk quavonlimab mk boserolimab mk lenvima nonsmallcell lung neoplasm malignant head neck mka quavonlimabpembrolizumab mk welireg dengue fever virus vaccine colorectal endometrial v mk zilovertamab vedotin esophageal hiv infection hematological malignancy hepatocellular mkb islatravirmk mk ifinatamab deruxtecan prostate mkd islatravirlenacapavir smallcell lung rare cancer hiv prevention mk mk lynparza mk neoplasm malignant advanced solid tumor nonalcoholic steatohepatitis nash mk keytruda mka vibostolimabpembrolizumab mk efinopegdutide advanced solid tumor biliary pulmonary arterial hypertension prostate bladder mk mka pembrolizumabhyaluronidase subcutaneous breast pulmonary hypertension left heart disease cutaneous squamous cell cervical mk sotatercept mk favezelimab colorectal schizophrenia nonsmallcell lung endometrial mk mka favezelimabpembrolizumab esophageal systemic lupus erythematosus bladder gastric mk cutaneous squamous cell head neck thrombosis endometrial hepatocellular mk esophageal ovarian melanoma prostate renal cell table content phase phase entry date review antiviral covid new molecular entity certain supplemental filing mk lagevrio cancer cancer cancer mk patritumab deruxtecan mk keytruda mk patritumab deruxtecan nonsmallcell lung primary advanced recurrent endometrial carcinoma nonsmallcell lung eu mk welireg keynote mk nemtabrutinib von hippellindau vhl disease eu resectable stage ii iiia iiib nsclc hematological malignancy march cough keynote eu jpn mka quavonlimabpembrolizumab mk gefapixant firstline locally advanced metastatic urothelial cancer renal cell april pneumococcal vaccine adult keynotea eu jpn mk v highrisk locally advanced cervical cancer endometrial december pulmonary arterial hypertension keynotea eu nonsmallcell lung november mk sotatercept eu firstline negative locally advanced unresectable mk keytruda metastatic gastric cancer cutaneous squamous cell august eu keynote jpn hepatocellular eu firstline locally advanced unresectable metastatic biliary mesothelioma tract cancer ovarian december keynote jpn smallcell lung mka pembrolizumabhyaluronidase subcutaneous nonsmallcell lung february mk bomedemstat myeloproliferative disorder mk welireg mka favezelimabpembrolizumab previously treat advanced renal cell carcinoma colorectal november lightspark eu hematological malignancies october mk prostate december mk lynparza nonsmallcell lung june smallcell lung december mka vibostolimabpembrolizumab melanoma january nonsmallcell lung april smallcell lung march mk lenvima esophageal july footnote gastric december v develop collaboration ne ol na n mm aa cju el ly l l u n g december develop combination keytruda hiv infection develop monotherapy andor combination keytruda hym pek r c h lea td eo rora lv emirin iaeislatravir february fda clinical hold mk august fda partial clinical hold high dose current clinical trial pne vu c jo uc lyc l v c c ein ue adult phase b development cost cofunde respiratory syncytial virus available emergency use authorization mk clesrovimab november ulcerative colitis december fda issue crl nda gefapixant merck review fdas feedback mk tulisokibart october determine step human capital december company approximately employee worldwide approximately employ include puerto rico additionally approximately thirdparty contractor globally approximately company employee fulltime employee globally woman comprise employee individual underrepresented ethnic group comprise workforce company define workforce employee woman comprise member board director additionally company senior management team woman approximately company employee represent collective bargaining group company voluntary turnover rate approximately respectively company recognize employee critical meet need patient customer ability excel depend integrity skill diversity employee party contractor include company temporary worker independent contractor freelancer view fulltime equivalent employee exclude outsource service provider talent acquisition company use comprehensive approach ensure recruit retention leadership development goal systematically execute company hire talented leader achieve improved gender parity representation dimension diversity company provide training table content manager external recruiting organization strategy mitigate unconscious bias candidate selection hiring process addition company utilize comprehensive communication strategy employee brand marketing outreach social medium strategic alliance partnership reach broad pool talent critical business area company hire approximately employee globe channel include company external career site direct passive candidate source diversity partnership employee referral university external source global diversity inclusion diversity inclusion fundamental company success core future innovation company foster globally diverse inclusive workforce employee create environment belong engagement equity empowerment company proactive intentional diversity hire development program advance talent company create competitive advantage leverage diversity inclusion accelerate business performance include foster global supplier diversity integrate diversity inclusion company commercialization strategy leverage employee insight improve performance addition effort company employee business resource group provide opportunity employee active contribute company inclusive culture work talent acquisition development business customer insight social community outreach gender ethnicity datum woman board director women senior management role woman management role woman workforce new hire woman member underrepresented ethnic group board director member underrepresented ethnic group senior management role member underrepresented ethnic group management role member underrepresented ethnic group workforce new hire member underrepresented ethnic group selfidentifie company senior management role define individual holding vice president senior vice president title management role define manager direct report compensation benefit company provide valuable suite compensation benefit program reflect commitment attract retain motivate talent support employee family stage life company continuously monitor adjust compensation benefit program ensure competitive contemporary helpful engaging support strategic imperative diversity inclusion equity flexibility quality security affordability example company regularly monitor evaluate pay practice policy ensure pay employee equitably gender race ethnicity company offer personal health care concierge service assist employee participate company medical plan health care need align business support cancer care strategy company provide enhanced cancer screening benefit cash incentive immediate access lead cancer center excellence employee high value cancer support resource eg caregive mental health employee family globally company implement minimum standard week pay parental leave inclusively apply parent company benefit rank quartile fortune company aon benefits index company include seramount previously work mother good company rank consecutive year name good company mom table content employee wellbee company commit help employee family improve health wellbee physical mental financial social company program ensure quality competitive value protection significant financial hardship access tool resource support employee family stage career live earn company accolade business group health good employer excellence health wellbeing ceo roundtable cancer global gold standard employer accreditation company foster array flexible work arrangement include flextime summer hour remote work telework job share parttime work help employee succeed personally professionally company overall culture wellbee offer onsite service employee thrive example include onsite health care professional major site cafeterias commit healthy menu offering onsite childcare onsite gym convenient option bank employee credit union engage employee company strive foster employee engagement promote safe positive diverse inclusive work environment provide numerous opportunity twoway communication employee company key program initiative include promote global employee engagement survey ongoe pulse check organization interim feedback specific topic foster professional networking collaboration identify provide opportunity volunteer establish positive cooperative business relation designate employee representative talent management development company pursue goal world premier researchbase biopharmaceutical company consistent focus importance continuously develop diverse talented people company commit talent growth allow employee fluidly organization unlocking environment allow shape career pathway nonlinear inclusive opportunity experience merck current talent management system support companywide performance management leadership development talent review succession plan annual performance review help professional development company employee ensure company workforce align company objective company seeks continuously build skill capability workforce accelerate talent improve performance mitigate risk relevant continuous learning experience include limited building leadership management skill provide technical functional training employee environmental matter environmental sustainability company commit enable safe sustainable healthy future strive strong environmental steward evolve effort face change world company environmental sustainability strategy focus area drive operational efficiency design new product minimize environmental impact reduce impact company upstream downstream value chain company ensure ongoing commitment area thoughtful governance company effort area oversee environmental health safety ehs council company ehs council crossfunctional body leadership representation area company business include toplevel executive ehs council provide enterprise leadership sponsorship company environmental sustainability strategy monitor progress company public target influence decision environmental sustainability strategy implementation increase visibility transparency internally business executive team board director addition company environmental sustainability implementation steering committee comprise toplevel executive oversee progress initiative enterprise level provide support guidance implementation plan resource company environmental sustainability strategy globally steer committee inform leader environmental sustainability center excellence coe global energy sustainability coe energy procurement coe develop company goal alignment stakeholder expectation track progress develop provide continuous improvement plan achieve sustain company public commitment table content merck believe climate change present risk business discuss detail item risk factor heading climate change legal regulatory market measure address climate change negatively affect company business result operation cash flow prospect environmental social governance esg matter impact company business reputation potential impact climate change company business include increase operating cost additional regulatory requirement physical risk company facility water limitation disruption supply chain potential risk integrate company business planning include investment reduce energy usage water use greenhouse gas emission company adopt set climate goal help position succeed increasingly resourceconstraine world goal develop align late climate science address rise expectation company customer investor external stakeholder employee environmental impact operation supply chain company climate goal include reduce scope operational greenhouse gas emission baseline achieve carbon neutrality scope greenhouse emission operation source purchase electricity renewable source reduce scope greenhouse gas emission baseline company commit sciencebased target initiative sbti set netzero target greenhouse gas emission global operation scope environmental sustainability initiative company include playbook sustainable environment company local site crucial achieve ambitious environmental sustainability goal company continue launch tool assist particularly climate waste target company launch low carbon transition playbook lctp common platform include gap assessment help companys global site evaluate maturity energy program help create short longterm plan reduce site carbon intensity build lowcarbon future base learning use company issue lctp capability facilitate knowledge sharing site company create waste diversion playbook take similar approach guide site develop roadmap company share goal waste diversion include local wastediversion strategy environmentally responsible procurement practice tool aid report tracking project support achievement meeting company corporate target realize benefit green sustainable science company believe meet environmental sustainability goal intrinsically link creation innovative costefficient manufacturing process low environmental impact company aim develop efficient sustainable process product launch goal minimize material use waste commercial manufacturing company utilize innovative greenbydesign development strategy goal progress initial early clinical supply route fully optimize sustainable commercial manufacturing process fourth year row company receive peter j dunn award green chemistry engineering impact award give american chemical society recognition outstanding implementation novel green chemistry pharmaceutical industry partner progress company value chain company engage strategic supplier identify way reduce greenhouse gas emission supply chain waste diversion company continuously evaluate site waste disposal method gain well understand network change identify risk opportunity value chain base evaluation company implement program divert nonhazardous landfill waste high landfillgenerating site company remain committed public waste diversion goal company global operational waste send landfill incinerator energy recovery site send zero waste landfills water share resource water key input company manufacture operation company assess water risk network standard business practice company priority waterstress risk site conservation plan place actively work water use reduction recycling improvement project project consistent company ongoing commitment achieving state target maintain global water use level company site employ technology technique aim reduce water footprint improve operational performance company table content continue endorsement united nations ceo water mandate enable continue alignment company water program mandate principle directly company operation company continue identify partnership help advance water stewardship priority area operate company continue review explore opportunity environmental strategy evaluate potential impact commitment management believe expenditure relate initiative material adverse effect company financial condition result operation liquidity capital resource year environmental regulation remediation company believe compliance issue associate applicable environmental law regulation material adverse effect company company remediate environmental contamination result past industrial activity certain site expenditure remediation environmental liability million estimate million aggregate year amount consider potential recovery party company take active role identify accrue cost management opinion liability environmental matter probable reasonably estimable accrue total million million december respectively possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed approximately million aggregate management believe expenditure result material adverse effect company financial condition result operation liquidity year geographic area information company operation outside conduct primarily subsidiarie sale worldwide subsidiary outside percentage total company sale company worldwide business subject risk currency fluctuation governmental action governmental proceeding abroad company regard risk deterrent expansion operation abroad company closely review method operation adopt strategy responsive change economic political condition merck operation country locate latin america middle east africa eastern europe asia pacific business develop area stable offer important opportunity growth time available information company internet website address merckcom company available free charge investor portion website annual report quarterly report form q current report form k amendment report file furnish pursuant section security exchange act amend soon reasonably practicable report electronically file furnish securities exchange commission sec address website secgov addition company provide charge copy annual report include financial statement schedule write request shareholder office secretary merck co inc east lincoln avenue rahway nj usa companys corporate governance guideline charter board director stand committee available company website wwwmerckcomcompanyoverviewleadershipboardofdirector information available print shareholder request company company impact report provide enhanced esg disclosure available company website wwwmerckcomcompanyoverviewesgesgresource information company impact report incorporate reference item risk factor summary risk factor company subject number risk realize materially adversely affect business result operation cash flow financial condition prospect follow summary principal risk factor face company table content company dependent patent right patent right invalidate circumvent business materially adversely affect company product lose market exclusivity company generally experience significant rapid loss sale product key product generate significant company profit cash flow event adversely affect market lead product material adverse effect company result operation financial condition company research development effort succeed develop commercially successful product company able acquire commercially successful product way consequently company able replace sale successful product lose patent protection company success dependent successful development marketing new product subject substantial risk company face continue pricing pressure respect product unfavorable uncertain economic condition costreduction measure take certain government negatively affect company operating result company face intense competition low cost generic product competitor product company significant global operation expose additional risk adverse event material adverse effect company result operation financial condition climate change legal regulatory market measure address climate change negatively affect company business result operation cash flow prospect environmental social governance esg matter impact company business reputation failure attract retain highly qualified personnel affect company ability successfully develop commercialize product company experience difficulty delay manufacture certain product include vaccine company able realize expect benefit investment emerge market company expose market risk fluctuation currency exchange rate interest rate pharmaceutical product develop unexpected safety efficacy concern reliance thirdparty relationship outsource arrangement materially adversely affect company business negative event animal health industry material adverse effect future result operation financial condition company animal health business biologic vaccine carry unique risk uncertainty material adverse effect company future result operation financial condition health care industry continue subject increase regulation political action company product include product development market company obtain maintain regulatory approval development follow regulatory approval adversely affect sale company product company subject variety international law regulation table content company subject evolve complex tax law result additional liability affect result operation financial condition adverse outcome current future legal matter negatively affect merck business product liability insurance product limit cost prohibitive unavailable company increasingly dependent sophisticated software application compute infrastructure company continue target cyberattack lead disruption worldwide operation include manufacture research sale operation social medium mobile messaging platform present risk challenge list exhaustive company face additional challenge risk investor carefully consider information set forth include follow risk factor decide invest company security risk factor risk one company face additional risk currently know company company presently deem immaterial impair business operation company business financial condition result operation cash flow prospect materially adversely affect risk contain forwardlooke statement involve risk uncertainty company result materially differ anticipate forwardlooke statement result certain factor include risk face describe cautionary factor affect future result risk relate company business company dependent patent right patent right invalidate circumvent business materially adversely affect patent protection consider aggregate material importance company market human health animal health product major foreign market patent cover product introduce normally provide market exclusivity important successful marketing sale product company seek patent cover product market intend sell product meaningful patent protection available company succeed obtain patent cover product party government authority challenge seek invalidate circumvent patent patent application important company business successfully assert defend patent right provide market exclusivity product company involve patent dispute relate challenge patent claim party infringement company company assert defend patent outside include file claim infringement party item financial statement supplementary datum note contingency environmental liability particular manufacturer generic biosimilar pharmaceutical product time time file abbreviate nda blas fda seek market genericbiosimilar form company product prior expiration relevant patent own license company company normally respond assert patent lawsuit allege patent infringement patent litigation challenge company patent costly unpredictable deprive company market exclusivity patent product case thirdparty patent prevent company marketing selling product particular geographic area additionally certain foreign government indicate compulsory license patent grant case national emergency circumstance diminish eliminate sale profit region negatively affect company result operation court decision relate company patent potential legislation certain foreign market relate patent regulatory initiative result general weaken intellectual property protection important product lose patent protection profitable market sale product likely decline significantly result generic version product available company result operation adversely affect lost sale company launch commercially successful product replace lose sale addition product measure fair value capitalize connection acquisition experience difficulty market negatively affect product cash flow company recognize material noncash impairment charge respect value product table content chart list key patent protection certain company market product patent protection candidate phase clinical development set forth item business patent trademark license company product lose market exclusivity company generally experience significant rapid loss sale product company depend patent provide exclusive marketing right product period time loss patent protection company product typically lead significant rapid loss sale product lower price generic version drug available case product contribute significantly company sale loss market exclusivity material adverse effect company business cash flow result operation financial condition prospect company lose market exclusivity bridion eu company experience substantial decline bridion sale market bridion lose market exclusivity japan january lose market exclusivity subject patent litigation discuss company expect sale market decline substantially addition company expect lose market exclusivity keytruda company anticipate sale keytruda decline substantially key product generate significant company profit cash flow event adversely affect market lead product material adverse effect company result operation financial condition company ability generate profit operate cash flow depend largely continue profitability company key product keytruda gardasilgardasil lynparza bravecto bridion company oncology portfolio lead keytruda vaccine portfolio lead gardasilgardasil represent substantially company revenue growth particular aggregate sale keytruda gardasilgardasil represent company total sale result company dependence key product event adversely affect product market product significant adverse impact result operation financial condition event include loss patent protection increase cost associate manufacturing generic overthecounter availability company product competitive product discovery previously unknown effect result postapproval trial increase competition introduction new effective treatment discontinuation removal market product reason event material adverse effect sale product company research development effort succeed develop commercially successful product company able acquire commercially successful product way consequently company able replace sale successful product lose patent protection order remain competitive company like major pharmaceutical company continue launch new product expect decline sale product loss market exclusivity mean company future success dependent pipeline new product include new product develop collaboration joint venture product able obtain license acquisition accomplish company commit substantial effort fund resource research development dedicate resource collaboration party high rate failure inherent research development process new drug vaccine result high risk fund invest company research program generate financial return risk profile compound fact research long investment cycle bring pharmaceutical compound discovery phase market decade failure occur point process include later process significant fund invest description research development process item business research development phase test highly regulate phase substantial risk company encounter obstacle achieve goal company abandon product invest substantial amount time resource risk encounter research development process include follow preclinical testing new compound yield disappointing result compete product manufacturer reach market clinical trial new drug successful new drug effective harmful effect new drug approve regulator intend use possible obtain patent new drug payer refuse cover reimburse new product sale new product disappointing table content company state certainty product development approve launch able develop license acquire compound product candidate product product launch commercially successful company maintain continuous flow successful new product successful new indication exist product sufficient cover substantial research development cost replace sale lose profitable product lose market exclusivity displace compete product therapie failure short term long term material adverse effect company business result operation cash flow financial condition prospect company success dependent successful development marketing new product subject substantial risk product appear promise development fail reach market fail succeed numerous reason include follow finding ineffectiveness superior safety efficacy compete product harmful effect clinical preclinical testing failure receive necessary regulatory approval include delay approval new product new indication anticipate labeling uncertainty time require obtain regulatory approval benefitrisk standard apply regulatory agency determine grant approval failure certain market obtain reimbursement commensurate level innovation clinical benefit present product lack economic feasibility manufacturing cost factor preclusion commercialization proprietary right future certain pipeline program cancel company believe commercial prospect reduce company recognize material noncash impairment charge program measure fair value capitalize connection acquisition certain collaboration failure successfully develop market new product short term long term material adverse effect company business result operation cash flow financial condition prospect company face continue pricing pressure respect product company face continue pricing pressure globally particularly mature market manage care organization government agency program negatively affect company sale profit margin include federal law regulation relate medicare medicaid include medicare prescription drug improvement modernization act aca ira ii practice manage care group institutional governmental purchaser iii state activity aim increase price transparency include new law note item competition health care environment change health care system enact health care reform increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary result pricing pressure note item competition health care environment hhs include januvia year ira price set program absent legislative court intervention result government set price effective january furthermore company anticipate hhs include keytruda subsequent selection product undergo ira price setting price likely effective early addition large customer receive high rebate drug certain highly competitive category company compete place formulary manage care organization exclusion product formulary lead reduce usage manage care organization order provide information company pricing practice company annually post website pricing transparency report report provide company average annual list price net price increase company portfolio date company gross sale reduce result rebate discount return outside numerous major market include eu japan china pervasive government involvement funding health care regard fix pricing reimbursement pharmaceutical vaccine product consequently market company subject government table content decision make budgetary action respect product japan pharmaceutical industry subject governmentmandate annual price reduction pharmaceutical product certain vaccine furthermore japanese government order reprice specific product determine use product exceed certain threshold define applicable repricing rule company expect pricing pressure continue future unfavorable uncertain economic condition costreduction measure take certain government negatively affect company operating result company business adversely affect local global economic condition include respect inflation interest rate cost raw material packaging uncertainty global economic geopolitical condition result slowdown global economy affect company business reduce price drug wholesaler retailer hospital government agency manage health care provider able willing pay company product reduce demand company product turn negatively impact company sale result material adverse effect company business cash flow result operation financial condition prospect discuss item competition health care environment global effort health care cost containment continue exert pressure product pricing market access worldwide change health care system health care reform increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary contribute pricing pressure international market governmentmandate pricing action reduce price generic patent drug addition company sale performance negatively affect costreduction measure take government party low health care cost company anticipate action additional action future negatively affect sale profit credit economic condition worsen result economic currency impact affect market globally material adverse effect company result company face intense competition low cost generic product competitor product general company face increase competition lowercost generic product patent right protect product vary strength duration addition country patent protection significantly weak eu eu political pressure reduce spending prescription drug lead legislation measure encourage use generic biosimilar product company policy actively protect patent right generic challenge company product arise time company patent prevent emergence generic competition product loss patent protection product typically follow promptly generic substitute reduce company sale product availability generic substitute company drug adversely affect result operation cash flow addition proposal emerge time time country legislation encourage early rapid approval generic drug proposal enact law worsen substantial negative effect company sale business cash flow result operation financial condition prospect company product face intense competition competitor product competition increase new product enter market event competitor product safer effective convenient use well insurance coverage reimbursement level effectively market sell company product alternatively case generic competition include generic availability competitor brand product equally safe effective product sell substantially low price company product result company fail maintain competitive position material adverse effect business cash flow result operation financial condition prospect addition product measure fair value capitalize connection acquisition experience difficulty market negatively impact product cash flow company recognize material noncash impairment charge respect value product table content company significant global operation expose additional risk adverse event material adverse effect company result operation financial condition extent company operation outside significant risk inherent conduct global business include change medical reimbursement policy program price restriction key market multiple regulatory requirement restrict company ability manufacture sell product key market trade protection measure import export licensing requirement include imposition trade sanction similar restriction government foreign exchange fluctuation diminish protection intellectual property country possible nationalization expropriation addition change companys business instability disruption destruction significant geographic region regardless cause include war terrorism riot civil insurrection social unrest natural manmade disaster include famine flood fire earthquake storm disease event like ongoing war russia ukraine rise conflict middle east result material adverse effect macroeconomic condition currency exchange rate financial market adversely affect company business result operation financial condition climate change legal regulatory market measure address climate change negatively affect company business result operation cash flow prospect company believe climate change potential negatively affect business result operation cash flow prospect company expose physical risk extreme weather condition inland flood rise sea level risk transition lowcarbon economy additional legal regulatory requirement change technology market risk reputational risk social human effect population dislocation harm health wellbeing associate climate change risk acute shortterm chronic longterm adverse impact climate change include increase frequency severity natural disaster extreme weather event hurricane tornado wildfire exacerbate drought flooding extreme heat extreme weather inland flood sealevel rise pose physical risk company facility supplier risk include loss incur result physical damage facility loss spoilage inventory business interruption cause natural disaster extreme weather event potential physical impact climate change include reduce access highquality water certain region loss biodiversity impact future product development risk disrupt company operation supply chain result increase cost new legal regulatory requirement enact prevent mitigate adapt implication change climate effect environment regulation differ jurisdiction result company subject new expand carbon pricing taxis increase compliance cost restriction greenhouse gas emission investment new technology increase greenhouse gas emission disclosure include cost result mandatory voluntary reporting diligence disclosure transparency recur investment datum gathering reporting system upgrade facility meet new building code redesign utility system increase company operating cost include cost electricity energy company company supply chain likely subject transitional risk likely pass increase cost company affect company ability procure raw material supply require operation company business quantity level require table content environmental social governance esg matter impact company business reputation governmental authority nongovernmental organization customer investor external stakeholder employee increasingly sensitive esg concern diversity inclusion climate change water use recyclability recoverability packaging plastic waste focus esg concern lead new requirement result increase cost associate develop manufacturing distribute companys product relate reporting obligation company ability compete affect change customer preference requirement grow demand validate net zero greenhouse gas emission target environmentally friendly product package supplier practice failure meet customer expectation demand company strive improve esg performance set certain esg goal initiative company risk negative shareholder reaction include proxy advisory service damage brand reputation inability attract retain employee talent company fail meet goal initiative act responsibly company perceive act responsibly key esg area include equitable access medicine vaccine product quality safety diversity inclusion environmental stewardship reduction greenhouse gas emission support local community corporate governance transparency address human capital factor company operation respond esg consideration implementation company esg goal initiative involve risk uncertainty require investment depend thirdparty performance datum outside company control addition stakeholder disagree company esg goal initiative company meet evolve varied esg expectation investor customer stakeholder company experience reduced demand product loss customer negative impact company business result operation addition company subject expand esg mandatory voluntary reporting diligence disclosure requirement include eus corporate sustainability report directive csrd potentially sec propose climaterelate reporting requirement recently enact legislation california require report greenhouse gas emission climate risk similar regulatory requirement jurisdiction evolve regulatory requirement likely result increase cost complexity compliance order collect measure report relevant esgrelate information failure attract retain highly qualified personnel affect company ability successfully develop commercialize product company success largely dependent continue ability attract retain highly qualified scientific technical management personnel personnel expertise clinical research development governmental regulation commercialization competition qualified personnel pharmaceutical industry internationally intense company sure able attract retain quality personnel cost materially increase company experience difficulty delay manufacture certain product include vaccine merck past experienced difficulty manufacture certain product include vaccine example company issue product recall zerbaxa follow identification product sterility issue company voluntarily recall certain batch vaxneuvance instance syringe breakage company future experience difficulty delay manufacture product failure company vendor supplier comply current good manufacturing practice applicable regulation quality assurance guideline lead manufacturing shutdown product shortage delay product manufacture ii delay relate construction new facility expansion exist facility include intended support future demand company product iii manufacture distribution problem include supply chain delay shortage raw material change manufacture production site limit manufacturing capacity regulatory requirement change type product produce physical limitation impact continuous supply previously disclose company work reduce level nitrosamine sitagliptincontaine medicine januvia company significant progress reduce level nitrosamine consistently release product major market expect comply health authority longterm limit difficulty reduce level achieve timely regulatory approval require change result product shortage addition company experience difficulty delay manufacturing product cause natural disaster hurricane manufacturing difficulty result product shortage lead lose sale reputational harm company table content company able realize expect benefit investment emerge market company take step increase sale emerge market guarantee company effort expand sale market succeed country emerge market especially vulnerable period global financial instability limited resource spend health care order company operate successfully emerge market attract retain qualified personnel company require increase reliance thirdparty agent develop market affect ability realize continued growth increase company risk exposure addition country currency fluctuate substantially currency devalue company offset devaluation company financial performance country adversely affect company business china grow rapidly past year importance china company overall pharmaceutical vaccine business outside increase accordingly addition commercial operation company significant research manufacturing operation china include work chinese entity wuxi apptech co ltd geopolitical tension increase disrupt company operation china disruption result material adverse effect company product development sale business cash flow result operation financial condition prospect continue growth company business china dependent ongoing development favorable environment innovative pharmaceutical product vaccine sustain access company currently market product absence trade impediment adverse pricing control note item competition health care environment pricing pressure china increase chinese government take step reduce cost include implement health care reform lead acceleration generic substitution available mechanism drug add nrdl evolve inclusion require price negotiation impact outlook market select brand new nrdl recently complete new entry average price reduction pricing pressure exist china health care reform increase pressure acceleration generic substitution government vbp program government implement vbp program tendering process mature product generic substitute generic quality consistency evaluation approval mature product enter round vbp average price reduction company expect vbp semiannual process significant impact mature product move forward reason sale emerge market carry significant risk time macroeconomic growth select emerge market expect lead significant increase health care spending country access innovative medicine patient failure maintain company presence emerge market material adverse effect company business cash flow result operation financial condition prospect company expose market risk fluctuation currency exchange rate interest rate company operate multiple jurisdiction virtually sale denominate currency local jurisdiction additionally company enter enter business development transaction borrowing financial transaction rise currency interest rate exposure company certainty foresee mitigate adverse change fluctuation currency exchange rate interest rate inflation negatively affect company business cash flow result operation financial condition prospect example argentina currently experience hyperinflation affecting company operation market order mitigate adverse impact market fluctuation company time time enter hedge agreement hedge agreement currency option forwards interest rate swap limit exposure exchange rate interest rate fluctuation attempt mitigate risk costly successful pharmaceutical product develop unexpected safety efficacy concern unexpected safety efficacy concern arise respect market product scientifically justified lead product recall withdrawal decline sale product liability consumer fraud andor claim include potential civil criminal governmental action table content reliance thirdparty relationship outsource arrangement materially adversely affect company business company depend party include supplier distributor alliance pharmaceutical biotechnology company party service provider key aspect business include development manufacture commercialization product support information technology system failure party meet contractual regulatory obligation company development factor materially disrupt relationship company party material adverse effect company business negative event animal health industry material adverse effect future result operation financial condition company animal health business future sale key animal health product adversely affect number risk factor include certain risk specific animal health business example outbreak disease carry animal african swine fever avian influenza lead widespread death precautionary destruction reduce consumption demand animal adversely affect company result operation outbreak highly contagious disease near company main production site require company immediately halt manufacture animal health product site force company incur substantial expense procure raw material product risk specific animal health include epidemic pandemic affect livestock government procurement pricing practice weather global agribusiness economic event addition sale bravecto billion represent company animal health segment sale negative event respect bravecto material adverse effect company animal health sale animal health segment company business significant impact event future result operation significant biologic vaccine carry unique risk uncertainty material adverse effect company future result operation financial condition successful development testing manufacturing commercialization biologic vaccine particularly human animal health vaccine long complex expensive uncertain process unique risk uncertaintie relate biologic vaccine include limited access supply normal diseased tissue sample cell line pathogen bacteria viral strain biological material addition government regulation multiple jurisdiction eu result restrict access transport use material company lose access sufficient source material tight restriction impose use material company able conduct research activity plan incur additional development cost development manufacturing marketing biologic vaccine subject regulation fda ema regulatory body regulation complex extensive regulation applicable pharmaceutical product example bla include preclinical clinical trial datum extensive datum manufacturing procedure require human vaccine candidate fda approval generally require release manufacture commercial human vaccine lot manufacture biologic vaccine especially large quantity complex require use innovative technology handle living microorganism lot approve biologic vaccine undergo thorough testing identity strength quality purity potency manufacturing biologic require facility specifically design validate purpose sophisticated quality assurance quality control procedure necessary slight deviation manufacturing process include fill labeling packaging storage shipping quality control testing result lot failure product recall spoilage change manufacturing process company require provide preclinical clinical datum show comparable identity strength quality purity potency biologic vaccine change biologic vaccine costly manufacture production ingredient derive live animal plant material biologic vaccine synthetically particular keeping demand vaccine difficult complexity produce vaccine table content use biologically derive ingredient lead variability manufacturing process lead allegation harm include infection allergic reaction allegation review standard investigation process lead closure product facility possible contamination event result substantial cost risk relate government regulation legal proceeding health care industry continue subject increase regulation political action discuss item competition health care environment company believe health care industry continue subject increase regulation political legal action future proposal reform health care system consider executive branch congress state legislature congress pass ira make significant change drug cover pay medicare program include creation financial penalty drug price rise fast rate inflation redesign medicare program require manufacturers bear liability certain drug benefit government pricesette certain medicare drug start medicare b drug start note item competition health care environment hhs include januvia year ira price set program absent legislative court intervention result government set price effective january furthermore company anticipate hhs include keytruda subsequent selection product undergo ira price setting price likely effective early addition congress pass american rescue plan act include provision eliminate statutory cap rebate drug manufacturer pay medicaid begin january rebates act discount list price eliminate cap mean manufacturer discount pay medicaid increase prior change manufacturer require pay average manufacturer price amp rebate state medicaid program medicaidcovere drug result provision begin manufacturer pay state medicaid programs rebate receive sale particular product change present risk merck drug high medicaid utilization rebate exposure amp biden administration congress continue discuss legislation design control health care cost include cost drug company predict additional future change health care industry general pharmaceutical industry particular occur change material adverse effect company business cash flow result operations financial condition prospect company product include product development market company obtain maintain regulatory approval company activity include research preclinical testing clinical trial manufacturing marketing product subject extensive regulation numerous federal state local governmental authority include fda foreign regulatory authority include eu japan china fda administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceutical vaccine case fda requirement increase time resource necessary develop new product bring market regulation outside primarily focus drug safety effectiveness case reduction cost drug fda foreign regulatory authority include eu japan china substantial discretion require additional testing delay withhold registration marketing approval preclude distribution sale product company successful develop new product able market product obtain require regulatory approval limited circumstance include authorization emergency use jurisdiction propose market new product obtain company maintain approval long plan market new product jurisdiction approval require company failure obtain approval significant delay approval process failure maintain approval jurisdiction prevent selling product jurisdiction realize sale table content development follow regulatory approval adversely affect sale company product product reach market certain development follow regulatory approval decrease demand company product include follow result postapproval phase trial study rereview product market recall loss marketing approval product market change government standard public expectation safety efficacy quality labeling change scrutiny advertising promotion withdrawal indication grant pursuant accelerate approval past clinical trial postmarkete surveillance certain market drug company competitor industry raise concern lead recall withdrawal adverse labeling market product clinical trial postmarkete surveillance certain market drug raise concern prescriber patient relate safety efficacy pharmaceutical product general negatively affect sale product addition increase scrutiny outcome clinical trial lead increase volatility market reaction matter attract litigation basis litigation groundless considerable resource need respond addition follow wake product withdrawal significant safety issue health authority fda ema japans pmda chinas nmpa increase focus safety assess benefitrisk balance drug health authority appear cautious making decision approvability new product indication previously unknown effect discover increase negative publicity know effect company product significantly reduce demand product require company action negatively affect sale include remove product market restrict distribution apply labeling change current environment pharmaceutical company operate company risk product liability consumer protection claim civil criminal governmental action relate product research andor marketing activity addition dissemination promotional material evolve digital channel serve increase visibility scrutiny marketplace company subject variety international law regulation company currently subject number government law regulation future subject new government law regulation cost compliance law regulation negative result noncompliance adversely affect business cash flow result operation financial condition prospect company law regulation include additional health care reform initiative country include additional mandatory discount fee ii foreign corrupt practice act fcpa antibribery corruption law iii new law regulation judicial governmental decision affect pricing drug reimbursement access marketing jurisdiction iv change intellectual property law v change accounting standard vi new increase datum privacy regulation enforcement particularly eu china vii legislative mandate preference local manufacturing pharmaceutical vaccine product viii emerge new global regulatory requirement report payment value transfer health care professional ix environmental regulation eus csrd x potential impact importation restriction embargo trade sanction legislative andor regulatory change company subject evolve complex tax law result additional liability affect result operation financial condition company subject evolve complex tax law jurisdiction operate significant judgment require determine company tax liability company tax return routinely examine tax authority connection organization economic cooperation development oecd base erosion profit shift project company require disclose information tax authority operation world lead great audit scrutiny profit earn table content country company believe accrual tax contingency adequate open year base past experience interpretation tax law judgment potential action tax authority complexity tax contingency ultimate resolution tax matter result payment great amount accrue addition company negatively affect change tax law new tax law affect example tax rate andor revise tax law interpretation domestic foreign jurisdiction include potential change exist tax law current presidential administration congress change tax law result implementation oecd pillar solution reform international tax landscape company take position base opinion tax counsel distribution organon common stock connection spinoff qualify transaction taxfree federal income tax purpose fact assumption representation undertaking company organon past future conduct respective business matter incorrect satisfied spin qualify taxfree treatment result significant federal income tax liability company shareholder adverse outcome current future legal matter negatively affect merck business current future litigation claim proceeding government investigation preclude delay commercialization merck product adversely affect merck business result operation cash flow prospect financial condition legal matter include limited intellectual property dispute ii adverse decision litigation include product safety liability consumer protection commercial case iii anti bribery regulation fcpa include compliance ongoe reporting obligation government result settlement iv recall withdrawal pharmaceutical product force closing manufacture plant v product pricing promotional matter vi lawsuit claim administrative proceeding assert investigation violation security antitrust federal state pricing consumer protection datum privacy law regulation vii environmental health safety sustainability matter include regulatory action response climate change viii tax liability result assessment tax authority item financial statement supplementary datum note contingency environmental liability information company legal matter product liability insurance product limit cost prohibitive unavailable result number factor product liability insurance available cost insurance increase significantly company subject substantial number product liability claim item financial statement supplementary datum note contingency environmental liability information company current product liability litigation respect product liability company self insure substantially risk availability commercial insurance restrictive company evaluate risk determine cost obtain product liability insurance outweighs likely benefit coverage available insurance product liability company continually assess efficient mean address risk guarantee insurance coverage obtained obtain sufficient fully cover product liability arise risk relate technology company increasingly dependent sophisticated software application compute infrastructure company continue target cyberattack lead disruption worldwide operation include manufacture research sale operation company increasingly dependent sophisticated software application complex information technology system compute infrastructure cloud service provider collectively system conduct critical operation financial report certain system manage host provide party assist conduct company business disruption degradation manipulation system intentional accidental mean company employee party authorize access unauthorized party adversely affect key business process cyberattack company system thirdparty provider system cloudbase system result exposure confidential information modification critical datum andor failure critical operation misuse system result disclosure sensitive personal information theft trade secret intellectual property confidential business information company continue leverage new innovative technology enterprise replace outmoded technology improve efficacy efficiency business process include datum table content acquisition use create new risk addition company animal health business sell technology product deploy potentially compromise party cause disruption internally externally aggregate impact cyberattack network disruption companys operation financial condition material date company continue target event nature expect continue company monitor datum information technology personnel usage company system identify attempt reduce risk continue ongoing basis current potential threat assurance company effort protect datum system effort thirdparty provider protect system successful prevent disruption companys operation include manufacture research sale operation disruption past future result loss revenue loss critical sensitive information company company thirdparty provider database system past future result financial legal business reputational harm company substantial remediation cost company grow use artificial intelligence ai system automate process analyze data support decisionmake pose inherent risk flaw bias malfunction system lead operational disruption datum loss erroneous decisionmake impact company business operation financial condition reputation ethical legal challenge arise include bias discrimination ai outcome non compliance datum protection regulation lack transparency furthermore deployment ai system expose company increase cybersecurity threat datum breach unauthorized access lead financial loss legal liability reputational damage company face competitive risk fail adopt ai machine learn technology timely fashion social medium mobile messaging platform present risk challenge inappropriate andor unauthorized use certain social medium mobile message channel cause brand damage information leakage lead legal implication include improper collection andor dissemination personally identifiable information addition negative inaccurate post comment company product social networking platform damage company reputation brand image goodwill disclosure nonpublic companysensitive information company workforce external medium channel lead information loss internal company social medium mobile message policy guide employee appropriate personal professional use platform communication company process place completely secure protect information identify new point entry new communication tool expand present new challenge cautionary factor affect future result cautionary statement private security litigation reform act report write report oral statement time time company contain socalled forwardlooke statement base management current expectation subject risk uncertainty cause result differ materially set forth statement identify forwardlooke statement use word anticipate expect plan estimate forecast project word similar meaning negative variation forego identify fact relate strictly historical current fact statement likely address company growth strategy financial result product approval product potential development program environmental sustainability initiative carefully consider statement understand factor cause actual result differ materially company forwardlooke statement factor include inaccurate assumption broad variety risk uncertainty include know forwardlooke statement guarantee actual future result vary materially company assume obligation update forwardlooke statement company caution place undue reliance forwardlooke statement possible predict identify factor include follow competition generic andor biosimilar product company product lose patent protection increase brand competition therapeutic area important company longterm business performance difficulty uncertaintie inherent new product development outcome lengthy complex process new product development inherently uncertain drug candidate fail stage table content process latestage product candidate fail receive regulatory approval new product candidate appear promise development fail reach market efficacy safety concern inability obtain necessary regulatory approval difficulty excessive cost manufacture andor infringement patent intellectual property right furthermore sale new product prove disappointing fail reach anticipate level price pressure abroad include rule practice manage care group judicial decision governmental law regulation relate medicare medicaid health care reform pharmaceutical reimbursement pricing general change government law regulation include law govern intellectual property enforcement thereof affect company business efficacy safety concern respect market product scientifically justified lead product recall withdrawal decline sale significant change customer relationship change behavior spend pattern purchaser health care product service include delay medical procedure ration prescription medication reduce frequency physician visit forego health care insurance coverage legal factor include product liability claim antitrust litigation governmental investigation include tax dispute environmental concern patent dispute brand generic competitor preclude commercialization product negatively affect profitability exist product cyberattack company thirdparty provider information technology system disrupt company operation lose market opportunity result delay uncertaintie approval process fda andor foreign regulatory authority increase focus privacy issue country world include eu china legislative regulatory landscape privacy datum protection continue evolve increase focus privacy datum protection issue potential affect directly company business include law majority state require security breach notification change tax law include change relate taxation foreign earning change accounting pronouncement promulgate standardsette regulatory body include financial accounting standard board sec adverse company economic factor company control include change inflation interest rate foreign currency exchange rate list consider exhaustive statement potential risk uncertainty risk factor item b unresolved staff comment item c cybersecurity company cybersecurity measure primarily focus ensure security protection information technology system datum companys information security program manage dedicated chief information security officer ciso group responsible lead enterprisewide cybersecurity risk management strategy policy standard architecture process ciso work cybersecurity national security field year master science telecommunication computer serve board member health information share analysis center year oversight information security program integrate company overall enterprise risk management program ciso provide periodic report audit committee audit committee board director board board company chief executive officer member senior management appropriate report include update company cybersecurity risk threat status project intend strengthen information security system assessment information security program include remediation mitigation management identify vulnerability emerge threat landscape information security program regularly evaluate internal external consultant auditor table content result review report senior management audit committee comprise entirely independent director oversight responsibility risk companys information security group monitor company information system prevent detect mitigate remediate cybersecurity incident company use tool technique continually assess monitor manage mitigate cybersecurity threat systems manner consistent industry practice company engage key vendor industry participant intelligence law enforcement community continue effort obtain current threat intelligence collaborate security enhancement evaluate improve effectiveness information security program program company conduct periodic tabletop exercise assess cybersecurity incident response process company maintain vendor management diligence oversight process identify monitor potential risk cybersecurity threat attendant use thirdparty service provider additionally company monitor cybersecurity threat intelligence receive key thirdparty service provider associate company event cybersecurity incident company process place member security group alert ciso ciso alert appropriate level management include incident assessment team legal finance department materiality event assess furtherance fulfil reporting requirement warrant senior management notify audit committee board appropriate company continue target cyberattack network disruption date risk pose cybersecurity threat materially affected company business strategy result operation financial condition date report company aware material risk cybersecurity threat reasonably likely assurance company materially affect risk future information item risk factor company increasingly dependent sophisticated software application compute infrastructure company continue target cyberattack lead disruption worldwide operation include manufacture research sale operation item property companys corporate headquarters locate rahway new jersey company maintain divisional headquarters upper gwynedd pennsylvania principal research facility locate rahway kenilworth new jersey west point pennsylvania boston cambridge massachusetts south san francisco california elkhorn nebraska animal health principal research facility outside locate united kingdom switzerland china mercks manufacturing operation currently headquarter rahway new jersey company production facility human health product location puerto rico outside subsidiary company own interest manufacturing plant property western europe africa asia company subsidiarie principal facility manufacturing plant title consider satisfactory company believe property good operating condition machinery equipment maintain company believe plant manufacture product suitable intend purpose capacity project capacity include previously disclose capital expansion project adequate current project need exist company product capacity plant convert need modification requirement newly introduce future product item legal proceeding information call item incorporate reference item financial statement supplementary datum note contingency environmental liability item safety disclosure applicable table content executive officer registrant age february officer list serve pleasure board director officer elect pursuant arrangement understand officer person age office business experience robert davis chairman chief executive officer president december chief executive officer president july december executive vice president global services chief financial officer april july sanat chattopadhyay executive vice president president merck manufacturing division march richard r deluca jr executive vice president president merck animal health september cristal downing executive vice president chief communication public affair officer august prior vice president medical devices global communication public affairs johnson johnson december august vice president financial communication johnson johnson january december chirfi guindo senior vice president chief marketing officer human health july prior executive vice president head global product strategy commercialization biogen inc july july michael klobuchar executive vice president chief strategy officer july senior vice president cfo merck rd head global portfolio alliance management january june dean li executive vice president president merck research laboratory january senior vice president discovery sciences translational medicine merck research laboratory november january caroline litchfield executive vice president chief financial officer april senior vice president corporate treasurer january march steven c mizell executive vice president chief human resource officer october johannes j oosthuizen senior vice president president merck human health january senior vice president head global oncology commercial january december senior vice president president msd kk july december joseph romanelli senior vice president president msd international human health july prior chief executive officer jixing pharmaceuticals july july president msd china december july dalton smart senior vice president finance global controller december vice president assistant controller september december vice president internal audit march september david williams executive vice president chief information digital officer august act chief information digital officer december august vice president chief information officer merck animal health december jennifer zachary executive vice president general counsel april february company announce steven c mizell chief human resource officer retire company effective july february company announce ms betty larson join company assume role chief human resource officer effective begin april time ms larson mr mizell cease executive officer company mr mizell remain strategic advisory role company retirement age office business experience betty larson chief people officer ge healthcare february executive vice president chief human resource officer becton dickinson june february table content ii item market registrant common equity relate stockholder matter issuer purchase equity security principal market trading company common stock new york stock exchange nyse symbol mrk january approximately shareholder record company common stock issuer purchase equity security month end december follow issuer purchase equity security total number million share purchase total number average price publicly approximate dollar value share share pay announce plan purchase period purchase share program plan programs october october november november december december total share purchase period plan approve board director october purchase billion merck share treasury table content performance graph follow graph assume investment december reinvestment dividend companys common stock sp index composite peer group major europeanbase pharmaceutical company abbvie inc amgen inc astrazeneca plc bristolmyers squibb company johnson johnson eli lilly company gilead sciences inc glaxosmithkline plc novartis ag pfizer inc roche holding ag sanofi sa comparison fiveyear cumulative total return merck co inc composite peer group sp index end period value cagr merck peer group sp merck peer group sp compound annual growth rate peer group average calculate market cap weight basis december performance graph deem incorporate reference file security act securities exchange act extent company specifically incorporate reference addition performance graph deem soliciting material file sec subject regulation c provide regulation sk liabilities section securities exchange act extent company specifically request information treat soliciting material specifically incorporate reference filing security act exchange act item reserve table content item management discussion analysis financial condition result operation follow section generally discuss result yeartoyear comparison discussion result yeartoyear comparison include find ii item management discussion analysis financial condition result operation company annual report fiscal year end december file february description mercks business merck co inc merck company global health care company deliver innovative health solution prescription medicine include biologic therapy vaccine animal health product company operation principally manage product basis include operate segment pharmaceutical animal health reportable segment pharmaceutical segment include human health pharmaceutical vaccine product human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution human health vaccine product consist preventive pediatric adolescent adult vaccine company sell human health vaccine primarily physicians wholesaler distributor government entity animal health segment discover develop manufacture market wide range veterinary pharmaceutical vaccine product health management solution service prevention treatment control disease major livestock companion animal specie company offer extensive suite digitally connect identification traceability monitoring product company sell product veterinarian distributor animal producer farmer pet owner june merck complete spinoff product women health biosimilar establish brand business new independent publicly trade company name organon co organon distribution organon publicly trade stock company shareholder establish brand include transaction consist dermatology nonopioid pain management respiratory select cardiovascular product rest merck diversify brand franchise historical result business contribute organon spinoff reflect discontinued operation company consolidate financial statement date spinoff note consolidated financial statement overview financial highlight change exclude change foreign exclude foreign million share amount change exchange change exchange sale net income continue operation attributable merck co inc gaap nongaap earning common share assume dilution continue operation attributable merck co inc common shareholder gaap nongaap nongaap net income nongaap earning share eps exclude acquisition divestiturerelate cost restructure cost income loss investment equity security certain item merck result prepare accordance generally accept accounting principle gaap discussion reconciliation gaap nongaap net income eps nongaap income nongaap ep continue operation executive summary merck performance reflect strong execution sciencele strategy company benefit strong underlying demand innovative portfolio discipline investment leverage table content lead edge science advance broad pipeline include grow diversity new therapeutic area modality additionally merck complete strategic business development transaction return capital shareholder primarily dividend worldwide sale billion increase compare exclude unfavorable effect foreign exchange sale increase primarily growth oncology vaccine hospital acute care animal health partially offset decline virology drive low sale covid medication lagevrio diabetes merck continue execute strategic business development opportunitie augment robust internal pipeline compel external science highlight activity include follow enter global development commercialization agreement daiichi sankyos deruxtecan dxd antibody drug conjugate adc candidate stage clinical development treatment multiple solid tumor monotherapy andor combination treatment acquire prometheus biosciences inc prometheus clinicalstage biotechnology company pioneer precision medicine approach discovery development commercialization novel therapeutic companion diagnostic product treatment immunemediate disease include ulcerative colitis crohns disease autoimmune condition close license collaboration agreement expand company relationship kelunbiotech pursuant merck gain exclusive right research development manufacture commercialization investigational preclinical adcs treatment cancer kelunbiotech retain right certain license option adcs chinese mainland hong kong macau acquire imago biosciences inc imago clinicalstage biopharmaceutical company develop new medicine treatment myeloproliferative neoplasm bone marrow disease company receive regulatory approval major market include numerous regulatory approval oncology keytruda receive approval additional indication andor internationally monotherapy therapeutic area nonsmallcell lung cancer nsclc primary mediastinal large bcell lymphoma pmbcl combination chemotherapy therapeutic area biliary tract cancer gastric gastroesophageal junction gej adenocarcinoma nsclc combination padcev enfortunab vedotinejfv advanced urothelial cancer lynparza develop collaboration astrazeneca plc astrazeneca receive approval combination abiraterone prednisone prednisolone japan combination abiraterone prednisolone treatment certain adult patient brcamutate brcam metastatic castrationresistant prostate cancer mcrpc welireg approve supplemental indication treatment adult patient advance renal cell carcinoma rcc follow program death receptor pd program deathligand pdl inhibitor vascular endothelial growth factor tyrosine kinase inhibitor vegftki additionally prevymis approve supplemental indication eu prophylaxis prevention cytomegalovirus cmv disease certain adult kidney transplant recipient high risk addition recent regulatory approval discuss company advanced latestage pipeline regulatory submission mk sotatercept novel investigational activin signal inhibitor priority review food drug administration fda review european medicine agency treatment adult patient pulmonary arterial hypertension pah table content v investigational valent pneumococcal conjugate vaccine prevention invasive pneumococcal disease pneumococcal pneumonia adult priority review fda mk patritumab deruxtecan adc evaluate treatment certain type nsclc priority review fda patritumab deruxtecan collaboration daiichi sankyo additionally keytruda review andor international market supplemental indication treatment certain patient biliary tract cervical endometrial gastric nonsmallcell lung urothelial cancer welireg review eu treatment certain patient advance rcc treatment von hippellindau disease company initiate phase study multiple asset class include progression novel candidate company diversify oncology portfolio execute strategy broadly base strategic pillar immunooncology precision molecular target tissue target merck phase oncology program pillar follow immunooncology keytruda therapeutic area cutaneous squamous cell hepatocellular mesothelioma ovarian smallcell lung cancer mka coformulation quavonlimab merck novel investigational antictla antibody pembrolizumab rcc mka subcutaneous coformulation pembrolizumab hyaluronidase certain type nsclc mka coformulation favezelimab merck novel investigational antilag therapy pembrolizumab colorectal cancer hematological malignancy mka coformulation vibostolimab antitigit therapy pembrolizumab certain type melanoma nonsmallcell smallcell lung cancer v investigational individualized neoantigen therapy combination keytruda certain type melanoma nsclc develop collaboration moderna precision molecular target lynparza combination keytruda nonsmallcell lung smallcell lung cancer lenvima develop collaboration eisai co ltd eisai combination keytruda certain type esophageal gastric cancer mk nemtabrutinib oral reversible noncovalent bruton tyrosine kinase btk inhibitor hematological malignancies mk bomedemstat investigational orally available lysinespecific demethylase inhibitor myeloproliferative disorder mk investigational cytochrome p cypa inhibitor develop collaboration orion corporation orion mcrpc tissue target mk investigational trophoblast cellsurface antigen tropdirecte adc develop collaboration kelunbiotech endometrial carcinoma certain type nsclc additionally company currently candidate phase clinical development therapeutic area include mk investigational oral proprotein convertase subtilisinkexin type pcsk inhibitor hypercholesterolemia mk clesrovimab human monoclonal antibody prevention respiratory syncytial virus rsv mk tulisokibart humanize monoclonal antibody direct tumor necrosis factorlike ligand target associate intestinal inflammation fibrosis ulcerative colitis table content mka islatravir investigational nucleoside reverse transcriptase translocation inhibitor combination doravirine treatment hiv infection partial clinical hold high dose current clinical trial mk lagevrio reflect phase development remain investigational follow emergency use authorization eua merck capital allocation strategy continue prioritize investment business drive near longterm growth include invest opportunity address important unmet medical need support company commercial opportunity addition merck remain committed dividend continue pursue compelling external science technology valueenhance business development transaction research development expense reflect high charge business development transaction increase development spend particularly therapeutic area oncology cardiovascular infectious disease vaccine november mercks board director approve increase company quarterly dividend raising share share company outstanding common stock company return billion shareholder dividend billion share repurchase billion gaap nongaap eps negatively affect respectively charge certain upfront preapproval milestone payment relate collaboration license agreement charge relate preapproval asset obtain transaction account asset acquisition price global effort health care cost containment continue exert pressure product pricing market access worldwide change health care system enact prior year health care reform increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary contribute pricing pressure international market governmentmandate pricing action reduce price generic patent drug addition company sale performance negatively affect costreduction measure take government party low health care cost congress pass inflation reduction act ira make significant change drug cover pay medicare program include creation financial penalty drug price rise fast rate inflation redesign medicare program require manufacturers bear liability certain drug benefit government pricesette certain medicare drug start medicare b drug start august department health human service hhs center medicare medicaid services cms announced januvia include year iras drug price negotiation program program pursuant iras program discussion government occur continue government pricesetting effective january company sue government iras program note consolidated financial statement furthermore biden table content administration congress continue discuss legislation design control health care cost include cost drug company anticipate action additional action future negatively affect sale profit operate result sale change change exclude foreign exclude foreign million change exchange change exchange united states international total worldwide sale grow billion primarily high sale oncology franchise largely strong growth keytruda welireg increase alliance revenue lenvima lynparza contribute revenue growth high sale vaccine franchise primarily attributable growth combine sale gardasilgardasil ongoing launch vaxneuvance pediatric use high sale hospital acute care product include prevymis bridion high sale animal health product drive revenue growth sale growth largely offset low sale virology franchise largely lagevrio isentressisentress hd low sale diabete franchise januvia janumet low sale pneumovax vaccine low revenue thirdparty manufacturing arrangement offset sale growth sale grow billion primarily drive high sale keytruda vaxneuvance bridion welireg revenue growth partially offset low sale lagevrio pneumovax janumet januvia low revenue thirdparty manufacturing arrangement international sale decline primarily low sale lagevrio januvia janumet isentressisentress hd international sale decline largely offset high combine sale gardasilgardasil high sale keytruda prevymis vaxneuvance international sale represent total sale respectively note consolidated financial statement detail sale company product discussion performance select product franchise follow pharmaceutical segment oncology change change exclude foreign exclude foreign million change exchange change exchange keytruda alliance revenue lynparza alliance revenue lenvima welireg alliance revenue reblozyl alliance revenue represent merck share profit product sale net cost sale commercialization cost note consolidated financial statement alliance revenue represent royalty include payment receive related achievement regulatory approval milestone note consolidated financial statement keytruda antipd therapy approve indication include tumor type tumoragnostic indication similarly approve market worldwide indication keytruda clinical development program include study broad range cancer type global sale keytruda grow primarily drive high demand reflect launch multiple new indication globally couple continue uptake exist indication sale growth reflect increase uptake earlierstage indication include highrisk earlystage triplenegative breast cancer tnbc certain type rcc melanoma high demand multiple approve table content metastatic indication particular treatment certain type rcc nsclc tnbc head neck squamous cell carcinoma hnscc endometrial bladder cancer high pricing keytruda sale growth international market reflect high demand predominately tnbc rcc earlierstage indication uptake hnscc rcc metastatic indication particularly europe latin america asia pacific region include japan summarize keytruda regulatory approval receive date date approval fda approval single agent adjuvant treatment follow surgical resection platinumbase chemotherapy adult patient january stage ib ta cm ii iiia nsclc base keynote trial fda approval treatment adult pediatric patient unresectable metastatic microsatellite instabilityhigh msih mismatch repair deficient dmmr solid tumor progress follow prior treatment satisfactory alternative march treatment option conversion accelerate regular approval base keynote keynote keynote trial fda accelerate approval combination padcev enfortumab vedotinejfv treatment adult patient locally advanced april metastatic urothelial carcinoma eligible cisplatincontaine chemotherapy base keynote trial dose escalation cohort cohort cohort k conduct collaboration seagen pfizer inc pfizer astellas june japans ministry health labor welfare mhlw approval treatment patient relapse refractory pmbcl base keynote keynotea studies european commission ec approval combination trastuzumab fluoropyrimidine platinumcontaine chemotherapy august firstline treatment locally advanced unresectable metastatic human epidermal growth factor receptor herpositive gastric gej adenocarcinoma adult tumor express pdl base keynote trial china national medical products administration nmpa approval monotherapy treatment adult patient advance unresectable metastatic msih dmmr solid tumor include patient colorectal cancer progress follow treatment september fluoropyrimidine oxaliplatin irinotecan solid tumor progress follow prior therapy satisfactory alternative treatment option base keynote keynote trial ec approval monotherapy adjuvant treatment adult nsclc high risk recurrence follow complete october resection platinumbase chemotherapy base keynote trial fda approval treatment patient resectable tumor cm node positive nsclc combination platinum october contain chemotherapy neoadjuvant treatment continue single agent adjuvant treatment surgery base keynote trial fda approval treatment adult pediatric patient recurrent locally advanced metastatic merkel cell carcinoma october conversion accelerate regular approval base keynote keynote trial fda approval combination gemcitabine cisplatin treatment patient locally advance unresectable metastatic october biliary tract cancer base keynote trial fda approval combination fluoropyrimidine platinumcontaine chemotherapy firstline treatment adult locally november advance unresectable metastatic hernegative gastric gej adenocarcinoma base keynote trial fda approval combination padcev enfortumab vedotinejfv adc treatment adult patient locally advanced december metastatic urothelial cancer conversion accelerate regular approval base keynotea trial conduct collaboration seagen pfizer astella ec approval combination fluoropyrimidine platinumcontaine chemotherapy firstline treatment locally advanced december unresectable metastatic hernegative gastric gej adenocarcinoma adult tumor express pdl base keynote trial ec approval combination gemcitabine cisplatin firstline treatment locally advanced unresectable metastatic biliary december tract carcinoma adult base keynote trial table content china nmpa approval combination fluoropyrimidine platinumcontaine chemotherapy firstline treatment patient december locally advanced unresectable metastatic hernegative gastric gej adenocarcinoma base keynote trial fda approval combination chemoradiotherapy treatment patient figo international federation gynecology january obstetrics stage iiiiva cervical cancer base keynotea trial fda approval treatment patient hepatocellular carcinoma hcc secondary hepatitis b receive prior january systemic therapy pdpdl contain regimen conversion accelerate regular approval base keynote trial chinas nmpa approval combination gemcitabine cisplatin firstline treatment patient locally advanced february metastatic biliary tract carcinoma base keynote trial company party certain thirdparty license agreement pursuant company pay royalty sale keytruda term significant agreement merck pay royalty worldwide sale keytruda december party royalty decline terminate company pay additional royalty worldwide sale keytruda party termination date vary country royalty expire september vary date major european market second half royalty include cost sale lynparza oral poly adpribose polymerase parp inhibitor develop collaboration astrazeneca note consolidated financial statement lynparza approve treatment certain type advance recurrent ovarian early metastatic breast metastatic pancreatic metastatic castrationresistant prostate cancer alliance revenue relate lynparza grow largely high price high demand international market lynparza receive follow regulatory approval summarize date approval fda approval combination abiraterone prednisone prednisolone treatment adult patient deleterious suspect deleterious brcam mcrpc base propel trial august japans mhlw approval combination abiraterone prednisolone treatment adult patient brcam mcrpc distant metastasis base propel trial lenvima oral receptor tyrosine kinase inhibitor develop collaboration eisai note consolidated financial statement lenvima approve treatment certain type thyroid cancer rcc hcc combination everolimus certain patient advance rcc combination keytruda certain patient advance endometrial carcinoma advance rcc alliance revenue relate lenvima grow reflect high demand price high demand europe partially offset low demand china sale welireg treatment adult patient certain von hippellindau diseaseassociate tumor certain adult patient previously treat advanced rcc increase continued uptake follow launch december fda approve supplemental new drug application nda welireg treatment adult patient advance rcc follow pd pdl inhibitor vegftki base litespark clinical trial reblozyl firstinclass erythroid maturation recombinant fusion protein obtain merck november acquisition acceleron pharma inc acceleron commercialize global collaboration bristol myers squibb company bm note consolidated financial statement reblozyl approve treatment anemia certain rare blood disorder alliance revenue relate collaboration consist royalty include receipt regulatory approval milestone payment million alliance revenue increase strong underlying sale performance partially offset receipt regulatory approval milestone note table content vaccine change change exclude foreign exclude foreign million change exchange change exchange gardasilgardasil proquad mmr ii varivax vaxneuvance pneumovax combine worldwide sale gardasil gardasil vaccine help prevent certain cancer disease cause certain type human papillomavirus hpv grew drive strong demand outside particularly china continue uptake expand indication gardasil girl woman year age sale gardasil increase slightly high pricing demand largely offset public sector buy pattern company party certain thirdparty license agreement pursuant company pay royalty sale gardasilgardasil term significant agreement merck pay royalty sale gardasilgardasil party royalty expire december merck pay additional royalty worldwide sale gardasilgardasil party expire december royalty include cost sale global sale proquad pediatric combination vaccine help protect measle mump rubella varicella grow primarily high pricing partially offset low demand europe worldwide sales mmr ii vaccine help protect measle mump rubella grow primarily high demand certain international market high pricing partially offset low demand global sale varivax vaccine help prevent chickenpox varicella grow primarily attributable high pricing demand high demand asia pacific region partially offset low demand latin america worldwide sale vaxneuvance vaccine help protect invasive pneumococcal disease increase million primarily continued uptake pediatric indication launch european market vaxneuvance currently launch market additional launch plan merck party thirdparty license agreement pursuant company pay royalty net sale vaxneuvance royalty decline net sale royalty include cost sale worldwide sale pneumovax vaccine help prevent pneumococcal disease decline low demand market continue shift new adult pneumococcal conjugate vaccine follow change recommendation center disease control prevention advisory committee immunization practice company expect decline sale pneumovax continue pneumovax sale decline partially offset high demand international market hospital acute care change change exclude foreign exclude foreign million change exchange change exchange bridion prevymis dificid global sale bridion reversal type neuromuscular block agent surgery grew reflect high demand attributable bridion increase share neuromuscular blockade reversal agent high pricing partially offset generic competition table content international market particularly eu patent provide market exclusivity bridion eu expire july accordingly company experience sale decline bridion market expect decline continue patent provide market exclusivity bridion japan expire january company anticipate sale bridion japan decline future period worldwide sale prevymis medicine prophylaxis prevention cmv infection disease certain high risk adult recipient allogenic hematopoietic stem cell transplant prophylaxis cmv disease certain high risk adult recipient kidney transplant grow largely high demand europe continue uptake launch china june fda approve prevymis prophylaxis cmv disease certain adult kidney transplant recipient high risk follow priority review base p clinical trial november ec approve prevymis indication worldwide sale dificid treatment c difficileassociate diarrhea grow high demand cardiovascular change change exclude foreign exclude foreign million change exchange change exchange alliance revenue adempasverquvo adempas alliance revenue represent merck share profit sale bayer marketing territory product sale net cost sale commercialization cost note consolidated financial statement adempas verquvo worldwide collaboration bayer ag bayer market develop soluble guanylate cyclase sgc modulator note consolidated financial statement adempas approve treatment certain type pah chronic pulmonary hypertension verquvo approve reduce risk cardiovascular death heart failure hospitalization follow hospitalization heart failure need outpatient intravenous diuretic adult symptomatic chronic heart failure reduce ejection fraction verquvo approve eu japan approve market alliance revenue collaboration grow reflect high profit sharing reflect increase demand bayer marketing territory revenue include sale adempas verquvo merck marketing territory sale adempas merck marketing territory grew primarily reflect high demand virology change change exclude foreign exclude foreign million change exchange change exchange lagevrio isentressisentress hd lagevrio investigational oral antiviral covid medicine develop collaboration ridgeback biotherapeutic lp ridgeback note consolidated financial statement follow initial authorization certain market fourth quarter lagevrio receive multiple additional authorization sales lagevrio decline billion compare billion decline sale lagevrio primarily reflect sale lagevrio uk recur low sale japan australia sales lagevrio consist sale government november follow authorization fda company begin transition government supply commercial distribution lagevrio eua april japans mhlw grant approval lagevrio lagevrio previously grant special approval emergency japan december give company fulfil government purchase supply commitment lagevrio wane impact covid pandemic company expect sales lagevrio decline worldwide combine sale isentressisentress hd hiv integrase inhibitor use combination antiretroviral agent treatment hiv infection decline primarily competitive pressure particularly europe patent provide market exclusivity isentressisentress hd table content eu expire july accordingly company experience sale decline isentressisentress hd market result generic competition expect decline continue additionally company anticipate competitive pressure sale decline isentressisentress hd continue immunology change change exclude foreign exclude foreign million change exchange change exchange simponi remicade simponi remicade treatment certain inflammatory disease company market europe russia trkiye company marketing right respect product revert johnson johnson innovative medicine october diabetes change change exclude foreign exclude foreign million change exchange change exchange januviajanumet worldwide combine sale januvia janumet medicine help lower blood sugar level adult type diabete decline primarily reflect ongoing impact loss exclusivity market europe asia pacific region canada couple low demand low price competitive pressure key patent januvia janumet claim sitagliptin compound expire january result favorable court ruling settlement agreement relate later expire patent direct specific sitagliptin salt form product note consolidated financial statement company expect januvia janumet lose market exclusivity janumet xr lose market exclusivity july nonautomatically substitutable form sitagliptin differ form company sitagliptin product approve fda result competitive pressure company anticipate pricing volume decline januvia janumet continue august department hhs cms announce januvia include year iras program pursuant iras program discussion government occur continue government pricesetting effective january company sue government iras program note consolidated financial statement company lose market exclusivity januvia eu janumet european country september exclusivity janumet lose european country april accordingly company experience sale decline market expect decline continue company lose market exclusivity januvia china launch generic equivalent product additional generic equivalent product launch impact sale modest generic equivalent janumet approve china launch december settlement agreement company combine sale januvia janumet europe china represent respectively total combine januvia janumet sale response request regulatory authority merck evaluate sitagliptincontaine product presence nitrosamine nitrosamine organic compound find trace level water food nitrosamine result chemical reaction form drug drug manufacturing process chemical structure condition drug store package company detect nitrosamine identify nitrosostg nttp batch sitagliptincontaine medicine company engage major health authority world implement additional quality control ensure portfolio sitagliptincontaine product meet health authority interim acceptable nttp limit continue distribution product market company significant progress reduce level nitrosamine sitagliptin contain medicine consistently release product major market expect comply health authority longterm limit product shelflife company anticipate product shortage time table content animal health segment change change exclude foreign exclude foreign million change exchange change exchange livestock companion animal sale livestock product grow primarily high pricing increase demand poultry swine product partially offset low demand ruminant product sale companion animal product grow reflect high pricing partially offset low demand sale bravecto line product billion increase compare exclude impact foreign exchange january ec approve injectable formulation bravecto dog persistent killing flea tick month treatment february merck enter definitive agreement acquire aqua business elanco animal health incorporate billion cash acquisition expect complete mid subject approval regulatory authority customary closing condition transaction account acquisition business note consolidated financial statement additional information relate transaction cost expense million change change cost sale sell general administrative research development restructuring cost income expense net cost sale cost sale billion billion cost sale include million billion respectively relate sale lagevrio develop collaboration ridgeback note consolidated financial statement cost sale include amortization intangible asset record connection acquisition collaboration license arrangement total billion amortization expense include million million respectively cumulative catchup amortization relate merck collaboration eisai astrazeneca respectively note consolidated financial statement include cost sale expense associate restructuring activity amount million million primarily reflect accelerated depreciation asset writeoff relate plan sale closure manufacturing facility separation cost associate manufacturingrelate headcount reduction incur reflect restructure cost discuss gross margin compare gross margin improvement primarily reflect favorable impact product mix include low lagevrio sale low revenue thirdparty manufacturing arrangement low gross margin lower manufacturingrelate cost partially offset unfavorable impact foreign exchange sell general administrative selling general administrative sga expense billion increase compare increase primarily high administrative cost include compensation benefit increase promotional spending selling cost partially offset favorable effect foreign exchange low acquisitionrelate cost table content research development research development rd expense billion compare billion increase primarily high charge business development activity include charge billion acquisition prometheus billion relate formation collaboration daiichi sankyo billion acquisition imago compare charge million aggregate record relate collaboration licensing agreement moderna orna therapeutic orion increase rd expense attributable high development spending include recently acquire program high compensation benefit cost reflect increase headcount increase rd expense partially offset low intangible asset impairment charge rd expense comprise cost directly incur merck research laboratory mrl company research development division focus human healthrelated activity billion billion include rd expense animal health research cost upfront payment collaboration licensing agreement include charge daiichi sankyo moderna orna orion transaction note charge transaction account asset acquisition include charge prometheus imago note cost incur division support rd activity include depreciation production general administrative aggregate billion billion rd expense include impairment charge million relate gefapixant billion largely relate nemtabrutinib note consolidated financial statement additional information relate impairment charge company recognize additional impairment charge future relate cancellation delay pipeline program measure fair value capitalize connection business combination charge material restructuring cost january company approve new restructure program restructuring program intend continue optimization company human health global manufacturing network future pipeline shift new modality optimize animal health global manufacturing network improve supply reliability increase efficiency action contemplate restructuring program expect substantially complete end cumulative pretax cost incur company implement program estimate approximately billion approximately cumulative pretax cost noncash relate primarily accelerate depreciation facility close divested remainder cost result cash outlay relate primarily facility shutdown cost company expect record charge approximately million related restructuring program company anticipate action restructure program result cumulative annual net cost saving approximately million end merck approve global restructuring program restructuring program worldwide initiative focus optimize company manufacture supply network reduce global real estate footprint action restructure program substantially complete restructuring cost million million include separation cost associate restructuring activity separation cost incur associate actual headcount reduction estimate expense exist severance program involuntary headcount reduction probable reasonably estimate expense restructure cost include facility shutdown relate cost employeerelate cost curtailment settlement termination charge associate pension postretirement benefit plan sharebase compensation plan cost segment report restructuring cost unallocated expense additional cost associate company restructuring activity include cost sale sell general administrative expense research development cost company record aggregate pretax cost related restructuring program activity million million related restructuring program million note consolidated financial statement additional detail income expense net income expense net million expense compare billion expense change primarily net gain investment equity security record compare net loss investment equity security record low pension settlement cost partially offset million charge relate settlement certain plaintiff zetia antitrust litigation note consolidated financial statement high foreign exchange loss table content detail component income expense net note consolidated financial statement segment profit million pharmaceutical segment profit animal health segment profit income continue operation taxis pharmaceutical segment profit comprise segment sale standard cost sga expense directly incur segment animal health segment profit comprise segment sale cost sale sga rd expense directly incur segment internal management reporting present chief operating decision maker merck allocate remain cost sale include segment profit describe rd expense incur mrl general administrative expense directly incur segment cost financing activity separate division maintain responsibility monitor managing cost include depreciation relate fix asset utilize division include segment profit exclude determination segment profit cost related restructuring activity acquisition divestiturerelated cost include amortization intangible asset amortization purchase accounting adjustment intangible asset impairment charge expense income relate change estimate fair value measurement liability contingent consideration additionally segment profit reflect expense corporate manufacturing cost center miscellaneous income expense unallocated item reflect table include miscellaneous corporate profit loss operate profit loss relate thirdparty manufacture arrangement pharmaceutical segment profit grow primarily high sale partially offset high administrative promotional cost unfavorable effect foreign exchange animal health segment profit decline reflect high production cost high inventory writeoff increase administrative promotional cost unfavorable effect foreign exchange taxis income effective income tax rate continue operation high tax rate continue operation include percentage point combine unfavorable impact charge acquisition prometheus imago tax benefit recognize daiichi sankyo collaboration charge reduce domestic pretax income approximately billion addition tax rate continue operation reflect high foreign taxis impact rd capitalization provision tax cut job act tcja company global intangible lowtaxed income inclusion partially offset favorable mix income expense high foreign tax credit tax rate continue operation reflect favorable mix income expense tax rate continue operation reflect favorable impact net unrealized loss investment equity security intangible asset impairment charge tax tax rate item reduce domestic pretax income approximately billion jurisdiction merck operate adopt global minimum tax provision organisation economic cooperation development oecd pillar effective tax year begin january company anticipate minimal impact tax rate accounting tax effect intercompany transaction company expect impact global minimum tax increase tax rate great extent event provision tcja require capitalization amortization rd expense tax purpose repeal line recently propose tax relief american family worker act company able realize benefit rd expense incur expect material impact effective income tax rate table content nongaap income nongaap ep continue operation nongaap income nongaap ep alternative view company performance merck provide management believe information enhance investor understand company result management use nongaap measure assess performance nongaap income nongaap eps exclude certain item nature item impact analysis underlie business performance trend exclude item consider nonrecurre consist acquisition divestiturerelate cost restructure cost income loss investment equity security certain item exclude item significant component understand assess financial performance nongaap income nongaap ep important internal measure company senior management receive monthly analysis operating result include nongaap eps metric management use nongaap measure internally plan forecasting purpose measure performance company metric addition annual employee compensation include senior management compensation derive nongaap pretax income metric nongaap income nongaap ep measure determine accordance gaap standardize mean prescribed gaap comparable calculation similar measure company information nongaap income nongaap eps consider addition substitute superior net income ep prepared accordance gaap reconciliation gaap financial measure nongaap financial measure continue operation follow million share amount income continue operation taxis report gaap increase decrease exclude item acquisition divestiturerelated cost restructure cost income loss investment equity security net item charge zetia antitrust litigation settlement charge discontinuation covid development program nongaap income continue operation taxis tax income continue operation report gaap estimate tax benefit exclude item net tax benefit settlement certain federal income tax matter nongaap tax income continue operation nongaap net income continue operation net income attributable noncontrolle interest report gaap nongaap net income continue operation attributable merck co inc eps assume dilution continue operation report gaap ep difference nongaap ep assume dilution continue operation amount include million billion million respectively intangible asset impairment charge estimate tax impact exclude item determine apply statutory rate originate territory nongaap adjustment gaap nongaap eps negatively affect respectively charge certain upfront preapproval milestone payment relate collaboration license agreement charge relate preapproval asset obtain transaction account asset acquisition acquisition divestiturerelated cost nongaap income nongaap eps exclude impact certain amount record connection acquisition divestiture business amount include amortization intangible asset amortization purchase accounting adjustment inventory intangible asset impairment charge table content expense income relate change estimate fair value measurement liability contingent consideration exclude integration transaction certain cost associate acquisition divestiture nongaap income nongaap eps exclude amortization intangible asset relate collaboration license arrangement restructuring cost nongaap income nongaap eps exclude cost relate restructuring action note consolidated financial statement amount include employee separation cost accelerate depreciation associate facility close divested accelerated depreciation cost represent difference depreciation expense recognize revise useful life asset base anticipate date site close divest equipment dispose depreciation expense determine utilize useful life prior restructure action restructure cost include asset abandonment facility shutdown relate cost employeerelate cost curtailment settlement termination charge associate pension postretirement benefit plan sharebase compensation cost income loss investment equity security nongaap income nongaap eps exclude realize unrealized gain loss investment equity security own directly ownership interest investment fund certain item nongaap income nongaap eps exclude certain item item adjusted evaluate individual basis consider quantitative qualitative aspect typically consist item unusual nature significant result particular period indicative future operating result exclude nongaap income nongaap eps charge relate settlement certain plaintiff zetia antitrust litigation note consolidated financial statement charge relate discontinuation covid development program net tax benefit relate settlement certain federal income tax matter note consolidated financial statement research development research pipeline company currently candidate regulatory review internationally latestage clinical development chart reflect company current research pipeline february relate discussion set forth item business research development acquisition research collaboration licensing agreement merck continue remain focused pursue opportunity potential drive near longterm growth certain recent transaction summarize additional detail include note note consolidated financial statement merck actively monitor landscape growth opportunity meet company strategic criterion january merck enter agreement acquire harpoon therapeutics inc harpoon clinicalstage immunotherapy company develop novel class tcell engager design harness power bodys immune system treat patient suffer cancer disease term agreement merck acquire outstanding share harpoon share cash approximate total equity value million harpoon lead candidate hpn tcell engager target deltalike ligand dll inhibitory canonical notch ligand express high level smallcell lung cancer neuroendocrine tumor hpn currently evaluate phase clinical trial monotherapy patient advanced cancer associate expression dll combination atezolizumab patient certain type smallcell lung cancer closing acquisition expect half subject certain condition include approval merger harpoon stockholder expiration waiting period hartscottrodino antitrust improvement act customary condition propose transaction close company anticipate account acquisition asset company expect record charge approximately million research development expense close approximately share october merck daiichi sankyo enter global development commercialization agreement daiichi sankyos deruxtecan dxd adc candidate patritumab deruxtecan herdxd mk ifinatamab deruxtecan idxd mk raludotatug deruxtecan rdxd mk potentially firstinclass dxd adcs stage clinical development treatment multiple solid tumor monotherapy andor combination treatment company jointly develop table content potentially commercialize adc candidate worldwide japan daiichi sankyo maintain exclusive right daiichi sankyo solely responsible manufacturing supply term agreement merck upfront payment billion onetime continuation payment million daiichi sankyo additionally daiichi sankyo eligible receive future contingent salesbase milestone payment merck record aggregate pretax charge billion research development expense share relate transaction june merck acquire prometheus clinicalstage biotechnology company pioneer precision medicine approach discovery development commercialization novel therapeutic companion diagnostic product treatment immunemediate disease total consideration pay billion include billion cost settle sharebased equity award include million settle unvested equity award prometheus lead candidate tulisokibart mk pra humanize monoclonal antibody direct tumor necrosis factorlike ligand target associate intestinal inflammation fibrosis tulisokibart develop treatment immunemediate disease include ulcerative colitis crohns disease autoimmune condition phase clinical trial evaluate tulisokibart ulcerative colitis commence transaction account acquisition asset merck record net asset million charge billion research development expense share relate transaction future contingent payment associate acquisition february merck kelunbiotech close license collaboration agreement expand relationship merck gain exclusive right research development manufacture commercialization seven investigational preclinical adcs treatment cancer kelun biotech retain right research develop manufacture commercialize certain license option adcs chinese mainland hong kong macau merck upfront payment million record research development expense october merck notify kelun biotech terminate seven candidate agreement kelunbiotech remain eligible receive future contingent milestone payment tiere royalty future net sale commercialize adc product connection agreement merck invest million kelunbiotech share january january merck acquire imago clinicalstage biopharmaceutical company develop new medicine treatment myeloproliferative neoplasm bone marrow disease billion include payment settle sharebased equity award incur approximately million transaction cost imago lead candidate bomedemstat mk img investigational orally available lysinespecific demethylase inhibitor currently evaluate multiple clinical trial treatment essential thrombocythemia myelofibrosis polycythemia vera addition indication phase clinical trial evaluate bomedemstat treatment certain patient essential thrombocythemia underway transaction account acquisition asset merck record net asset million charge billion research development expense relate transaction future contingent payment associate acquisition acquire inprocess research development connection business combination company record fair value inprocess research project time acquisition reach technological feasibility december balance inprocess research development iprd billion primarily consist mk sotatercept billion mk nemtabrutinib million sotatercept review eu nemtabrutinib phase clinical development iprd project remain development subject inherent risk uncertaintie drug development possible company able successfully develop complete iprd program profitably commercialize underlie product candidate time period receive approval fda regulatory agency subject uncertainty significant delay approval process company failure obtain approval delay prevent company realize revenue product additionally iprd program require additional clinical trial datum previously anticipate program fail abandon development company recover fair value iprd record asset acquisition date circumstance occur company future operating result adversely affect company recognize impairment charge material company record iprd impairment charge research development expense million billion million respectively note consolidated financial statement table content additional research development require remain program reach technological feasibility cost complete research project depend project bring final stage development ultimately submit fda regulatory agency approval capital expenditure capital expenditure billion billion billion expenditure billion billion billion company invest billion capital expenditure half relate expenditure company plan invest approximately billion capital project billion relate investment include expand manufacturing capacity oncology vaccine animal health product depreciation expense billion billion billion billion billion billion relate location total depreciation expense include accelerate depreciation million million million respectively associate restructuring activity note consolidated financial statement analysis liquidity capital resource merck strong financial profile enable fund research development finance acquisition external alliance support inline product maximize upcoming launch provide significant cash return shareholder select datum millions work capital total debt total liability equity cash provide operating activity continue operation total debt decline work capital compare primarily reflect use cash investment fund business development activity partially offset strong operating performance cash proceed issuance longterm debt cash provide operating activity continue operation billion compare billion cash provide operating activity continue operation reduce upfront milestone option payment relate certain collaboration billion include payment relate formation collaboration daiichi sankyo compare billion cash provide operating activity continue operation reduce payment million previously disclose zetia antitrust settlement cash provide operating activity continue operation continue company primary source fund finance operating need excess cash serve primary source fund finance business development transaction capital expenditure dividend pay shareholder treasury stock purchase mandatory change rd capitalization rule effective tax year begin december relate tax cut job act tcja increase taxis company pay begin cash investing activity continue operation billion compare billion high use cash investing activity continue operation primarily acquisition prometheus imago partially offset high proceed sale security investment include proceed sale seagen inc common stock low capital expenditure low purchase security investment cash financing activity continue operation billion compare billion low use cash financing activity continue operation primarily proceed issuance debt low payment longterm debt partially offset treasury stock purchase high dividend pay shareholder low proceed exercise stock option company issue billion principal senior unsecured note company portion billion net proceed offer fund portion cash consideration pay acquisition prometheus include related fee expense remain net proceed general corporate purpose include repay commercial paper borrowing indebtedness upcoming maturity table content december company issue billion principal senior unsecured note merck portion net proceed offer general corporate purpose include repayment outstanding commercial paper borrowing include commercial paper borrowing connection mercks acquisition acceleron indebtedness allocate finance refinance project partnership company priority environmental social governance esg area company billion note mature accordance term repay company billion note companys billion note mature accordance term repay company billion note companys billion note mature accordance term repay company billion credit facility mature facility provide backup liquidity company commercial paper borrowing facility general corporate purpose company draw funding facility march company file security registration statement securities exchange commission sec automatic shelf registration process available wellknown seasoned issuer effective year effective november company execute unconditional guarantee exist debt subsidiary merck sharp dohme corp msd msd execute unconditional guarantee exist debt company exclude commercial paper include payment principal interest guarantee extend debt issue subsequent date november mercks board director increase quarterly dividend declare quarterly dividend share company outstanding common stock quarter pay january january board director declare quarterly dividend share company outstanding common stock second quarter payable april mercks board director authorize purchase billion merck common stock treasury treasury stock purchase authorization time limit time openmarket transaction block transaction exchange privately negotiate transaction company purchase billion approximately million share common stock treasury program december company remain share repurchase authorization billion company purchase share common stock program company purchase million common stock authorize share repurchase program company believe maintain conservative financial profile company place cash investment instrument meet high credit quality standard specify investment policy guideline guideline limit credit exposure issuer company participate offbalance sheet arrangement involve unconsolidated subsidiary provide financing potentially expose company unrecorde financial obligation company expect foreseeable liquidity capital resource requirement meet exist cash cash equivalent anticipate cash flow operation commercial paper borrowing longterm borrowing need merck believe source finance adequate meet future requirement company material cash requirement arise normal course business primarily include debt obligation interest payment note consolidated financial statement detail company debt obligation timing expect future principal interest payment tax liability connection enactment tcja company require pay onetime transition tax company elect pay period year permit tcja additionally company liability unrecognize tax benefit include interest penalty note consolidated financial statement information pertain transition tax liability unrecognize tax benefit operating lease note consolidated financial statement detail companys lease obligation timing expect future lease payment collaborationrelate payment company accrue liability contingent salesbase milestone payment relate collaboration astrazeneca eisai payment deem probable company remain subject achievement relate salesbase milestone additionally table content company accrue liability future continuation payment relate collaboration daiichi sankyo note consolidated financial statement additional information relate future payment purchase obligation purchase obligation enforceable legally bind obligation purchase good service include minimum inventory contract research development advertising purchase obligation include future inventory purchase company commit connection certain divestiture december company total purchase obligation billion billion estimate payable financial instrument market risk disclosure company manage impact foreign exchange rate movement interest rate movement earning cash flow fair value asset liability operational mean use financial instrument include derivative instrument significant portion company revenue earning foreign affiliate expose change foreign exchange rate objective account relate companys foreign currency risk management program interest rate risk management activity discuss foreign currency risk management company establish revenue hedge balance sheet risk management net investment hedging program protect volatility future foreign currency cash flow change fair value cause change foreign exchange rate objective revenue hedging program reduce variability cause change foreign exchange rate affect dollar value future cash flow derive foreign currency denominate sale primarily euro japanese yen chinese renminbi achieve objective company hedge portion forecast foreign currency denominate thirdparty intercompany distributor entity sale forecast sale expect occur planning cycle typically year future company layer hedge time increase portion forecast sale hedge get close expect date forecast sale portion forecast sale hedge base assessment cost benefit profile consider natural offset exposure revenue exchange rate volatility correlation cost hedging instrument company manage anticipate transaction exposure principally purchase local currency option forward contract purchase collar option fair value derivative contract record asset gain position liability loss position consolidate balance sheet change fair value derivative contract record period current earning comprehensive income loss oci depend derivative designate hedge transaction type hedge transaction derivative designate cash flow hedge unrealize gain loss contract record accumulate comprehensive loss aocl reclassify sale hedge anticipate revenue recognize derivative designate cash flow hedge serve economic hedge forecast sale unrealize gain loss record sale period cash flow designate nondesignate contract report operating activity consolidate statement cash flow company enter derivative trade speculative purpose merck principally sell foreign currency revenue hedging program uniform weaken dollar yield large overall potential loss market value hedge instrument market value merck hedge decline estimate million million december respectively uniform weaken dollar market value determine foreign exchange option pricing model hold factor exchange rate constant predictive nature company believe threshold reflect reasonably possible nearterm change merck major foreign currency exposure relative dollar company manage operating activity net asset position local subsidiary order mitigate effect exchange monetary asset liability monetary asset liability denominate currency functional currency give subsidiary remeasure spot rate effect balance sheet date effect change spot rate report income expense net company use balance sheet risk management program mitigate exposure asset liability effect volatility foreign exchange merck principally utilize forward exchange contract offset effect exchange exposure deem economical base costbenefit analysis consider magnitude exposure volatility exchange rate cost hedging instrument primarily euro swiss franc japanese yen chinese renminbi forward contract designate hedge mark market income expense net accordingly fair value change forward contract table content help mitigate change value remeasure asset liability attributable change foreign currency exchange rate extent spotforward difference difference significant shortterm nature contract typically average maturity inception month cash flow contract report operating activity consolidate statement cash flow sensitivity analysis change value dollar foreign currency denominate derivative investment monetary asset liability indicate dollar uniformly weaken currency exposure company december income continue operation taxis decline approximately million million respectively company net short payable position relative major foreign currency consideration forward contract uniform weaken dollar yield large overall potential net loss earning exchange measurement assume change foreign currency relative dollar affect foreign currency relative dollar predictive nature company believe threshold reflect reasonably possible nearterm change merck major foreign currency exposure relative dollar cash flow contract report operating activity consolidate statement cash flow company use forward exchange contract hedge portion net investment foreign operation movement exchange rate forward contract designate hedge net investment foreign operation unrealize gain loss contract record foreign currency translation adjustment oci remain aocl sale complete substantially complete liquidation subsidiary company exclude certain portion change fair value derivative instrument assessment hedge effectiveness exclude component change fair value exclude component recognize oci company recognize earning initial value exclude component straightline basis life derivative instrument marktomarket approach cash flow contract report investing activity consolidate statement cash flow foreign exchange risk manage use foreign currency debt company senior unsecured eurodenominate note designate effective economic hedge net investment foreign operation accordingly foreign currency transaction gain loss spot rate fluctuation eurodenominate debt instrument include foreign currency translation adjustment oci interest rate risk management company use interest rate swap contract certain investing borrowing transaction manage net exposure interest rate change reduce overall cost borrowing company use leveraged swap general leverage investment activity principal risk december company party payfloate receivefixe interest rate swap contract designate fair value hedge portion fixedrate note detailed table million number interest rate swap total swap notional debt instrument par value debt hold note company investment portfolio include cash equivalent shortterm investment market value significantly affect change interest rate market value company medium longterm fixedrate investment modestly affect change interest rate change medium longterm interest rate significant impact market value company fixedrate borrowing generally long maturity sensitivity analysis measure potential change market value merck investment debt change interest rate indicate percentage point increase interest rate december positively affect net aggregate market value instrument billion billion respectively percentage point decrease december negatively affect net aggregate market value billion billion respectively fair value merck debt determine pricing model reflect percentage point shift appropriate yield curve fair value merck investment determine combination pricing duration model table content critical accounting estimate companys consolidated financial statement prepare conformity gaap accordingly include certain amount base management good estimate judgment estimate accounting amount record connection acquisition include initial fair value determination asset liability business combination primarily iprd intangible asset contingent consideration subsequent fair value measurement additionally estimate determine item provision sale discount rebate return depreciable amortizable live recoverability inventory include produce preparation product launch amount record contingency environmental liability accrual contingent salesbase milestone payment reserve pension postretirement benefit plan assumption sharebase compensation assumption restructure cost impairment longlive asset include intangible asset goodwill investment tax income uncertainty inherent estimate actual result differ estimate application follow accounting policy result accounting estimate potential significant impact financial statement acquisition disposition determine transaction account acquisition disposal asset business company make certain judgment include assessment input process output associate acquire set activity company determine substantially fair value gross asset include transaction concentrate single asset group similar asset asset represent business consider business asset transaction need include input substantive process significantly contribute ability create output business combination acquisition method accounting require asset acquire liability assume record date acquisition respective fair value limited exception fair value intangible asset determine utilize information available near acquisition date base expectation assumption deem reasonable management give considerable judgment involve determine fair value company typically obtain assistance thirdparty valuation specialist significant item asset acquire liability assume business combination arise contingency generally recognize fair value fair value determine asset liability recognize probable reasonably estimable criterion meet asset liability recognize fair value define exchange price received asset pay transfer liability exit price principal advantageous market asset liability orderly transaction market participant measurement date accordingly company require value asset fair value measure reflect company intend use asset excess purchase price consideration transfer estimate fair value net asset acquire record goodwill transaction cost cost restructure acquire company expense incur operating result acquire business reflect company consolidate financial statement date acquisition judgment determine estimate fair value assign asset acquire liability assume business combination asset life materially affect company result operation fair value identifiable intangible asset relate currently market product primarily determine income approach fair value estimate base asset discount project net cash flow company estimate market participant net cash flow consider historical project pricing margin expense level performance compete product applicable relevant industry therapeutic area growth driver factor current expect trend technology product life cycle time investment require develop product technology ability obtain additional marketing regulatory approval ability manufacture commercialize product extent time potential new product introduction company competitor life asset underlie patent relate patent term extension net cash flow probabilityadjuste appropriate consider uncertainty associate underlie assumption risk profile net cash flow utilize valuation probabilityadjuste future net cash flow product discount present value utilize appropriate discount rate fair value identifiable intangible asset relate iprd determine income approach fair value estimate base asset probabilityadjuste future net cash flow reflect different stage development product associate probability successful completion net cash flow discount present value appropriate discount rate amount allocate acquire iprd capitalize account indefinitelive intangible asset subject impairment testing completion abandonment project successful completion iprd table content project merck determination thenuseful life intangible asset generally determine period substantial majority cash flow expect generate begin amortization certain company business combination involve potential future payment consideration contingent achievement performance milestone include product development milestone royalty payment future product sale fair value contingent consideration liability determine acquisition date unobservable input input include estimate time project cash flow probability success achievement contingent event riskadjuste discount rate present value probabilityweighte cash flow subsequent acquisition date report period contingency resolve contingent consideration liability remeasure current fair value change expense income record earning change input result significantly different fair value adjustment company determine transaction account acquisition business transaction account asset acquisition business combination goodwill record asset acquisition acquire iprd alternative future use charge expense contingent consideration recognize acquisition date contingent salesbase milestone term certain collaborative arrangement require company payment contingent achievement salesbase milestone salesbase milestone payable merck collaborative partner accrue capitalize subject cumulative amortization catchup determine probable achieve company base future sale forecast amortization catchup calculate time regulatory approval indication unapproved time collaboration form time formation collaboration approve product relate intangible asset recognize amortize remain useful life subject impairment testing revenue recognition recognition revenue require evidence contract probable collection sale proceed completion substantially performance obligation merck act principal substantially customer arrangement record revenue gross basis majority company contract relate pharmaceutical animal health segment single performance obligation promise transfer good shipping consider immaterial context overall customer arrangement damage loss good transit rare shipping deem separately recognize performance obligation vast majority revenue sale product recognize point time control good transfer customer company determine title risk reward ownership transfer customer company entitle payment certain service animal health segment revenue recognize time generally ratably contract term service provide service revenue material nature company business gives rise type variable consideration include discount return estimate time sale generally expect value method likely method prompt pay discount sale discount issue customer pointofsale intermediary wholesaler know chargeback form rebate additionally sale generally limited right return certain condition revenue record net provision sale discount return establish time sale addition collection account receivable expect excess year sale record net time value money discount material provision aggregate customer discount cover chargeback rebate chargeback discount occur contract customer purchase intermediary wholesaler wholesaler charge company difference price initially pay wholesaler contract price agree merck customer provision chargeback base expect sellthrough level company wholesale customer contract customer estimate wholesaler inventory level rebate amount owe base definitive contractual agreement legal requirement private sector public sector medicaid medicare benefit provider final dispense product benefit plan participant provision rebate base expect patient usage inventory level distribution channel determine contractual obligation benefit provider company use historical customer segment utilization mix sale forecast change product mix price inventory level distribution channel government pricing calculation prior payment history order estimate expect table content provision amount accrue aggregate customer discount evaluate quarterly basis comparison information provide wholesaler health maintenance organization pharmacy benefit manager federal state agency customer amount accrue merck remain committed b program provide b discount eligible cover entity note consolidated financial statement information b legal proceeding summarize information change aggregate customer discount accrual relate sale follow million balance january current provision adjustment prior year payment balance december accrual chargeback reflect direct reduction account receivable accrual rebate current liability accrue balance relative provision include account receivable accrue current liability million billion respectively december million billion respectively december outside variable consideration form discount rebate combination commerciallydriven discount highly competitive product class discount require gain maintain reimbursement legislatively mandate rebate certain european country legislatively mandate rebate calculate base estimate government total unbudgeted spending company specific payback obligation rebate require base specific product sale threshold company apply estimate factor actual invoice sale represent expect level future discount rebate obligation associate sale company maintain return policy allow pharmaceutical customer return product specify period prior subsequent expiration date generally month month product expiration estimate provision return base historical experience actual return additionally company consider factor level inventory distribution channel product date expiration period product discontinue entrance market generic competition change formulary launch thecounter product product return provision pharmaceutical sale percentage net pharmaceutical sale outside return allow certain country limit basis merck payment term pharmaceutical customer typically day receipt invoice animal health customer typically day receipt invoice certain product long payment term include keytruda payment term day payment term vaccine sale typically range day outside payment term typically day day certain market long payment term distribution program wholesaler company encourage wholesaler align purchase underlie demand maintain inventory specify level term program allow wholesaler earn fee provide visibility inventory level achieve certain performance parameter inventory management customer service level reduce shortage claim reduce product return information provide wholesaler distribution program include item sale trend inventory onhand onorder quantity product return inventory produce preparation product launch company capitalize inventory produce preparation product launch sufficient support estimate initial market demand typically capitalization inventory begin regulatory approval consider company probable company monitor status respective product research regulatory approval process company aware specific risk contingency normal regulatory approval process specific issue identify research process relate safety efficacy manufacturing marketing label relate inventory generally capitalize expiry date inventory affect stage completion company manage level inventory stage optimize shelf life inventory relation anticipate market demand order avoid product expiry issue inventory capitalize anticipated future sale shelf live support table content realization inventory value inventory shelf life sufficient meet initial product launch requirement inventory produce preparation product launch capitalize december million million respectively contingency environmental liability company involve claim legal proceeding nature consider normal business include product liability intellectual property commercial litigation certain additional matter include governmental environmental matter note consolidated financial statement company record accrual contingency probable liability incur reasonably estimate accrual adjust periodically assessment change additional information available product liability claim portion overall accrual actuarially determine consider factor past experience number claim report estimate claim incur report individually significant contingent loss accrue probable reasonably estimable legal defense cost expect incur connection loss contingency accrue probable reasonably estimable significant factor consider review legal defense reserve follow actual cost incur company development company legal defense strategy structure light scope litigation number case bring company cost outcome complete trial current information anticipated timing progression relate cost pretrial activity trial associate litigation legal defense reserve december approximately million million respectively represent company good estimate minimum defense cost incur connection outstanding litigation event additional trial event arise course litigation affect ultimate legal defense cost incur company company continue monitor legal defense cost review adequacy associate reserve determine increase reserve time future base factor set forth believe appropriate company subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund federal state equivalent legitimate claim contribution assert liability initially accrue base estimate transaction cost manage site accrual adjust site investigation feasibility study relate cost assessment remedial technique complete extent potentially responsible party jointly severally liable expect contribute determine company remediate environmental contamination result past industrial activity certain site take active role identify accrue cost past merck perform worldwide survey assess site potential contamination result past industrial activity assessment indicate physical investigation warrant investigation perform provide well evaluation need remedial action need identify remedial action initiate definitive information available course investigation andor remedial effort site estimate refined accrual establish adjust accordingly estimate related accrual continue refine annually company believe compliance issue associate applicable environmental law regulation material adverse effect company expenditure remediation environmental liability million estimate million aggregate year management opinion liability environmental matter probable reasonably estimable accrue total million million december respectively liability undiscounted consider potential recovery party pay periods remediation applicable site expect occur primarily year possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed approximately million aggregate management believe expenditure result material adverse effect company financial condition result operation liquidity year table content sharebase compensation company expense sharebase payment award employee include grant stock option requisite service period base grant date fair value award company determine fair value certain sharebased award blackschole optionprice model use historical current market datum estimate fair value method incorporate assumption riskfree interest rate expect volatility expect dividend yield expect life option total pretax sharebase compensation expense continue operation million million million december million total pretax unrecognized compensation expense relate nonveste stock option restrict stock unit performance share unit award recognize weightedaverage period year segment report sharebased compensation cost unallocated expense pension postretirement benefit plan net periodic benefit cost pension plan total million million million net periodic benefit credit postretirement benefit plan million million million pension postretirement benefit plan information financial reporting purpose calculate actuarial assumption include discount rate plan benefit obligation expect rate return plan asset change net periodic benefit cost year year pension plan primarily attributable low settlement charge incur certain plan compare change expect return discount rate company reassesse benefit plan assumption regular basis pension postretirement benefit plan discount rate evaluate measurement date modify reflect prevail market rate portfolio highquality fixedincome debt instrument provide future cash flow need pay benefit include benefit obligation come discount rate company pension postretirement benefit plan range december compare range december expect rate return pension postretirement benefit plan represent average rate return earn plan asset period benefit include benefit obligation pay develop expect rate return company consider longterm compound annualize return historical market datum current market condition actual return company plan asset reference information company develop forwardlooke return expectation asset category weightedaverage expect longterm rate return target portfolio allocate investment category expect portfolio performance reflect contribution active management appropriate expect rate return company pension postretirement benefit plan compare company establish investment guideline pension postretirement plan create asset allocation expect deliver rate return sufficient meet longterm obligation plan give acceptable level risk target investment portfolio company pension postretirement benefit plan allocate equity international equity fixedincome investment cash investment portfolio equity weighting consistent longterm nature plan benefit obligation expect annual standard deviation return target portfolio approximate reflect equity allocation diversification benefit asset class portfolio invest international pension plan target investment portfolio varies base duration pension liability local government rule regulation significant percentage plan asset invest equity concentration risk mitigate use strategy diversify management guideline actuarial assumption base management good estimate judgment reasonably possible change plus minus basis point discount rate assumption assumption hold constant estimate million favorable unfavorable impact company net periodic benefit cost reasonably possible change plus minus basis point expect rate return assumption assumption hold constant estimate million favorable unfavorable impact merck net periodic benefit cost require funding obligation relate company pension postretirement benefit plan expect material precede hypothetical change discount rate expect rate return assumption impact company funding requirement net gainloss amount primarily reflect difference expect actual return plan asset effect change actuarial assumption record component aocl expect return pension plan base calculate marketrelated value asset net gainloss amount aocl table content excess certain threshold amortize net periodic benefit cost average remain service life employee restructure cost restructure cost record connection restructure program activity result company estimate judgment future plan include future employee termination cost incur conjunction involuntary separation separation probable estimable accrue termination cost company recognize range cost good estimate range range well estimate company recognize minimum range connection action management assess recoverability longlive asset employ business certain instance asset life shorten base change expect useful life affect asset severance employeerelate cost cost facility shutdown cost reflect restructuring cost assetrelate charge reflect cost sale sell general administrative expense research development expense depend nature asset impairment longlive asset company assess change economic regulatory legal condition make assumption estimate future cash flow evaluate value company property plant equipment goodwill intangible asset company periodically evaluate current fact circumstance indicate carry value longlive asset hold recoverable circumstance determine exist estimate undiscounted future cash flow asset appropriate asset grouping compare carry value determine impairment exist asset determine impair loss measure base difference asset fair value carry value quote market price available company estimate fair value discount value estimate future cash flow approach goodwill represent excess consideration transfer fair value net asset business acquire goodwill assign reporting unit evaluate impairment annual basis frequently impairment indicator exist assess qualitative factor determine likely fair value report unit carrying factor consider assessment include general macroeconomic condition condition specific industry market cost factor significant effect earning cash flow overall financial performance report unit sustained decline company share price company conclude likely fair value report unit carrying quantitative fair value test perform carrying value report unit great fair value goodwill impairment charge record difference carry value goodwill acquire intangible asset exclude iprd initially record fair value assign estimate useful life amortize primarily straightline basis estimate useful life event circumstance warrant review company assess recoverability future operation pretax undiscounte cash flow derive low appropriate asset grouping impairment recognize operating result extent carry value intangible asset exceed fair value determine base net present value estimate future cash flow iprd company acquire conjunction business combination represent fair value assign incomplete research project time acquisition reach technological feasibility amount capitalize account indefinitelive intangible asset subject impairment testing completion abandonment project company evaluate iprd impairment annually frequently impairment indicator exist unfavorable clinical trial datum change commercial landscape delay clinical development program relate regulatory filing approval timeline perform quantitative test compare fair value iprd intangible asset carry value impairment testing purpose company combine separately record iprd intangible asset unit account base relevant fact circumstance generally company combine iprd intangible asset testing purpose operate single asset essentially inseparable fair value carrying impairment loss recognize operating result judgment evaluate impairment longlive intangible materially affect company result operation table content tax income company effective tax rate base pretax income statutory tax rate tax planning opportunity available jurisdiction company operate estimate effective tax rate year apply company quarterly operating result event significant unusual onetime item recognize expect recognize company quarterly operating result tax attributable item separately calculate record time unusual onetime item company consider resolution prior year tax matter item significant judgment require determine company tax provision evaluate tax position recognition measurement tax position base management good judgment give fact circumstance information available reporting date company evaluate tax position determine benefit tax position likely sustain audit base technical merit tax position tax position likely sustain audit company recognize benefit greater likely realize ultimate settlement financial statement tax position likely sustain audit company recognize portion benefit financial statement likely threshold meet period tax position take company subsequently recognize benefit tax position tax matter effectively settle statute limitation expire likely threshold meet subsequent period note consolidated financial statement tax regulation require item include tax return different time item reflect financial statement time difference create defer tax asset liability defer tax asset generally represent item tax deduction credit tax return future year company record tax benefit financial statement company establish valuation allowance defer tax asset expect future taxable income likely support use deduction credit defer tax liability generally represent tax expense recognize financial statement payment defer expense company take deduction tax return recognize expense financial statement recently issue accounting standard discussion recently issue accounting standard note consolidated financial statement cautionary factor affect future result report write report oral statement time time company contain socalled forwardlooke statement base management current expectation subject risk uncertainty cause result differ materially set forth statement identify forwardlooke statement use word anticipate expect plan estimate forecast project word similar meaning negative variation forego identify fact relate strictly historical current fact statement likely address company growth strategy financial result product approval product potential development program environmental sustainability initiative carefully consider statement understand factor cause actual result differ materially company forwardlooke statement factor include inaccurate assumption broad variety risk uncertainty include know forwardlooke statement guarantee actual future result vary materially company assume obligation update forwardlooke statement carefully evaluate statement light factor include risk factor describe company filing securities exchange commission especially form q k item risk factor annual report company discuss detail important risk factor cause actual result differ expect historic result company note factor investor permit private security litigation reform act understand possible predict identify factor consequently reader consider list complete statement potential risk uncertaintie item quantitative qualitative disclosure market risk information require item incorporate reference discussion financial instrument market risk disclosure item management discussion analysis financial condition result operation table content item financial statement supplementary datum financial statement consolidate balance sheet merck co inc subsidiary december relate consolidated statement income comprehensive loss income equity cash flow year period end december note consolidated financial statement report date february pricewaterhousecooper llp independent register public accounting firm follow consolidated statement income merck co inc subsidiary year end december millions share amount sale cost expense cost sale sell general administrative research development restructuring cost income expense net income continue operation taxis tax income continue operation net income continue operation net income attributable noncontrolle interest net income continue operation attributable merck co inc income discontinue operation net taxis amount attributable noncontrolle interest net income attributable merck co inc basic earning common share attributable merck co inc common shareholder income continue operation income discontinue operation net income earning common share assume dilution attributable merck co inc common shareholder income continue operation income discontinue operation net income consolidate statement comprehensive loss income merck co inc subsidiary year end december million net income attributable merck co inc comprehensive loss income net taxis net unrealized loss gain derivative net reclassification benefit plan net loss gain prior service cost credit net amortization cumulative translation adjustment comprehensive loss income attributable merck co inc accompany note integral consolidated financial statement table content consolidate balance sheet merck co inc subsidiary december millions share amount asset current asset cash cash equivalent shortterm investment account receivable net allowance doubtful account inventory exclude inventory classify asset note current asset total current asset investment property plant equipment cost land building machinery equipment office furnishing construction progress accumulate depreciation goodwill intangible net asset liabilitie equity current liability loan payable current portion longterm debt trade account payable accrue current liability income taxis payable dividend payable total current liability longterm debt defer income taxis noncurrent liability merck co inc stockholders equity common stock par value authorize share issue share paidin capital retain earning accumulate comprehensive loss treasury stock cost share share total merck co inc stockholders equity noncontrolle interest total equity accompany note integral consolidated financial statement table content consolidate statement equity merck co inc subsidiary year end december millions share amount accumulate non common paidin retain comprehensive treasury control stock capital earning loss stock interest total balance january net income attributable merck co inc comprehensive income net taxis cash dividend declare common stock share treasury stock share purchase spinoff organon co net income attributable noncontrolle interest distribution attributable noncontrolle interest sharebase compensation plan balance december net income attributable merck co inc comprehensive loss net taxis cash dividend declare common stock share net income attributable noncontrolle interest distribution attributable noncontrolle interest sharebase compensation plan balance december net income attributable merck co inc comprehensive loss net taxis cash dividend declare common stock share treasury stock share purchase net income attributable noncontrolle interest distribution attributable noncontrolle interest sharebase compensation plan balance december accompanying note integral consolidated financial statement table content consolidate statement cash flow merck co inc subsidiary year end december million cash flow operating activity continue operation net income continue operation adjustment reconcile net income continue operation net cash provide operating activity continue operation amortization depreciation intangible asset impairment charge income loss investment equity security net charge acquisition prometheus biosciences inc charge acquisition imago biosciences inc charge acquisition pandion therapeutics inc defer income taxis sharebase compensation net change asset liability account receivable inventory trade account payable accrue current liability income taxis payable noncurrent liability net cash provide operating activity continue operation cash flow invest activity continue operation capital expenditure purchase security investment proceed sale seagen inc common stock proceed sale security investment acquisition prometheus biosciences inc net cash acquire acquisition imago biosciences inc net cash acquire acquisition acceleron pharma inc net cash acquire acquisition pandion therapeutics inc net cash acquire acquisition net cash acquire net cash investing activity continue operation cash flow financing activity continue operation net change shortterm borrowing payment debt proceed issuance debt distribution organon co purchase treasury stock dividend pay stockholder proceed exercise stock option net cash provide financing activity continue operation cash flow discontinue operation net cash provide operating activity net cash investing activity net cash financing activity net cash flow provide discontinued operation effect exchange rate change cash cash equivalent restrict cash net decrease increase cash cash equivalent restrict cash cash cash equivalent restrict cash beginning year includes restrict cash january respectively include current asset cash cash equivalent restrict cash end year includes restrict cash december respectively include current asset accompany note integral consolidated financial statement table content note consolidated financial statement merck co inc subsidiarie million share amount nature operation merck co inc merck company global health care company deliver innovative health solution prescription medicine include biologic therapy vaccine animal health product company operation principally manage product basis include operate segment pharmaceutical animal health reportable segment pharmaceutical segment include human health pharmaceutical vaccine product human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution human health vaccine product consist preventive pediatric adolescent adult vaccine company sell human health vaccine primarily physicians wholesaler distributor government entity animal health segment discover develop manufacture market wide range veterinary pharmaceutical vaccine product health management solution service prevention treatment control disease major livestock companion animal specie company offer extensive suite digitally connect identification traceability monitoring product company sell product veterinarian distributor animal producer farmer pet owner spinoff organon co june merck complete spinoff product women health biosimilar establish brand business new independent publicly trade company name organon co organon distribution organon publicly trade stock company shareholder establish brand include transaction consist dermatology nonopioid pain management respiratory select cardiovascular product rest merck diversify brand franchise historical result business contribute organon spinoff reflect discontinued operation company consolidate financial statement date spinoff note summary accounting policy principle consolidation consolidated financial statement include account company subsidiary control interest maintain intercompany balance transaction eliminate control interest determine majority ownership interest absence substantive thirdparty participate right case variable interest entity majority exposure expect loss residual return consolidate subsidiary merck ownership outside shareholder interest show noncontrolle interest equity investment affiliate company significant influence control interest interest entity own equally company party share control carry equity method basis acquisition business combination acquisition method accounting require asset acquire liability assume record date acquisition respective fair value limited exception asset acquire liability assume business combination arise contingency generally recognize fair value fair value determine asset liability recognize probable reasonably estimable criterion meet asset liability recognize fair value define exchange price received asset pay transfer liability exit price principal advantageous market asset liability orderly transaction market participant measurement date accordingly company require value asset fair value measure reflect company intend use asset excess purchase price consideration transfer estimate fair value net asset acquire record goodwill transaction cost cost restructure acquire company expense incur operating result acquire business reflect company consolidate financial statement date acquisition company determine asset acquire meet definition business acquisition method accounting transaction account acquisition asset business combination goodwill record asset acquisition acquire inprocess research development iprd alternative future use charge expense contingent consideration recognize acquisition date table content foreign currency translation net asset international subsidiary local currency determine functional currency translate dollar current exchange rate result operation translate average exchange rate dollar effect arise translate net asset subsidiary change rate record comprehensive income oci remain accumulated comprehensive loss aocl sale complete substantially complete liquidation subsidiary subsidiary operate highly inflationary economy subsidiarie dollar determine functional currency nonmonetary foreign currency asset liability translate historical rate monetary asset liability translate current rate dollar effect rate change include income expense net cash equivalent cash equivalent comprise certain highly liquid investment original maturity month inventory inventory value low cost net realizable value cost substantial majority human health inventory determine lastin firstout lifo method financial report tax purpose cost inventory determine firstin firstout fifo method inventory consist currently market product certain inventory produce preparation product launch consider company probable obtain regulatory approval evaluate recoverability inventory produce preparation product launch company consider likelihood revenue obtain future sale relate inventory status product research regulatory approval process investment investment marketable debt security classify availableforsale report fair value fair value company investment marketable debt security determine quote market price active market identical asset quote price similar asset input observable corroborate observable market datum substantially term asset liability change fair value impairment relate report net taxis oci company consider available evidence evaluate potential impairment investment marketable debt security include extent fair value cost allowance credit loss require adverse factor affect value security impairment occur company expect recover entire amortize cost basis marketable debt security company intend sell impair debt security likely require sell debt security recovery amortize cost basis impairment recognize earning record income expense net limited portion attribute credit loss remain portion impairment relate factor recognize oci realize gain loss debt security include income expense net investment publicly trade equity security report fair value determine quote market price active market identical asset quote price similar asset input observable corroborate observable market datum change fair value include income expense net unrealized gain loss investment directly own determined end report period gain loss ownership interest investment fund account equity method investment report quarter lag investment equity security readily determinable fair value record cost plus minus subsequent observable price change orderly transaction identical similar investment minus impairment adjustment recognize income expense net realize gain loss equity security include income expense net revenue recognition recognition revenue require evidence contract probable collection sale proceed completion substantially performance obligation merck act principal substantially customer arrangement record revenue gross basis majority company contract relate pharmaceutical animal health segment single performance obligation promise transfer good shipping consider immaterial context overall customer arrangement damage loss good transit rare shipping deem separately recognize performance obligation vast majority revenue sale product recognize point time control good transfer customer company determine title risk reward ownership transfer customer company entitle payment company recognize revenue sale vaccine federal government placement vaccine stockpile accordance security exchange commission sec interpretation commission guidance accounting sale vaccine bioterror countermeasure federal government placement pediatric vaccine stockpile strategic national stockpile interpretation allow company recognize revenue sale vaccine government stockpile sale meet criterion revenue recognition table content accounting guidance certain service animal health segment revenue recognize time generally ratably contract term service provide service revenue material nature company business gives rise type variable consideration include discount return estimate time sale generally expect value method likely method prompt pay discount sale discount issue customer pointofsale intermediary wholesaler know chargeback form rebate additionally sale generally limited right return certain condition revenue record net provision sale discount return establish time sale addition collection account receivable expect excess year sale record net time value money discount material provision aggregate customer discount cover chargeback rebate billion billion billion chargeback discount occur contract customer purchase intermediary wholesaler wholesaler charge company difference price initially pay wholesaler contract price agree merck customer provision chargeback base expect sellthrough level company wholesale customer contract customer estimate wholesaler inventory level rebate amount owe base definitive contractual agreement legal requirement private sector public sector medicaid medicare benefit provider final dispense product benefit plan participant provision rebate base expect patient usage inventory level distribution channel determine contractual obligation benefit provider company use historical customer segment utilization mix sale forecast change product mix price inventory level distribution channel government pricing calculation prior payment history order estimate expect provision amount accrue aggregate customer discount evaluate quarterly basis comparison information provide wholesaler health maintenance organization pharmacy benefit manager federal state agency customer amount accrue accrue balance relative provision chargeback rebate include account receivable accrue current liability million billion respectively december million billion respectively december outside variable consideration form discount rebate combination commerciallydriven discount highly competitive product class discount require gain maintain reimbursement legislatively mandate rebate certain european country legislatively mandate rebate calculate base estimate government total unbudgeted spending company specific payback obligation rebate require base specific product sale threshold company apply estimate factor actual invoice sale represent expect level future discount rebate obligation associate sale company maintain return policy allow pharmaceutical customer return product specify period prior subsequent expiration date generally month month product expiration estimate provision return base historical experience actual return additionally company consider factor level inventory distribution channel product date expiration period product discontinue entrance market generic competition change formulary launch thecounter product outside return allow certain country limit basis merck payment term pharmaceutical customer typically day receipt invoice animal health customer typically day receipt invoice certain product long payment term include keytruda payment term day payment term vaccine sale typically range day outside payment term typically day day certain market long payment term note disaggregate revenue disclosure depreciation depreciation provide estimate useful life asset principally straightline method tax purpose accelerate tax method estimate useful life primarily range year building year machinery equipment office furnishing depreciation expense billion billion billion table content advertising promotion cost advertising promotion cost expense incur company record advertising promotion expense billion billion billion software capitalization company capitalize certain cost incur connection obtain develop internaluse software include external direct cost material service payroll cost employee directly involve software development cost include property plant equipment addition company capitalize certain cost incur implement cloud computing arrangement consider service agreement include asset capitalize software cost amortize period range year long live generally associate enterprisewide project implement multiple year cost incur preliminary project stage post implementation stage maintenance training cost expense incur goodwill goodwill represent excess consideration transfer fair value net asset business acquire goodwill assign reporting unit evaluate impairment annually frequently impairment indicator exist assess qualitative factor determine likely fair value report unit carrying company conclude likely fair value report unit carrying quantitative fair value test perform carrying value report unit great fair value goodwill impairment charge record difference carry value goodwill acquire intangible intangible acquire business combination include product right trade name patent license initially record fair value assign estimate useful life amortize primarily straightline basis estimate useful life range year company periodically evaluate current fact circumstance indicate carry value acquire intangible recoverable circumstance determine exist estimate undiscounted future cash flow asset appropriate asset grouping compare carry value determine impairment exist asset determine impair loss measure base difference carry value intangible asset fair value determine base net present value estimate future cash flow acquire inprocess research development iprd company acquire conjunction acquisition business represent fair value assign incomplete research project time acquisition reach technological feasibility amount capitalize account indefinitelive intangible asset subject impairment testing completion abandonment project successful completion iprd project merck determination thenuseful life intangible asset generally determine period substantial majority cash flow expect generate begin amortization company evaluate iprd impairment annually frequently impairment indicator exist perform quantitative test compare fair value iprd intangible asset carrying value fair value carrying impairment loss recognize operating result contingent consideration certain company acquisition involve potential future payment consideration contingent achievement performance milestone include product development milestone royalty payment future product sale transaction account business combination fair value contingent consideration liability determine acquisition date unobservable input input include estimate time project cash flow probability success achievement contingent event riskadjuste discount rate present value probabilityweighte cash flow subsequent acquisition date report period contingency resolve contingent consideration liability remeasure current fair value change expense income record earning significant event increase decrease probability achieve development regulatory milestone increase decrease project cash flow result correspond increase decrease fair value relate contingent consideration obligation research development research development expense incur nonrefundable advance payment good service future research development activity expense activity perform good receive payment research development expense include restructure cost iprd impairment charge addition research development expense include expense income relate change estimate fair value measurement liability contingent consideration associate iprd asset research table content development expense include upfront milestone payment relate asset acquisition licensing transaction involve clinical development program receive regulatory approval collaborative arrangement merck enter collaborative arrangement provide company vary right develop produce market product collaborative partner merck principal sale transaction party company recognize sale cost sale sell general administrative expense gross basis profit sharing amount pay collaborative partner record cost sale collaborative partner principal sale transaction party company record profit sharing amount receive collaborative partner alliance revenue sale alliance revenue record net cost sale include adjustment share commercialization cost partner accordance collaboration agreement adjustment determine compare commercialization cost merck incur directly report sell general administrative expense cost collaborative partner incur research development cost merck incur relate collaboration record research development expense cost reimbursement collaborative partner payment receive collaborative partner share cost pursuant term collaboration agreement record increase decrease research development expense addition term collaboration agreement require company payment base achievement certain developmental regulatory approval commercial milestone upfront milestone payment payable merck collaborative partner prior regulatory approval expense incur include research development expense payment collaborative partner subsequent regulatory approval capitalize amortize cost sale estimate useful life correspond intangible asset provide future cash flow support amount capitalize salesbased milestone payable merck collaborative partner accrue capitalize subject cumulative amortization catchup determine probable achieve company amortization catchup calculate time regulatory approval indication unapproved time collaboration form time formation collaboration approve product relate intangible asset recognize amortize cost sale remain useful life subject impairment testing sharebase compensation company expense sharebased payment employee requisite service period base grant date fair value award restructuring cost company record liability cost associate exit disposal activity period liability incur accordance exist benefit arrangement future employee termination cost incur conjunction involuntary separation accrue separation probable estimable accrue cost company recognize range cost good estimate range range well estimate company recognize minimum range cost onetime termination benefit employee require render service termination order receive benefit recognize ratably future service period contingency legal defense cost company record accrual contingency legal defense cost expect incur connection loss contingency probable liability incur reasonably estimate taxis income defer taxis recognize future tax effect temporary difference financial income tax reporting base enact tax law rate company evaluate tax position determine benefit tax position likely sustain audit base technical merit tax position tax position likely sustain audit company recognize benefit greater likely realize ultimate settlement financial statement tax position likely sustain audit company recognize portion benefit financial statement company recognize interest penalty associate uncertain tax position component taxis income continue operation company account tax effect tax global intangible lowtaxed income gilti certain foreign subsidiary income tax provision period tax arise company policy release disproportionate income tax effect aocl utilize itembyitem approach reclassification certain reclassification prior year amount conform current year presentation table content use estimate consolidated financial statement prepare conformity accounting principle generally accept gaap accordingly include certain amount base management good estimate judgment estimate accounting amount record connection acquisition include initial fair value determination asset liability business combination primarily iprd intangible asset contingent consideration subsequent fair value measurement additionally estimate determine item provision sale discount rebate return depreciable amortizable live recoverability inventory include produce preparation product launch amount record contingency environmental liability accrual contingent salesbase milestone payment reserve pension postretirement benefit plan assumption sharebase compensation assumption restructure cost impairment longlive asset include intangible asset goodwill investment tax income uncertainty inherent estimate actual result differ estimate recently adopt accounting standard october financial accounting standard board fasb issue amend guidance require acquire entity recognize measure contract asset liabilitie business combination accordance exist revenue recognition guidance company adopt guidance effective january adoption guidance impact company consolidate financial statement prior acquisition impact future period dependent contract asset contract liability acquire future business combination june fasb issue guidance relate fair value measurement equity security subject contractual restriction prohibit sale equity security new guidance introduce new disclosure requirement equity security subject contractual sale restriction measure fair value company adopt guidance effective july impact company consolidate financial statement adoption recently issue accounting standard adopt august fasb issue amend guidance require newly form joint venture recognize initially measure asset liability fair value formation amend guidance include exception fair value measurement consistent accounting business combination guidance amend guidance effective prospectively joint venture formation date january exist joint venture option apply guidance retrospectively early adoption permit interim annual period company anticipate impact consolidated financial statement adoption november fasb issue guidance intend improve reportable segment disclosure requirement primarily expand disclosure significant segment expense guidance effective annual period begin interim period begin early adoption permit guidance result incremental disclosure company segment reporting disclosure december fasb issue guidance intend improve transparency income tax disclosure require consistent category disaggregation information effective income tax rate reconciliation income taxis pay disclosure jurisdiction guidance include amendment improve effectiveness income tax disclosure remove certain previously require disclosure guidance effective annual reporting early adoption permit company currently evaluate impact adoption disclosure consolidated financial statement acquisition research collaboration licensing agreement company continue pursue acquisition establishment external alliance research collaboration license agreement complement internal research capability arrangement include upfront payment expense reimbursement payment party milestone royalty profit share arrangement contingent occurrence certain future event link success asset development include option continuation payment company review market product pipeline examine candidate provide value outlicense portfolio assessment process divest certain asset pro forma financial information acquire business present historical financial result acquire entity significant compare company financial result recent transaction february merck enter definitive agreement acquire aqua business elanco animal health incorporate elanco billion cash elanco aqua business acquire consist table content innovative portfolio medicine vaccine nutritional supplement aquatic specie relate aqua manufacture facility canada vietnam research facility chile closing acquisition broaden merck animal health aqua portfolio product clynav new generation dnabase vaccine protect atlantic salmon pancrea disease imvixa antiparasitic sea lice treatment acquisition bring portfolio water treatment product warm water production complement merck animal health warm water vaccine portfolio addition product dnabase vaccine technology business potential accelerate development novel vaccine address unmet need aqua industry acquisition expect complete mid subject approval regulatory authority customary closing condition transaction account acquisition business january merck enter agreement acquire harpoon therapeutics inc harpoon clinicalstage immunotherapy company develop novel class tcell engager design harness power bodys immune system treat patient suffer cancer disease term agreement merck acquire outstanding share harpoon share cash approximate total equity value million harpoon lead candidate hpn tcell engager target deltalike ligand dll inhibitory canonical notch ligand express high level smallcell lung cancer neuroendocrine tumor hpn currently evaluate phase clinical trial monotherapy patient advanced cancer associate expression dll combination atezolizumab patient certain type smallcell lung cancer closing acquisition expect half subject certain condition include approval merger harpoon stockholder expiration waiting period hartscottrodino antitrust improvement act customary condition propose transaction close company anticipate account acquisition asset hpn account substantially fair value gross asset acquire exclude cash defer income taxis company expect record charge approximately million research development expense closing transaction october merck daiichi sankyo enter global development commercialization agreement daiichi sankyos deruxtecan dxd antibody drug conjugate adc candidate patritumab deruxtecan herdxd mk ifinatamab deruxtecan idxd mk raludotatug deruxtecan rdxd mk note additional information relate collaboration june merck acquire prometheus biosciences inc prometheus clinicalstage biotechnology company pioneer precision medicine approach discovery development commercialization novel therapeutic companion diagnostic product treatment immunemediate disease total consideration pay billion include billion cost settle sharebased equity award include million settle unvested equity award prometheus lead candidate tulisokibart mk pra humanize monoclonal antibody direct tumor necrosis factorlike ligand target associate intestinal inflammation fibrosis tulisokibart develop treatment immunemediate disease include ulcerative colitis crohns disease autoimmune condition phase clinical trial evaluate tulisokibart ulcerative colitis commence transaction account acquisition asset tulisokibart account substantially fair value gross asset acquire exclude cash defer income taxis merck record net asset million include cash million investment million defer tax asset million net liability million charge billion research development expense relate transaction future contingent payment associate acquisition february merck kelunbiotech hold subsidiary sichuan kelun pharmaceutical co ltd closed license collaboration agreement expand relationship merck gain exclusive right research development manufacture commercialization seven investigational preclinical adcs treatment cancer kelunbiotech retain right research develop manufacture commercialize certain license option adcs chinese mainland hong kong macau merck upfront payment million record research development expense october merck notify kelunbiotech terminate seven candidate agreement kelun biotech remain eligible receive future contingent payment aggregate million developmentrelate payment billion regulatory milestone billion salesbase milestone kelunbiotech retain chinese mainland hong kong macau right option adcs remain candidate achieve regulatory approval addition kelunbiotech eligible receive tiere royalty range midsingledigit rate low doubledigit rate future net sale commercialize adc product connection agreement merck invest million kelunbiotech share january table content january merck acquire imago biosciences inc imago clinicalstage biopharmaceutical company develop new medicine treatment myeloproliferative neoplasm bone marrow disease billion include payment settle sharebased equity award incur approximately million transaction cost imago lead candidate bomedemstat mk img investigational orally available lysinespecific demethylase inhibitor currently evaluate multiple clinical trial treatment essential thrombocythemia myelofibrosis polycythemia vera addition indication phase clinical trial evaluate bomedemstat treatment certain patient essential thrombocythemia underway transaction account acquisition asset bomedemstat represent substantially fair value gross asset acquire exclude cash defer income taxis merck record net asset million charge billion research development expense relate transaction future contingent payment associate acquisition transaction october merck royalty pharma plc royalty pharma enter funding arrangement royalty pharma pay merck million cofund merck development cost phase b trial mk investigational oral phosphodiesterase pdea inhibitor evaluate treatment schizophrenia royalty pharma share risk technical regulatory success merck development funding recognize merck obligation perform contractual service accordingly payment receive recognize merck reduction research development expense ratably estimate phase b research period agreement royalty pharma right mk decisionmake authority program merck elect advance mk phase study royalty pharma option provide additional funding development cost million royalty pharma eligible receive royalty future sale royalty pharma elect provide additional funding note royalty pharma eligible receive future regulatory milestone payment contingent certain marketing approval high royalty rate merck record milestone payment expense income expense net receipt relate approval september merck exercise option jointly develop commercialize v mrna investigational individualized neoantigen therapy pursuant term exist collaboration license agreement moderna inc moderna note additional information relate collaboration august merck orna therapeutics orna biotechnology company pioneer new investigational class engineer circular rna orna therapy enter collaboration agreement discover develop commercialize multiple program include vaccine therapeutic area infectious disease oncology term agreement merck upfront payment orna million record research development expense addition orna eligible receive future contingent payment aggregate million development relate payment million regulatory milestone billion salesbased milestone associate progress multiple vaccine therapeutic program royaltie range highsingledigit rate lowdoubledigit rate approve product derive collaboration merck invest million ornas series b prefer share july merck orion corporation orion announce global codevelopment cocommercialization agreement orion investigational candidate odm mk drug target cytochrome p cypa enzyme important steroid production mk oral nonsteroidal inhibitor cypa currently evaluate phase clinical trial treatment patient metastatic castrationresistant prostate cancer merck upfront payment orion million record research development expense orion responsible manufacture clinical commercial supply mk addition contract provide party option convert initial codevelopment cocommercialization agreement global exclusive license merck option exercise merck assume responsibility past development commercialization expense associate program inception agreement future development commercialization expense addition orion eligible receive milestone payment associate progress development commercialization mk tiere doubledigit royalty sale product approve july merck kelunbiotech close license collaboration agreement merck gain exclusive worldwide right development manufacture commercialization investigational adc mk treatment solid tumor term agreement merck kelunbiotech collaborate early clinical development investigational adc merck upfront payment million record research development expense kelunbiotech eligible receive future contingent milestone payment aggregate million developmental milestone million table content regulatory milestone million salesbase milestone agreement provide merck pay tiere royalty range midsingle digit rate lowdoubledigit rate future net sale connection exist arrangement merck exercise option obtain exclusive license outside chinese mainland hong kong macau taiwan development manufacture commercialization kelunbiotech trophoblast antigen troptargete adc program include lead compound skb mk currently phase clinical development term agreement merck kelunbiotech collaborate certain early clinical development plan include evaluate potential mk monotherapy combination keytruda advance solid tumor option exercise merck payment million record research development expense additionally merck additional payment million technology transfer merck agree quarterly payment aggregate million fund kelunbiotech ongoing research development activity million pay december addition kelunbiotech eligible receive future contingent milestone payment include program compound aggregate million developmental milestone million commercial sale milestone million salesbase milestone agreement provide merck pay tiere royalty range midsingledigit rate lowdoubledigit rate future net sale transaction november merck acquire acceleron pharma inc acceleron publicly trade biopharmaceutical company total consideration billion acceleron development work focus evaluate transform growth factor tgfbeta superfamily protein know play central role regulation cell growth differentiation repair acceleron lead therapeutic candidate sotatercept mk novel mechanism action potential improve shortterm andor longterm clinical outcome patient pulmonary arterial hypertension pah sotatercept priority review review european union eu treatment certain adult patient pah previous agreement assume merck bristolmyers squibb company bm grant exclusive license develop commercialize sotatercept outside pulmonary hypertension ph field merck eligible receive contingent milestone royalty payment merck retain worldwide exclusive right develop commercialize sotatercept ph field agreement provide merck pay royalty future sale sotatercept ph field bms addition sotatercept acceleron portfolio include reblozyl luspatercept develop commercialize global collaboration bm note additional information relate collaboration transaction account business combination company incur million cost directly relate acquisition acceleron consist primarily sharebase compensation payment settle nonveste equity award attributable postcombination service severance investment bank legal fee cost include sell general administrative expense research development cost estimate fair value asset acquire liability assume acceleron inclusive measurement period adjustment follow november cash cash equivalent investment identifiable intangible asset iprd sotatercept product right reblozyl year useful life defer income tax liability net asset liability net total identifiable net asset goodwill consideration transfer estimate fair value identifiable intangible asset relate sotatercept reblozyl determine income approach specifically multiperiod excess earning method future probabilityweighte net cash flow discount present value utilize discount rate sotatercept reblozyl actual cash flow likely different assumed goodwill recognize largely attributable anticipate synergy expect arise acquisition allocate pharmaceutical segment goodwill deductible tax purpose table content april merck acquire pandion therapeutics inc pandion clinicalstage biotechnology company develop novel therapeutic design address unmet need patient live autoimmune disease pandion development work focus advance pipeline precision immune modulator target critical immune control node total consideration pay billion include million cost primarily comprise sharebased compensation payment settle equity award transaction account acquisition asset merck record net asset million primarily cash charge billion research development expense relate transaction future contingent payment associate acquisition march merck gilead sciences inc gilead enter agreement jointly develop commercialize longacting treatment hiv combine merck investigational nucleoside reverse transcriptase translocation inhibitor islatravir gilead investigational capsid inhibitor lenacapavir upfront payment party enter agreement initial focus collaboration longacte oral formulation longacte injectable formulation combination product formulation potentially add collaboration mutually agree party continue study longacte oral formulation combination product terminate study longacte injectable formulation combination product furthermore merck gilead subsequently amend agreement include joint development commercialization longacte injectable formulation lenacapavir gs development candidate result collaboration scripps research gilead novel prodrug islatravir term agreement merck gilead share operational responsibility development commercialization marketing cost future revenue global development commercialization cost share gilead merck oral injectable formulation program longacte oral product gilead lead commercialization merck lead commercialization eu rest world longacte injectable product merck lead commercialization gilead lead commercialization eu rest world gilead merck copromote certain major market merck gilead share global product revenue equally product revenue surpass certain preagreed formulation revenue tier pass billion year net product sale oral combination revenue split adjust gilead merck revenue threshold pass billion year net product sale injectable combination revenue split adjust gilead merck revenue threshold potential combination investigational lenacapavir investigational islatravir gilead option license certain merck investigational oral integrase inhibitor develop combination lenacapavir reciprocally merck option license certain gilead investigational oral integrase inhibitor develop combination islatravir company exercise option investigational oral integrase inhibitor company follow completion phase clinical trial integrase inhibitor exercise option company split development cost revenue nonexercise company decide optout december food drug administration fda place partial clinical hold investigational new drug application certain oral implant injectable formulation islatravir base observation decrease total lymphocyte cd tcell count participant receive islatravir clinical study phase clinical trial evaluate oral onceweekly combination low dose islatravir lenacapavir virologically suppress adult complete enrollment investigational new drug application islatravir lenacapavir onceweekly treatment regimen remain partial clinical hold study use islatravir dose high dose consider revise clinical program company remain committed develop compound longacte hiv prevention believe potential nucleoside reverse transcriptase translocation inhibitor nrtti mechanism collaborative arrangement merck enter collaborative arrangement provide company vary right develop produce market product collaborative partner party arrangement active participant expose significant risk reward dependent commercial success activity collaboration merck significant collaborative arrangement discuss table content astrazeneca plc merck astrazeneca plc astrazeneca enter global strategic oncology collaboration codevelop cocommercialize astrazenecas lynparza olaparib multiple cancer type independently merck astrazeneca develop commercialize lynparza combinations respective pd pdl medicine keytruda imfinzi company jointly develop commercialize astrazenecas koselugo selumetinib multiple indication term agreement astrazeneca merck share development commercialization cost lynparza koselugo monotherapy nonpdlpd combination therapy opportunitie profit lynparza koselugo product sale generate monotherapie combination therapy share equally astrazeneca principal lynparza koselugo sales transaction merck records share lynparza koselugo product sale net cost sale commercialization cost alliance revenue share development cost associate collaboration research development expense reimbursement receive astrazeneca research development expense recognize reduction research development cost agreement merck upfront payment astrazeneca payment multiyear period certain license option addition agreement provide contingent payment merck astrazeneca relate successful achievement salesbase regulatory milestone merck salesbased milestone payment astrazeneca million previously accrue additionally merck determine probable sale lynparza future trigger million salesbase milestone payment merck astrazeneca accordingly merck record million liability remain accrue december correspond increase intangible asset relate lynparza merck recognize million cumulative amortization catchup expense relate recognition milestone potential future salesbase milestone payment billion accrue deem company probable time lynparza receive regulatory approval trigger capitalize milestone payment million million respectively merck astrazeneca january merck additional million regulatory milestone payment astrazeneca potential future regulatory milestone payment million remain agreement intangible asset balance relate lynparza includes capitalize salesbased regulatory milestone payment billion december include intangible net amortize estimate useful life support project future cash flow subject impairment testing summarize financial information relate collaboration follow year end december alliance revenue lynparza alliance revenue koselugo total alliance revenue cost sale sell general administrative research development december receivables astrazeneca include current asset payable astrazeneca include accrue current liability payable astrazeneca include noncurrent liability represent amortization capitalize milestone payment include million cumulative amortization catchup expense note include accrue milestone payment eisai co ltd merck eisai co ltd eisai announce strategic collaboration worldwide codevelopment cocommercialization lenvima lenvatinib orally available tyrosine kinase inhibitor table content discover eisai agreement merck eisai develop commercialize lenvima jointly monotherapy combination keytruda eisai record lenvima product sale globally eisai principal lenvima sale transaction merck eisai share applicable profit equally merck record share lenvima product sale net cost sale commercialization cost alliance revenue expense incur co development share company accordance collaboration agreement reflect research development expense certain expense incur solely merck eisai shareable collaboration agreement include cost incur excess agree cap cost relate certain combination study keytruda lenvima agreement merck upfront payment eisai payment multiyear period certain option right addition agreement provide contingent payment merck eisai relate successful achievement salesbase regulatory milestone merck salesbased milestone payment eisai aggregate million million million respectively merck determine probable sale lenvima future trigger million salesbase milestone payment merck eisai accordingly merck record million liability million subsequently pay noted million remain accrue december corresponding increase intangible asset relate lenvima merck recognize million cumulative amortization catchup expense relate recognition milestone potential future salesbase milestone payment billion accrue deem company probable time lenvima receive regulatory approval trigger capitalize milestone payment million million respectively merck eisai regulatory milestone payment remain agreement intangible asset balance relate lenvima includes capitalize salesbased regulatory milestone payment million december include intangible net amortize estimate useful life support project future cash flow subject impairment testing summarize financial information relate collaboration follow year end december alliance revenue lenvima cost sale sell general administrative research development december receivables eisai include current asset payable eisai include accrued current liability represent amortization capitalize milestone payment include million cumulative amortization catchup expense note represent accrue milestone payment bayer ag company enter worldwide clinical development collaboration bayer ag bayer market develop soluble guanylate cyclase sgc modulator include bayer adempas riociguat company implement joint development commercialization strategy collaboration include development bayer verquvo vericiguat approve eu japan approve market agreement bayer commercialize adempas americas merck commercialize rest world verquvo merck commercialize bayer commercialize rest world company share development cost profit sale merck record sale adempas verquvo marketing territory alliance revenue alliance revenue represent merck share profit sale adempas verquvo bayer marketing territory product sale net cost sale commercialization cost cost sale include bayer share profit sale merck marketing territory table content addition agreement provide contingent payment merck bayer relate successful achievement salesbase milestone merck final million salesbase milestone payment collaboration bayer intangible asset balance relate adempas includes acquire intangible asset balance capitalize salesbased milestone payment attribute adempas verquvo reflect portion final salesbase milestone payment attribute verquvo million million respectively december include intangible net asset amortize estimate useful life adempas verquvo support project future cash flow subject impairment testing summarize financial information relate collaboration follow year end december alliance revenue adempasverquvo net sale adempas record merck net sale verquvo record merck total sale cost sale sell general administrative research development december receivables bayer include current asset payable bayer include accrued current liability include amortization intangible asset include million cumulative amortization catchup expense ridgeback biotherapeutic lp merck ridgeback biotherapeutic lp ridgeback closely hold biotechnology company enter collaboration agreement develop lagevrio molnupiravir investigational orally available antiviral candidate treatment patient covid merck gain exclusive worldwide right develop commercialize lagevrio relate molecule follow initial authorization certain market fourth quarter lagevrio receive multiple additional authorization term agreement ridgeback receive upfront payment eligible receive future contingent payment dependent achievement certain developmental regulatory approval milestone agreement provide merck reimburse ridgeback portion certain thirdparty contingent milestone payment royaltie net sale profitshare calculation merck principal sale transaction recognize sale relate cost profitshare amount record cost sale profit collaboration split equally partner reimbursement ridgeback share research development cost deduct ridgeback share profit reflect decrease research development expense summarize financial information relate collaboration follow year end december net sales lagevrio record merck cost sale sell general administrative research development december payable ridgeback include accrued current liability include royalty expense amortization capitalize milestone payment inventory reserve include accrue royalty december include accrue milestone payment table content bristolmyer squibb company reblozyl luspaterceptaamt firstinclass erythroid maturation recombinant fusion protein obtain merck november acquisition acceleron commercialize global collaboration bms reblozyl approve europe certain market treatment anemia certain rare blood disorder evaluate additional indication hematology therapie bms principal sale transaction reblozyl merck copromote reblozyl copromote future product approve collaboration north america reimburse bms merck receive sale royalty bms increase maximum base sale level royalty reduce early patent expiry generic entry indicationbyindication basis market additionally merck eligible receive future contingent salesbase milestone payment million alliance revenue relate collaboration record sale consist royalty include receipt regulatory approval milestone payment million merck record alliance revenue relate collaboration million million million moderna inc september merck exercise option jointly develop commercialize v mrna investigational individualized neoantigen therapy pursuant term exist collaboration license agreement moderna result million payment charge research development expense v mrna currently evaluate combination keytruda multiple phase clinical trial merck moderna share cost profit equally worldwide collaboration merck record share development cost associate collaboration research development expense reimbursement receive moderna research development expense recognize reduction research development cost summarize financial information relate collaboration follow year end december sell general administrative research development december payable moderna include accrue current liability expense include million option payment note daiichi sankyo october merck daiichi sankyo enter global development commercialization agreement daiichi sankyos dxd adc candidate patritumab deruxtecan herdxd mk ifinatamab deruxtecan idxd mk raludotatug deruxtecan rdxd mk potentially firstinclass dxd adcs stage clinical development treatment multiple solid tumor monotherapy andor combination treatment company jointly develop potentially commercialize adc candidate worldwide japan daiichi sankyo maintain exclusive right daiichi sankyo solely responsible manufacturing supply term agreement merck payment daiichi sankyo total billion payment include billion million patritumab deruxtecan ifinatamab deruxtecan refundable prorate basis event early termination development respect program addition agreement provide continuation payment million relate patritumab deruxtecan merck october continuation payment million relate raludotatug deruxtecan merck october merck continuation payment date note patritumab deruxtecan raludotatug deruxtecan rights applicable program revert daiichi sankyo nonrefundable upfront payment pay retain daiichi sankyo agreement provide contingent payment merck daiichi sankyo additional billion dxd adc successful achievement certain salesbase milestone follow regulatory approval daiichi sankyo generally record sale worldwide daiichi sankyo principal sale transaction company equally share expense profit worldwide japan daiichi sankyo retain exclusive right merck receive salesbase royalty merck record share product sale net cost sale commercialization cost alliance revenue raludotatug deruxtecan merck responsible billion research development expense excess allowable research development expense company share equally table content expense profit worldwide merck include share development cost associate collaboration research development expense conjunction transaction merck record aggregate pretax charge billion research development expense billion upfront payment billion continuation payment merck determine appropriate expense billion refundable portion consideration significant number clinical study currently underway plan near future certain study advanced stage make highly likely program continue progress incur substantial expense likelihood program terminate end refundable period remote merck determine appropriate expense continuation payment execution agreement payment result company gain additional intellectual property right addition significant number ongoe plan clinical study shortterm nature option period make likelihood merck make payment remote spinoff organon co june merck complete spinoff organon distribution organon publicly trade stock company shareholder connection spinoff merck shareholder receive onetenth share organon common stock share merck common stock hold shareholder distribution treat tax free merck shareholder federal income tax purpose indebtedness billion principal consist term loan senior note issue connection spinoff assume organon merck long obligor organon debt financing arrangement cash proceed billion distribute organon merck connection spinoff connection spinoff merck organon enter separation distribution agreement enter agreement effect spinoff provide framework relationship merck organon spinoff include transition service agreement tsa manufacturing supply agreement msa trademark license agreement intellectual property license agreement employee matter agreement tax matter agreement certain commercial agreement tsa merck provide organon service similarly organon provide merck service majority service provide tsa terminate month follow spinoff majority remain service terminate month follow spinoff merck organon enter series interim operating agreement pursuant jurisdiction merck hold license permit right connection marketing import andor distribution organon product prior separation merck continue market import distribute product time relevant license permit transfer organon interim operating agreement accordance separation distribution agreement merck continue operation affect market behalf organon organon receive economic benefit burden activity december jurisdiction remain interim operating agreement additionally merck organon enter number msas pursuant merck manufacturing supply certain active pharmaceutical ingredient organon b manufacturing supply certain formulate pharmaceutical product organon c packaging label certain finished pharmaceutical product organon similarly organon merck enter number msas pursuant organon manufacturing supply certain formulate pharmaceutical product merck b packaging label certain finished pharmaceutical product merck term msa range initial duration year year amount include consolidated statement income msa include sale million million million respectively relate cost sale million million million respectively amount include consolidated statement income tsas immaterial amount organon agreement million million december respectively reflect current asset amount organon agreement million million december respectively include accrue current liability result women health biosimilar establish brand business previously include pharmaceutical segment contribute organon spinoff interest expense relate debt issuance reflect discontinued operation company consolidated statement income income discontinue operation net taxis amount attributable noncontrolle interest period prior spinoff june merck incurred separation cost million related spinoff organon include income discontinue operation net taxis table content amount attributable noncontrolle interest cost primarily relate professional fee separation activity finance tax legal information technology function investment banking fee detail income discontinue operation net taxis amount attributable noncontrolle interest follow year end december sale cost expense cost sale sell general administrative research development restructuring cost income expense net income discontinue operation tax tax provision income discontinue operation net taxis income discontinue operation attributable noncontrolle interest reflect amount june spinoff date restructuring restructuring program january company approve new restructure program restructuring program intend continue optimization company human health global manufacturing network future pipeline shift new modality optimize animal health global manufacturing network improve supply reliability increase efficiency action contemplate restructuring program expect substantially complete end cumulative pretax cost incur company implement program estimate approximately billion approximately cumulative pretax cost noncash relate primarily accelerate depreciation facility close divested remainder cost result cash outlay relate primarily facility shutdown cost company record total pretax cost million related restructuring program restructuring program merck approve global restructuring program restructuring program worldwide initiative focus optimize company manufacture supply network reduce global real estate footprint company record total pretax cost million million million related restructuring program inception restructuring program december merck record total pretax accumulate cost approximately billion approximately cumulative pretax cost cash outlay primarily relate employee separation expense facility shutdown cost approximately cumulative pretax cost noncash relate primarily accelerate depreciation facility close divest action restructure program substantially complete segment report restructuring charge unallocated expense table content follow table summarize charge related restructuring program type cost separation accelerate cost depreciation exit cost total year end december restructuring program cost sale restructuring cost restructure program cost sale sell general administrative research development restructuring cost year end december restructuring program cost sale sell general administrative research development restructuring cost year end december restructuring program cost sale sell general administrative research development restructuring cost separation cost associate actual headcount reduction involuntary headcount reduction probable reasonably estimate accelerated depreciation cost primarily relate manufacture research administrative facility equipment sell closed program accelerate depreciation cost represent difference depreciation expense recognize revise useful life asset base anticipate date site close divest equipment dispose depreciation expense determine utilize useful life prior restructure action site continue operate respective closure date future undiscounte cash flow sufficient recover respective book value merck recording accelerate depreciation revise useful life site asset anticipate site closure date particularly related manufacturing location continue adjust reflect change result regulatory factor exit cost include asset abandonment facility shutdown relate cost pretax gain loss result sale facility relate asset additionally activity include certain employeerelate cost associate pension postretirement benefit plan note sharebased compensation table content follow table summarize charge spend relate restructure program activity program separation accelerate cost depreciation exit cost total restructure program restructuring reserve january expense payment receipt net noncash activity restructure reserve december restructure program restructure reserve january expense payment receipt net noncash activity restructuring reserve december expense payment receipt net noncash activity restructure reserve december financial instrument derivative instrument hedging activity company manage impact foreign exchange rate movement interest rate movement earning cash flow fair value asset liability operational mean use financial instrument include derivative instrument significant portion company revenue earning foreign affiliate expose change foreign exchange rate objective account relate companys foreign currency risk management program interest rate risk management activity discuss foreign currency risk management company establish revenue hedge balance sheet risk management net investment hedging program protect volatility future foreign currency cash flow change fair value cause change foreign exchange rate objective revenue hedging program reduce variability cause change foreign exchange rate affect dollar value future cash flow derive foreign currency denominate sale primarily euro japanese yen chinese renminbi achieve objective company hedge portion forecast foreign currency denominate thirdparty intercompany distributor entity sale forecast sale expect occur planning cycle typically year future company layer hedge time increase portion forecast sale hedge get close expect date forecast sale portion forecast sale hedge base assessment cost benefit profile consider natural offset exposure revenue exchange rate volatility correlation cost hedging instrument company manage anticipate transaction exposure principally purchase local currency option forward contract purchase collar option fair value derivative contract record asset gain position liability loss position consolidate balance sheet change fair value derivative contract record period current earning oci depend derivative designate hedge transaction type hedge transaction derivative designate cash flow hedge unrealize gain loss contract record aocl reclassify sale hedge anticipate revenue recognize derivative designate cash flow hedge serve economic hedge forecast sale unrealize gain loss record sale period cash flow designate nondesignate contract report operating activity consolidate statement cash flow company enter derivative trade speculative purpose table content company manage operating activity net asset position local subsidiary order mitigate effect exchange monetary asset liability monetary asset liability denominate currency functional currency give subsidiary remeasure spot rate effect balance sheet date effect change spot rate report income expense net company use balance sheet risk management program mitigate exposure asset liability effect volatility foreign exchange merck principally utilize forward exchange contract offset effect exchange exposure deem economical base costbenefit analysis consider magnitude exposure volatility exchange rate cost hedging instrument primarily euro swiss franc japanese yen chinese renminbi forward contract designate hedge mark market income expense net accordingly fair value change forward contract help mitigate change value remeasure asset liability attributable change foreign currency exchange rate extent spotforward difference difference significant shortterm nature contract typically average maturity inception month cash flow contract report operating activity consolidate statement cash flow company use forward exchange contract hedge portion net investment foreign operation movement exchange rate forward contract designate hedge net investment foreign operation unrealize gain loss contract record foreign currency translation adjustment oci remain aocl sale complete substantially complete liquidation subsidiary company exclude certain portion change fair value derivative instrument assessment hedge effectiveness exclude component change fair value exclude component recognize oci company recognize earning initial value exclude component straightline basis life derivative instrument marktomarket approach cash flow contract report investing activity consolidate statement cash flow foreign exchange risk manage use foreign currency debt company senior unsecured eurodenominate note designate effective economic hedge net investment foreign operation accordingly foreign currency transaction gain loss spot rate fluctuation eurodenominate debt instrument include foreign currency translation adjustment oci effect company net investment hedge oci consolidated statement income show pretax gain loss recognize pretax gain loss recognize income expense net amount exclude comprehensive income effectiveness testing year end december net investment hedging relationship foreign exchange contract eurodenominate note amount reclassify aocl income relate sale subsidiary interest rate risk management company use interest rate swap contract certain investing borrowing transaction manage net exposure interest rate change reduce overall cost borrowing company use leveraged swap general leverage investment activity principal risk december company party payfloate receivefixe interest rate swap contract designate fair value hedge portion fixedrate note detailed table number interest rate swap total swap notional par value debt hold note interest rate swap contract designate hedge fair value change note attributable change benchmark secure overnight financing rate sofr swap rate fair value change note attributable change sofr swap rate record interest expense offset fair table content value change swap contract cash flow contract report operating activity consolidate statement cash flow table present location amount record consolidated balance sheet relate cumulative basis adjustment fair value hedge december cumulative fair value hedge adjustment increase decrease include carrying hedge liability carry balance sheet caption longterm debt present table fair value derivative gross basis segregate derivative designate hedge instrument designate hedge instrument december fair value fair value derivative derivative dollar dollar asset liability notional asset liability notional derivative designate hedge instrument balance sheet caption interest rate swap contract noncurrent asset foreign exchange contract current asset foreign exchange contract asset foreign exchange contract accrue current liability foreign exchange contract noncurrent liability derivative designate hedge instrument balance sheet caption foreign exchange contract current asset foreign exchange contract accrue current liability note company record derivative gross basis consolidated balance sheet company master netting agreement financial institution counterpartie concentration credit risk follow table provide information company derivative position subject master netting arrangement present net basis allow right offset counterparty cash collateral exchange master agreement relate credit support annexe december asset liability asset liability gross amount recognize consolidated balance sheet gross amount subject offset master netting arrangement offset consolidated balance sheet cash collateral receivedposte net amount table content table provide information location pretax gain loss derivative designate fair value cash flow hedging relationship year end december financial statement caption effect fair value cash flow hedge record sale income expense net comprehensive income loss loss gain fair value hedge relationship interest rate swap contract hedge item derivative designate hedge instrument impact cash flow hedging relationship foreign exchange contract gain recognize oci derivative increase decrease sale result aocl reclassification interest rate contract gain recognize income expense net derivative gain loss recognize oci derivative interest expense component income expense net table provide information income statement effect derivative designate hedge instrument derivative pretax gain loss recognize income year end december derivative designate hedge instrument income statement caption foreign exchange contract income expense net foreign exchange contract sale derivative contract primarily mitigate change value remeasure foreign currency denominate monetary asset liability attributable change foreign currency exchange rate include loss forward exchange contract enter conjunction spinoff organon derivative contract serve economic hedge forecast transaction december company estimate million pretax net unrealize loss derivative mature month hedge foreign currency denominate sale period reclassify aocl sale ultimately reclassify sale differ foreign exchange rate change realize gain loss ultimately determine actual exchange rate maturity table content investment debt equity security information investment debt equity security december follow gross unrealized gross unrealized amortize fair amortize fair cost gain loss value cost gain loss value commercial paper government agency security corporate note bond total debt security publicly trade equity security total debt publicly trade equity security unrealize net gain million record income expense net equity security hold december unrealize net loss million record income expense net equity security hold december december company million equity investment readily determinable fair value include asset company record unrealize gain equity investment base favorable observable price change transaction involve similar investment investee record unrealize loss base unfavorable observable price change include income expense net company record unrealized gain million unrealize loss million relate certain equity investment hold december company record unrealized gain million unrealize loss million relate certain equity investment hold december cumulative unrealized gain cumulative unrealized loss base observable price change investment equity investment readily determinable fair value hold december million million respectively december company million million billion respectively record asset equity security hold ownership interest investment fund loss gain record income expense net relate investment fund million billion billion year end december respectively fair value measurement fair value define exchange price received asset pay transfer liability exit price principal advantageous market asset liability orderly transaction market participant measurement date company use fair value hierarchy maximize use observable input minimize use unobservable input measure fair value level input measure fair value level high priority level low level quote price unadjuste active market identical asset liability level observable input level price quote price similar asset liability input observable corroborate observable market datum substantially term asset liability level unobservable input support little market activity level asset liability value determine pricing model discount cash flow methodology similar technique significant unobservable input asset liabilitie determination fair value require significant judgment estimation input measure financial asset liability fall level describe categorization base low level input significant fair value measurement instrument table content financial asset liability measure fair value recur basis financial asset liability measure fair value recur basis december summarize fair value measurement fair value measurement level level level total level level level total asset investment commercial paper publicly trade equity security asset government agency security corporate note bond publicly trade equity security derivative asset forward exchange contract purchase currency option interest rate swap total asset liability liabilities contingent consideration derivative liability forward exchange contract write currency option total liability investment include asset restrict use include payment benefit employee benefit plan balance december include security total fair value million subject contractual sale restriction expire july fair value determination derivative include impact credit risk counterpartie derivative companys credit risk effect significant december cash cash equivalent include billion billion cash equivalent respectively consider level fair value hierarchy contingent consideration summarize information change fair value liability contingent consideration associate business combination follow fair value january change estimate fair value payment fair value december record cost sale research development expense income expense net include cumulative translation adjustment december million million respectively liability relate termination sanofi pasteur msd joint venture termination merck record liability contingent future royalty payment net sale merck product previously sell joint venture december fair value liability determine utilize estimate time project cash flow riskadjusted discount rate present value cash flow balance december include million record current liability amount expect pay month table content payment contingent consideration year relate sanofi pasteur msd liability describe fair value measurement company financial instrument cash cash equivalent receivables payable reflect balance sheet carrying value approximate fair value shortterm nature estimate fair value loan payable longterm debt include current portion december billion compare carry value billion december billion compare carry value billion fair value estimate recent observable market price consider level fair value hierarchy concentration credit risk ongoing basis company monitor concentration credit risk associate corporate government issuer security financial institution conduct business credit exposure limit establish limit concentration single issuer institution cash investment place instrument meet high credit quality standard specify company investment policy guideline majority company account receivable arise product sale europe china primarily drug wholesaler distributor retailer hospital government agency company monitor financial performance creditworthiness customer properly assess respond change credit profile company continue monitor global economic condition include volatility associate international sovereign economy associate impact financial market business company customer large account receivable balance mckesson corporation cencora inc cardinal health inc represent approximately respectively total account receivable december account receivable balance december chongqing zhifei biological products co ltd zhifei sole distributor company vaccine product china significant china company factor program discuss vaccine sale distribute zhifei represent substantial portion total sale china company monitor creditworthiness customer grant credit term normal course business bad debt minimal company normally require collateral security support credit sale company account receivable factoring agreement financial institution certain country sell account receivable company factor billion billion account receivable december respectively factor arrangement reduce outstanding account receivable cash receive financial institution report operating activity consolidate statement cash flow certain factoring arrangement ease administration company collect customer payment relate factored receivables remit financial institution generally thirty day receipt december company collect million million respectively behalf financial institution reflect restrict cash current asset relate obligation remit cash accrue current liability net cash flow related collection report financing activity consolidate statement cash flow cost factoring account receivable de minimis derivative financial instrument execute international swap derivative association master agreement master agreement company financial institution counterpartie include credit support annexe annexe contain provision require collateral exchange depend value derivative asset liability company credit rating credit rating counterparty cash collateral receive company counterpartie million million december respectively obligation return collateral record accrue current liability cash collateral advanced company counterpartie million december table content inventory inventory december consist finished good raw material work process supply decrease lifo cost recognize inventory asset inventory value lifo method comprise approximately billion december reflect decrease lifo cost amount recognize asset comprise entirely raw material work process inventory december amount include billion billion respectively inventory expect sell year addition amount include million million december respectively inventory produce preparation product launch goodwill intangible follow table summarize goodwill activity segment pharmaceutical animal health total balance january balance december balance december include cumulative translation adjustment goodwill balance accumulate goodwill impairment loss million december acquire intangible december consist gross gross carrying accumulate carry accumulate amortization net amortization net product right iprd trade name license significant acquire intangible include product right net basis relate human health market product december reblozyl billion zerbaxa million sivextro million additionally company billion net acquire intangible related animal health december billion relate product right billion attributable trade name primarily relate allflex december iprd primarily relate mk sotatercept billion obtain acquisition acceleron note mk nemtabrutinib million obtain acquisition arqule inc arqule significant net intangible asset include license december include lynparza billion relate collaboration astrazeneca lenvima million relate collaboration eisai adempas million relate collaboration bayer note additional information relate intangible asset associate collaboration table content iprd company acquire business combination represent fair value assign incomplete research project time acquisition reach technological feasibility amount capitalize iprd account indefinitelive intangible asset subject impairment testing completion abandonment project successful completion iprd project company separate determination thenuseful life asset begin amortization company record million iprd impairment charge research development expense relate mk gefapixant nonnarcotic oral selective px receptor antagonist development treatment refractory chronic cough unexplained chronic cough adult december fda issue complete response letter crl resubmission merck new drug application nda gefapixant crl fda conclude merck application meet substantial evidence effectiveness treat refractory chronic cough unexplained chronic cough crl relate safety gefapixant marketing application gefapixant base result cough cough clinical trial january fda issue crl merck original nda gefapixant crl fda request additional information relate cough counting system assess efficacy receipt second crl fda constitute trigger event require evaluation gefapixant intangible asset impairment company estimate current fair value gefapixant utilize income approach calculate present value project future cash flow market participant assumption derive forecast cash flow update reflect revise market launch plan result reduction estimate fair value revise estimate fair value gefapixant compare related carrying value result impairment charge note remain intangible asset balance relate lyfnua gefapixant million include product right table december amortize expect useful life support project future cash flow market approve include japan eu company record billion intangible asset impairment charge research development expense billion represent iprd impairment charge related nemtabrutinib mk oral reversible noncovalent bruton tyrosine kinase btk inhibitor currently evaluate treatment hematological malignancy obtain acquisition arqule follow discussion regulatory authority quarter development period nemtabrutinib extend constitute trigger event require evaluation nemtabrutinib intangible asset impairment company estimate current fair value nemtabrutinib utilize income approach calculate present value project future cash flow market participant assumption derive forecast cash flow update reflect delay anticipate launch date nemtabrutinib result low cumulative revenue forecast reduction estimate fair value revise estimate fair value nemtabrutinib compare related carrying value result million impairment charge record quarter december regulatory authority provide additional feedback respect clinical study design lead reassessment development plan nemtabrutinib expect result change clinical study design correspond delay anticipate approval launch timeline constitute trigger event utilize income approach forecast cash flow update reflect decline forecast revenue couple increase development cost forecast reduce project cash flow lower estimate current fair value nemtabrutinib revise estimate fair value nemtabrutinib compare thenrelate carrying value result million impairment charge remain iprd intangible asset relate nemtabrutinib million assumption estimate fair value nemtabrutinib prove incorrect development nemtabrutinib progress anticipate adversely affect project future cash flow company record additional impairment charge future charge material company record million intangible asset impairment charge relate derazantinib result termination outlicense agreement decision merck pursue development derazantinib company record million iprd impairment charge research development expense relate nemtabrutinib merck annual impairment assessment iprd intangible asset company estimate current fair value nemtabrutinib utilize project future cash flow market participant assumption derive forecast cash flow update reflect current competitive landscape nemtabrutinib include increase expect development cost additional clinical trial datum need develop nemtabrutinib delay anticipate launch date nemtabrutinib collectively reduce project future cash flow estimate fair value additionally discount rate utilize determine current fair value asset reduce reflect current risk profile asset revise estimate fair value nemtabrutinib compare related carrying value result iprd impairment charge note table content iprd project remain development subject inherent risk uncertaintie drug development possible company able successfully develop complete iprd program profitably commercialize underlie product candidate company recognize additional noncash impairment charge future relate market product pipeline program charge material aggregate amortization expense primarily record cost sale billion billion billion estimate aggregate amortization expense year follow billion billion billion billion billion loan payable longterm debt lease loan payable loan payable december include billion note million longdate note subject repayment option holder loan payable december include billion note million longdate note subject repayment option holder weightedaverage interest rate commercial paper borrowing year end december respectively longterm debt longterm debt december consist note note note note note note note note note note note note note eurodenominate note note note note note note note note note eurodenominate note eurodenominate note note note note note debenture note debenture debenture note eurodenominate note present table include borrowing variable rate result effective interest rate respectively table content exception debenture note list table redeemable merck option time vary redemption price effective november company execute unconditional guarantee exist debt subsidiary merck sharp dohme corp msd msd execute unconditional guarantee exist debt company exclude commercial paper include payment principal interest guarantee extend debt issue subsequent date company issue billion principal senior unsecured note consist million note million note billion note million note billion note billion note company portion billion net proceed offer fund portion cash consideration pay acquisition prometheus note include relate fee expense remain net proceed general corporate purpose include repay commercial paper borrowing indebtedness upcoming maturity certain company borrowing require merck comply covenant december company compliance covenant aggregate maturity longterm debt year follow billion billion billion billion billion interest payment relate debt obligation follow billion billion billion billion billion company billion credit facility mature facility provide backup liquidity company commercial paper borrowing facility general corporate purpose company draw funding facility lease company operating lease primarily manufacture facility research development facility corporate office employee housing vehicle certain equipment company determine arrangement lease inception evaluate contract embed lease company exercise judgment determine explicit implicit identify asset contract merck control use asset embed lease primarily associate contract manufacturing organization immaterial lease term include option extend terminate lease reasonably certain merck exercise option real estate lease facility average remain lease term approximately seven year include option extend lease year applicable vehicle lease generally effect year company elect exclude shortterm lease lease initial term month lease asset liability balance sheet lease expense operating lease payment recognize straightline basis term lease operating lease asset liability recognize base present value lease payment lease term company lease readily determinable implicit discount rate company use incremental borrowing rate calculate present value lease payment asset class quarterly basis update incremental borrowing rate determine base average remain lease term asset class company pretax cost debt term update rate asset class apply prospectively new lease company separate lease component eg payment rent real estate taxis insurance cost nonlease component eg commonarea maintenance cost event agreement contain merck include lease nonlease component purpose calculate rightofuse asset relate lease liability nonlease component fix vehicle lease employee housing company apply portfolio approach account operating lease asset liability certain company lease agreement contain variable lease payment adjust periodically inflation actual operating expense trueup compare estimate amount amount immaterial sublease income activity relate sale leaseback transaction immaterial merck lease agreement contain material residual value guarantee material restrictive covenant operate lease cost million million million cash pay amount include measurement operating lease liability million million million operating lease asset obtain exchange lease obligation million million million table content supplemental balance sheet information relate operating lease follow december asset asset liability accrue current liability noncurrent liability weightedaverage remain lease term year weightedaverage discount rate include prepaid lease relate lease liability maturity operating lease liability follow total lease payment imputed interest december company enter additional real estate operating lease commence obligation associate lease total million contingency environmental liability company involve claim legal proceeding nature consider normal business include product liability intellectual property commercial litigation certain additional matter include governmental environmental matter opinion company unlikely resolution matter material company financial condition result operation cash flow give nature litigation discuss complexity involve matter company unable reasonably estimate possible loss range possible loss matter company know factor claim survive dispositive motion practice ii extent claim include size potential class particularly damage specify indeterminate iii discovery process affect litigation iv settlement posture party litigation v factor material effect litigation company record accrual contingency probable liability incur reasonably estimate accrual adjust periodically assessment change additional information available product liability claim portion overall accrual actuarially determine consider factor past experience number claim report estimate claim incur report individually significant contingent loss accrue probable reasonably estimable legal defense cost expect incur connection loss contingency accrue probable reasonably estimable company decision obtain insurance coverage dependent market condition include cost availability exist time decision company evaluate risk determine cost obtain product liability insurance outweighs likely benefit coverage available insurance product liability table content product liability litigation gardasilgardasil previously disclose merck defendant product liability lawsuit involve gardasil human papillomavirus quadrivalent type vaccine recombinant gardasil human papillomavirus valent vaccine recombinant december approximately case file pende merck federal state court action plaintiff allege thing suffer personal injury vaccination gardasil gardasil postural orthostatic tachycardia syndrome predominate allege injury august judicial panel multidistrict litigation order gardasilgardasil product liability case pende federal court nationwide transfer judge robert j conrad western district north carolina coordinate pretrial proceeding few product liability case pende outside governmental proceeding inflation reduction act previously disclose june merck file complaint district court district columbia government inflation reduction act drug price negotiation program medicare program litigation seek relief program challenge constitutionality violative fifth amendment constitution matter previously disclose april merck receive set investigative interrogatory california attorney general office pursuant investigation conduct agreement allegedly affect delay competition lantus insulin market interrogatory seek information concern merck development insulin glargine product subsequent termination merck patent litigation sanofi sa concern lantus resolution litigation merck cooperate california attorney general investigation previously disclose june merck receive civil investigative demand cid department justice cid request answer interrogatory document temperature excursion thirdparty storage facility contain certain merck product merck cooperate government investigation intend produce information andor document necessary response cid previously disclose time time company subsidiary china receive inquiry operation chinese governmental agency inquiry relate matter involve multinational pharmaceutical company chinese entity business company company policy cooperate authority provide response appropriate previously disclose time time company receive inquiry subject preliminary investigation activity competition governmental authority market outside authority include regulator administrative authority law enforcement similar official preliminary investigation activity include site visit formal informal request demand document material inquiry interview similar matter certain preliminary inquiry activity lead commencement formal proceeding proceeding determine adversely company monetary fine andor remedial undertaking require commercial litigation zetia antitrust litigation previously disclose merck msd schering corporation scheringplough corporation msp singapore company llc collectively merck defendant defendant number lawsuit file behalf direct indirect purchaser zetia ezetimibe allege violation federal state antitrust law state statutory common law cause action case consolidate federal multidistrict litigation zetia mdl judge rebecca beach smith eastern district virginia previously disclose april merck defendant reach settlement direct purchaser retailer plaintiff propose settlement subject court approval indirect purchaser class agreement merck agree pay million resolve direct purchaser retailer indirect purchaser plaintiff claim record expense company financial result october court grant final approval indirect purchaser class settlement table content united healthcare services inc united healthcare humana inc humana centene corporation centene kaiser foundation health plan inc kaiser collectively insurer plaintiff file lawsuit jurisdiction outside eastern district virginia merck defendant make similar allegation zetia mdl additional allegation vytorin case transfer eastern district virginia proceed zetia mdl february insurer plaintiff file amend complaint march merck defendant jointly defendant move dismiss certain aspect insurer plaintiff complaint include claim vytorin damage december prior decision motion dismiss judicial panel multidistrict litigation remand insurer plaintiff case transferor court northern district california kaiser district minnesota united healthcare district new jersey humana centene rotateq antitrust litigation previously disclose march mayor city council baltimore file putative class action msd eastern district pennsylvania behalf thirdparty payor state indirectly purchase pay andor provide reimbursement purchase price rotateq rotavirus vaccine live oral pentavalent resale march present plaintiff allege msd violate federal state antitrust law state consumer protection law plaintiff allege msd implement anticompetitive vaccine bundle scheme msd leverage allege monopoly power certain pediatric vaccine market maintain alleged monopoly power market rotavirus vaccine order charge supracompetitive price rotateq plaintiff seek permanent injunctive relief unspecified monetary damage purchase rotateq treble fee cost msd move dismiss complaint november court grant deny motion dismiss dismissing plaintiff idaho utah consumer law claim allow claim proceed bravecto litigation previously disclose january company serve complaint district court district new jersey follow motion practice plaintiff file second amend complaint july seek certify nationwide class action purchaser user bravecto fluralaner product territory july plaintiff contend bravecto cause neurological event dog cat allege violation new jersey consumer fraud act breach warranty product liability relate theory company move dismiss alternatively strike class allegation second amend complaint motion pende similar case file quebec canada superior court certify class dog owner quebec give bravecto chew dog february november dog experience condition postmarkete adverse reaction section label approve november company plaintiff appeal class certification decision court appeal quebec hear appeal february issue decision april allow party appeal court appeal amend class period start july allow second plaintiff serve class representative modify list condition class definition company seek leave appeal supreme court canada deny case proceed superior court b program litigation previously disclose merck file complaint district court district columbia challenge letter merck receive health resource services administration hrsa mercks b program integrity initiative hrsas letter merck assert merck violation b statute hrsa claim continue failure provide b price cover entity contract pharmacy result civil monetary penalty instance allege overcharging addition repayment instance overcharging letter similar letter hrsa send manufacturer letter hold unlawful multiple federal court merck disagree hrsas assertion merck remain committed b program provide b discount eligible cover entity mercks b program integrity initiative consistent requirement b statute intend ensure integrity sustainability b statute reduce prohibit duplicate discount diversion put patient center program merck continue offer company cover outpatient drug b cover entity purchase b ceiling price september court stay case pende dc circuit rule novartis pharmaceutical corp v johnson united therapeutics corp v johnson table content qui tam litigation previously disclose june district court eastern district pennsylvania unseal complaint file company federal false claim act employee allege thing company defraud government falsify datum connection clinical study conduct mump component company mmr ii vaccine complaint allege fraud take place government right participate prosecution lawsuit notify court decline exercise right employee pursue lawsuit involvement government addition previously disclose putative class action lawsuit behalf direct purchaser mmr ii vaccine charge company misrepresent efficacy mmr ii vaccine violation federal antitrust law state consumer protection law pende eastern district pennsylvania september court deny merck motion dismiss false claim act suit grant deny motion dismiss pende antitrust suit result false claim act suit antitrust suit proceed discovery complete party file brief crossmotion summary judgment july false claims act case court deny relator motion summary judgment grant company motion summary judgment deny company remain motion summary judgment moot court enter judgment favor company dismiss relator amend complaint prejudice relator appeal decision antitrust case court grant company motion summary judgment plaintiff state law claim deny motion plaintiff antitrust claim november circuit grant company petition permission appeal antitrust decision merck kgaa litigation previously disclose january protect longestablished brand right company file lawsuit merck kgaa darmstadt germany kgaa historically operate emd group allege improperly use merck kgaa file suit company number jurisdiction outside allege thing unfair competition trademark infringement andor corporate infringement certain jurisdiction kgaa allege breach party coexistence agreement litigation ongoe trial date set ongoing jurisdiction outside patent litigation time time generic manufacturers pharmaceutical product file abbreviate new drug application anda fda seek market generic form company product prior expiration relevant patent own company protect patent right company file patent infringement lawsuit generic company similar lawsuit defend company patent right exist country company intends vigorously defend patent believe valid infringement company attempt market product prior expiration patent litigation assurance outcome adverse result significantly shorten period exclusivity product respect product acquire acquisition account business combination potentially significant intangible asset impairment charge bridion previously disclose january november company receive multiple paragraph iv certification letter hatchwaxman act notify company generic drug company file application fda seek prepatent expiry approval sell generic version bridion sugammadex injection march april december company file patent infringement lawsuit district court district new jersey northern district west virginia generic company action district new jersey consolidated west virginia case jointly dismiss prejudice august favor proceed new jersey remain defendant new jersey action stipulate infringement assert claim withdraw remain claim defense defense seek shorten patent term extension pte sugammadex patent december district court district new jersey hold oneday trial december remain pte calculation defense court order posttrial briefing defense hold closing argument february new jersey action pende company settle generic company provide generic company bring generic version bridion market january delay applicable pediatric exclusivity early certain circumstance company agree stay lawsuit file generic company exchange agree bind judgment merit consolidate action district new jersey generic company consolidate action table content request dismissal action company oppose request subsequently grant court company expect company bring generic version bridion market january later depend applicable pediatric exclusivity previously disclose june district court district new jersey rule mercks favor court hold merck calculation pte sugammadex patent cover compound invalid patent trademark office correctly grant fiveyear extension ruling affirm validate merck patent protection bridion january june district court district new jersey issue final judgment prohibit fda approve pende tentatively approve generic application january subsequent agreement defendant merck order court july defendant file notice appeal united states court appeal federal circuit appeal currently pende february company receive paragraph iv certification letter hatchwaxman act notify company hikma pharmaceuticals usa inc file application fda seek prepatent expiry approval sell generic version bridion injection company currently consider option januvia janumet janumet xr previously disclose fda grant pediatric exclusivity respect januvia sitagliptin janumet sitagliptinmetformin hcl janumet xr sitagliptin metformin hcl extendedrelease provide month exclusivity expiration patent list fdas orange book add exclusivity term key patent protection extend exclusivity product january januvia janumet janumet xr contain sitagliptin phosphate monohydrate company patent cover certain phosphate salt polymorphic form sitagliptin expire include pediatric exclusivity saltpolymorph patent previously disclose begin number generic drug company file anda seek approval generic form januvia janumet paragraph iv certification challenge validity saltpolymorph patent company respond file infringement suit settle company settle total generic company provide generic company bring generic version januvia janumet market early certain circumstance generic version janumet xr market july early certain circumstance march company file patent infringement lawsuit district court district delaware zydus worldwide dmcc zydus pharmaceuticals usa inc cadila healthcare ltd collectively zydus lawsuit company allege infringement saltpolymorph patent base filing zyduss nda seek approval form sitagliptin different januvia december party reach settlement include dismissal case prejudice enable zydu seek final approval nonautomatically substitutable product january company receive paragraph iv certification letter hatchwaxman act notify company zydus file anda seek approval sitagliptinmetformin hcl tablet certify valid enforceable claim patent list fdas orange book janumet infringe propose zydus product march party reach settlement enable zydu seek final approval non automatically substitutable product contain different form sitagliptin janumet november company receive paragraph iv certification letter hatchwaxman act notify company zydus file anda seek approval sitagliptinmetformin hcl extend release tablet january party reach settlement enable zydu seek final approval nonautomatically substitutable version contain different form sitagliptin janumet xr result settlement agreement relate later expire saltpolymorph patent direct specific sitagliptin salt form product company expect januvia janumet lose market exclusivity janumet xr lose market exclusivity july zydus receive fda approval nonautomatically substitutable form sitagliptin differ form company sitagliptin product supplementary protection certificate spc janumet expire april majority european country prior expiration generic company seek revocation janumet spc number european country february finnish court refer certain question court justice european union cjeu determine validity janumet spc europe oral hearing hold march advocate general opinion expect april decision late table content cjeu render decision negatively impact validity janumet spc europe generic company prevent launch product spc period certain european country action damage country include belgium czech republic ireland finland france slovakia switzerland janumet spc ultimately uphold company reserve right relate pursuit damage country generic launch prior expiry janumet spc october company file patent infringement lawsuit sawai pharmaceuticals co ltd medisa shinyaku co ltd collectively defendant tokyo district court seek injunction stop manufacture sale offer sale defendant sitagliptin dihydrogen phosphate product company patent patent term extension force lawsuit response defendant application marketing authorization sell generic sitagliptin dihydrogen phosphate product anhydrate form approve august merck assert defendant activity infringe patent term extension associate mercks patent direct sitagliptin compound patent keytruda previously disclose company file complaint johns hopkins university jhu november district court maryland action concern patent emerge joint research collaboration merck jhu use pembrolizumab merck sell trade keytruda merck jhu partner design conduct clinical study administer keytruda cancer patient tumor genetic biomarker know microsatellite instabilityhigh msih conclusion study jhu secure patent cite joint research study merck allege jhu breach collaboration agreement filing obtain patent inform involve merck licensing patent merck bring action breach contract declaratory judgment noninfringement promissory estoppel jhu answer complaint april deny merck claim counterclaim willful infringement issue patent include demand damage november company file inter partes review united states patent trademark office patent trial appeal board challenge validity patent claim assert patent case lynparza december astrazeneca pharmaceutical lp receive paragraph iv certification letter hatchwaxman act notify astrazeneca natco pharma limited natco file application fda seek prepatent expiry approval sell generic version lynparza olaparib tablet february astrazeneca company file patent infringement lawsuit district court district new jerseydelaware natco lawsuit assert patent cover olaparib automatically stay fda approval generic application june adverse court decision whichever occur early december astrazeneca pharmaceutical lp receive second paragraph iv certification letter hatchwaxman act notify astrazeneca sandoz inc file application fda seek prepatent expiry approval sell generic version lynparza olaparib tablet february astrazeneca company file patent infringement lawsuit district court district new jersey sandoz lawsuit assert patent cover olaparib automatically stay fda approval generic application june adverse court decision whichever occur early litigation pende legal proceeding involve company principally product liability intellectual property lawsuit feasible predict outcome proceeding opinion company likelihood loss remote reasonably possible loss associate resolution proceeding expect material company financial condition result operation cash flow individually aggregate legal defense reserve legal defense cost expect incur connection loss contingency accrue probable reasonably estimable significant factor consider review legal defense reserve follow actual cost incur company development company legal defense strategy structure light scope litigation number case bring company cost outcome complete trial current information anticipated timing progression relate cost pretrial activity trial associate litigation legal defense reserve december approximately million million respectively represent company good estimate minimum defense cost incur connection outstanding litigation event additional trial event arise course litigation affect ultimate legal defense cost incur company company continue monitor legal defense cost review adequacy associate reserve determine table content increase reserve time future base factor set forth believe appropriate environmental matter company subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund federal state equivalent proceeding seek require operator hazardous waste disposal facility transporter waste site generator hazardous waste dispose site clean site reimburse government cleanup cost company party proceeding allege generator waste dispose site case government allege defendant jointly severally liable cleanup cost joint liability allege proceeding frequently resolve allocation cleanup cost party nearly reflect relative contribution party site situation company potential liability vary greatly site site site potential liability de minimis final cost cleanup determined feasible predict outcome proceeding bring federal state agency private litigant opinion company proceeding ultimately result liability material adverse effect financial condition result operation liquidity company company take active role identify accrue cost amount include reduction anticipate recovery cleanup cost site owner operator recalcitrant potentially responsible party management opinion liability environmental matter probable reasonably estimable accrue total million million december respectively liability undiscounted consider potential recovery party pay periods remediation applicable site expect occur primarily year possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed approximately million aggregate management believe expenditure result material adverse effect company financial condition result operation liquidity year equity merck certificate incorporation authorize share common stock share prefer stock capital stock summary common stock treasury stock transaction share millions follow common treasury common treasury common treasury stock stock stock stock stock stock balance january purchase treasury stock issuance balance december issuance primarily reflect activity sharebase compensation plan sharebase compensation plan company sharebase compensation plan company grant restrict stock unit rsus performance share unit psus certain management level employee addition employee nonemployee director grant option purchase share company common stock fair market value time grant plan approve company shareholder december million share collectively authorize future grant company sharebase compensation plan award settle treasury share employee stock option grant purchase share company stock fair market value time grant award generally vest onethird year threeyear period contractual term year rsus stock award grant employee entitle holder share common stock table content award vest fair value stock option rsu award determine fix grant date base company stock price psus stock awards ultimate number share issue contingent company performance preset objective set objective fair value psu determined date grant base company stock price rsus psus dividend declare vest period payable employee vest psu performance period number share stock expect issue adjust base probability achievement performance target final compensation expense recognize base ultimate number share issue rsu psu distribution share company stock end vest performance period subject term applicable award psu award generally vest year rsu award generally vest onethird year threeyear period total pretax sharebase compensation cost record million million million respectively include million related continue operation income tax benefit sharebase compensation expense recognize million million million respectively company use blackschole option pricing model determine fair value option grant apply model company use historical datum current market datum estimate fair value option blackschole model require assumption include expect dividend yield riskfree interest rate volatility term option expect dividend yield base historical pattern dividend payment risk free interest rate base rate grant date zerocoupon treasury notes term equal expect term option expect volatility estimate blend historical imply volatility historical component base historical monthly price change imply volatility obtain market datum company trade option expect life represent time option grant expect outstanding base historical forecast exercise behavior weight average exercise price option grant option respectively weight average fair value option grant option respectively determine follow assumption year end december expect dividend yield riskfree interest rate expect volatility expect life year summarize information relative stock option plan activity option thousand follows weight weight average average remain aggregate number exercise contractual intrinsic option price term year value outstanding january grant exercise forfeit outstanding december vest expect vest december exercisable december additional information pertain stock option plan provide table year end december total intrinsic value stock option exercise fair value stock option vest cash receive exercise stock option table content summary nonveste rsu psu activity share thousand follow rsus psus weight weight average average number grant date number grant date share fair value share fair value nonveste january grant vested forfeited nonveste december expect vest december december million total pretax unrecognized compensation expense relate nonveste stock option rsu psu award recognize weight average period year segment report sharebased compensation cost unallocated expenses pension postretirement benefit plan company define benefit pension plan cover eligible employee certain international subsidiary addition company provide medical benefit principally eligible retiree dependent postretirement benefit plan company use december yearend measurement date pension plan postretirement benefit plan net periodic benefit cost net periodic benefit cost credit pension postretirement benefit plan include certain cost report discontinue operation consist follow component pension benefit international postretirement benefit year end december service cost interest cost expect return plan asset amortization unrecognize prior service credit cost net loss gain amortization termination benefit curtailment settlement net periodic benefit cost credit net periodic benefit cost credit pension postretirement benefit plan include expense curtailment settlement termination benefit provide certain employee connection spinoff organon connection restructuring action note termination charge record pension postretirement benefit plan relate expand eligibility certain employee exit merck connection restructuring activity curtailment settlement record certain pension plan lump sum payment pension plan participant contribute settlement record component net periodic benefit cost credit service cost component include income expense net note exception certain amount termination benefit curtailment settlement record restructuring cost event give rise termination benefit curtailment settlement related restructuring action income discontinue operation net taxis amount attributable noncontrolle interest relate spinoff organon note table content obligation fund status summarize information change plan asset benefit obligation fund status amount record december follow pension benefit postretirement international benefit fair value plan asset january actual return plan asset company contribution effect exchange rate change benefit pay settlement fair value plan asset december benefit obligation january service cost interest cost actuarial loss gain benefit pay effect exchange rate change plan amendment curtailment termination benefit settlement benefit obligation december fund status december recognize asset accrue current liability noncurrent liability actuarial loss gain primarily reflect change discount rate december accumulate benefit obligation billion billion respectively pension plan billion billion respectively relate pension plan table content information relate fund status select pension plan december follow international pension plan project benefit obligation excess plan asset project benefit obligation fair value plan asset pension plan accumulate benefit obligation excess plan asset accumulate benefit obligation fair value plan asset plan asset entity require use fair value hierarchy maximize use observable input minimize use unobservable input measure fair value level input measure fair value level high priority level low level quote price unadjuste active market identical asset liability level observable input level price quote price similar asset liability input observable corroborate observable market datum substantially term asset liability level unobservable input support little market activity level asset value determine pricing model discount cash flow methodology similar technique significant unobservable input instrument determination fair value require significant judgment estimation december million million respectively approximately company pension investment categorize level asset input measure financial asset fall level describe categorization base low level input significant fair value measurement instrument table content fair value companys pension plan asset december asset category follow fair value measurement fair value measurement level level level nav total level level level nav total pension plan cash cash equivalent investment fund develop market equities emerge market equity real estate equity security develop market fix income security government agency obligation corporate obligation mortgage assetbacked security investment liability derivative plan asset fair value international pension plan cash cash equivalent investment fund develop market equity government agency obligation corporate obligation emerge market equity fix income obligation real estate equity security develop market fix income security government agency obligation corporate obligation mortgage assetbacke security investment insurance contract plan asset fair value certain investment measure net asset value nav share equivalent classify fair value hierarchy nav amount present table intend permit reconciliation fair value hierarchy fair value plan asset december plans level investment insurance contract generally value credit rate approximate market return invest underlying security market value unobservable determine pricing model discount cash flow methodology similar technique table content table provide summary change fair value include transfer andor financial asset measure fair value significant unobservable input level company pension plan asset insurance insurance contract total contract total pension plan balance january actual return plan asset relate asset hold december relate asset sell year purchase sale net balance december international pension plan balance january actual return plan asset relate asset hold december purchase sale net transfer level balance december fair value company postretirement benefit plan asset december asset category follow fair value measurement fair value measurement level level level nav total level level level nav total cash cash equivalent investment fund develop market equities emerge market equity real estate equity security develop market fix income security government agency obligation corporate obligation mortgage assetbacked security investment liability derivative plan asset fair value certain investment measure net asset value nav share equivalent classify fair value hierarchy nav amount present table intend permit reconciliation fair value hierarchy fair value plan asset december company establish investment guideline pension postretirement plan create asset allocation expect deliver rate return sufficient meet longterm obligation plan give acceptable level risk target investment portfolio company pension postretirement benefit plan allocate equity international equity fixedincome investment cash investment portfolio equity weighting consistent longterm nature plan benefit obligation expect annual standard deviation return target portfolio approximate reflect equity allocation diversification benefit asset class portfolio invest international pension plan target investment portfolio varies base duration pension liability local government rule regulation table content significant percentage plan asset invest equity concentration risk mitigate use strategy diversify management guideline expect contribution contribution expect approximately million pension plan approximately million international pension plan approximately million postretirement benefit plan expect benefit payment expect benefit payment follow international pension postretirement pension benefit benefit benefit expect benefit payment base assumption measure benefit obligation include estimate future employee service amount recognize comprehensive income loss net gainloss amount reflect difference expect actual return plan asset effect change actuarial assumption net gainloss amount excess certain threshold amortize net periodic benefit cost average remain service life employee follow amount reflect component oci pension plan postretirement international benefit plan year end december net loss gain arise period prior service cost arise period net loss gain amortization include benefit cost prior service credit cost amortization include benefit cost settlement curtailment table content actuarial assumption company reassesse benefit plan assumption regular basis weight average assumption determine pension postretirement benefit plan international pension plan information follow pension postretirement benefit plan international pension plan december net periodic benefit cost discount rate expect rate return plan asset salary growth rate interest credit rate benefit obligation discount rate salary growth rate interest credit rate pension postretirement benefit plan discount rate evaluate measurement date modify reflect prevail market rate portfolio highquality fixedincome debt instrument provide future cash flow need pay benefit include benefit obligation come expect rate return pension postretirement benefit plan represent average rate return earn plan asset period benefit include benefit obligation pay determine plan basis expect rate return plan develop consider longterm historical return data current market condition actual return plan asset reference information longterm return expectation asset category weightedaverage expect return plan target portfolio develop accord allocation investment category expect portfolio performance reflect contribution active management appropriate expect rate return company pension postretirement benefit plan compare health care cost trend rate assumption postretirement benefit plan follow december health care cost trend rate assume year rate cost trend rate assume decline year trend rate reach ultimate trend rate saving plan company maintain define contribution saving plan company match percentage employee contribution consistent provision plan employee eligible total employer contribution plan million million million respectively table content income expense net income expense net consist year end december interest income interest expense exchange loss income loss investment equity security net net periodic define benefit plan credit cost service cost net include net realize unrealized gain loss investment equity security own directly ownership interest investment fund unrealize gain loss investment directly own determined end report period gain loss ownership interest investment fund account quarter lag net reflect table include million charge relate settlement certain plaintiff zetia antitrust litigation note interest pay billion million million taxis income reconciliation effective tax rate income continue operation statutory rate follow tax rate tax rate tax rate statutory rate apply income continue operation taxis differential arise acquisition prometheus acquisition imago valuation allowance acquisitionrelate cost include amortization restructure foreign earning gilti foreignderive intangible income deduction rd tax credit state tax inventory donation tax settlement acquisition pandion applicable impact change uncertain tax position reflect reconcile item company remain transition tax liability tax cut job act tcja reduce payment expect utilization foreign tax credit billion december million include income taxis payable remainder million include noncurrent liability result transition tax tcja company long indefinitely reinveste respect undistribute earning foreign subsidiary provide defer tax liability foreign withholding taxis apply company remain indefinitely reinveste respect table content financial statement basis excess tax basis foreign subsidiary determination defer tax liability respect basis difference practicable foreign earning tax rate differential tax rate reconciliation primarily reflect impact operation jurisdiction different tax rate particularly ireland switzerland singapore puerto rico operate tax incentive grant begin expire yield favorable impact effective tax rate compare statutory rate company additional cantonal tax holiday switzerland provide tax rate reduction effective income continue operation taxis consist year end december domestic foreign taxis income continue operation consist year end december current provision federal foreign state defer provision federal foreign state table content defer income taxis december consist asset liability asset liability product intangible license rd capitalization inventory relate accelerated depreciation equity investment pension postretirement benefit compensation relate unrecognized tax benefit net operating loss tax credit carryforward subtotal valuation allowance total defer taxis net deferred income taxis recognize asset defer income taxis company net operating loss nol carryforward jurisdiction december million defer tax asset nol carryforward relate foreign jurisdiction valuation allowance million establish foreign nol carryforward foreign defer tax asset addition company million defer tax asset relate tax credit carryforward nol carryforward valuation allowance million establish tax credit carryforward nol carryforward income taxis pay include amount attributable discontinue operation consist year end december domestic foreign include tcja transition tax payment tax benefit relate stock option exercise million million million reconciliation begin end unrecognized tax benefit follow balance january addition relate current year position addition relate prior year position reduction tax position prior year settlement lapse statute limitation spinoff organon balance december reflect settlement irs discuss table content company recognize unrecognized tax benefit billion december income tax provision reflect favorable net impact billion company examination numerous tax authority jurisdiction globally company believe reasonably possible total unrecognized tax benefit december decrease approximately million month result audit closure settlement expiration statute limitation ultimate finalization company examination relevant tax authority include formal administrative legal proceeding significant impact time reversal unrecognized tax benefit company believe reserve uncertain tax position adequate cover exist risk exposure interest penalty associate uncertain tax position amount expense benefit million million million amount reflect beneficial impact tax settlement include settlement discuss liability accrue interest penalty million million december respectively internal revenue service irs conclude examination merck federal income tax return result company require payment million million related continue operation million relate discontinued operation company reserve unrecognize tax benefit year examination exceed adjustment relate examination period company record million net tax benefit million relate continue operation million relate discontinued operation net benefit reflect reduction reserve unrecognize tax benefit relate liability tax position relate year examination irs currently conduct examination company tax return year include onetime transition tax enact tcja irs disagree company transition tax position result significant tax liability addition state foreign tax examination progress jurisdiction company income tax return open examination period earning share calculation earning share share millions follow year end december net income continue operation attributable merck co inc income discontinue operation net taxis amount attributable noncontrolle interest net income attributable merck co inc average common share outstanding common share issuable average common share outstanding assume dilution basic earning common share attributable merck co inc common shareholder income continue operation income discontinue operation net income earning common share assume dilution attributable merck co inc common shareholder income continue operation income discontinue operation net income issuable primarily sharebased compensation plan million million million respectively common share issuable sharebased compensation plan exclude computation earning common share assume dilution effect antidilutive table content comprehensive income loss change component comprehensive income loss follow employee foreign currency benefit translation accumulate derivative plan adjustment comprehensive loss balance january net taxis comprehensive income loss reclassification adjustment pretax tax comprehensive income loss reclassification adjustment net taxis reclassification adjustment pretax tax reclassification adjustment net taxis comprehensive income loss net taxis spinoff organon note balance december net taxis comprehensive income loss reclassification adjustment pretax tax comprehensive income loss reclassification adjustment net taxis reclassification adjustment pretax tax reclassification adjustment net taxis comprehensive income loss net taxis balance december net taxis comprehensive income loss reclassification adjustment pretax tax comprehensive income loss reclassification adjustment net taxis reclassification adjustment pretax tax reclassification adjustment net taxis comprehensive income loss net taxis balance december net taxis primarily relate foreign currency cash flow hedge reclassify aocl sale note include net amortization prior service cost actuarial gain loss settlement curtailment include net periodic benefit cost note include pension plan net loss billion billion december respectively postretirement benefit plan net gain million million december respectively pension plan prior service credit million million december respectively postretirement benefit plan prior service credit million million december respectively table content segment reporting company operation principally manage product basis include operate segment pharmaceutical animal health reportable segment pharmaceutical segment include human health pharmaceutical vaccine product human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution human health vaccine product consist preventive pediatric adolescent adult vaccine company sell human health vaccine primarily physicians wholesaler distributor government entity large component pediatric adolescent vaccine sale center disease control prevention vaccine child program fund government additionally company sell vaccine federal government placement vaccine stockpile animal health segment discover develop manufacture market wide range veterinary pharmaceutical vaccine product health management solution service prevention treatment control disease major livestock companion animal specie company offer extensive suite digitally connect identification traceability monitoring product company sell product veterinarian distributor animal producer farmer pet owner table content sale company product follow year end december intl total intl total intl total pharmaceutical oncology keytruda alliance revenue lynparza alliance revenue lenvima welireg alliance revenue reblozyl vaccine gardasilgardasil proquadmmr iivarivax rotateq vaxneuvance pneumovax vaqta hospital acute care bridion prevymis dificid zerbaxa noxafil primaxin cardiovascular alliance revenue adempasverquvo adempas virology lagevrio isentressisentress hd neuroscience belsomra immunology simponi remicade diabete januvia janumet pharmaceutical total pharmaceutical segment sale animal health livestock companion animal total animal health segment sale total segment sale plus international equal total round alliance revenue lynparza lenvima represent merck share profit product sale net cost sale commercialization cost note alliance revenue reblozyl represent royalty include payment receive related achievement regulatory approval milestone note alliance revenue adempasverquvo represent merck share profit sale bayer marketing territory product sale net cost sale commercialization cost note pharmaceutical primarily reflect sale human health pharmaceutical product include product franchise list separately primarily comprise miscellaneous corporate revenue include revenue hedging activity increase decrease sale million million million respectively revenue thirdparty manufacturing arrangement include sale organon include million million million respectively relate upfront milestone payment receive merck outlicense arrangement table content consolidated sale geographic area derive follow year end december united states europe middle east africa china japan asia pacific china japan latin america reconciliation segment profit income continue operation taxis follow year end december segment profit pharmaceutical segment animal health segment total segment profit profit unallocate interest income interest expense amortization depreciation research development restructuring cost charge zetia antitrust litigation settlement unallocate net pharmaceutical segment profit comprise segment sale standard cost sell general administrative expense directly incur segment animal health segment profit comprise segment sale cost sale sell general administrative expense research development cost directly incur segment internal management reporting present chief operating decision maker merck allocate remain cost sale include segment profit describe research development expense incur merck research laboratory companys research development division focus human healthrelated activity general administrative expense directly incur segment cost financing activity separate division maintain responsibility monitor managing cost include depreciation relate fix asset utilize division include segment profit addition cost related restructuring activity amortization intangible asset amortization purchase accounting adjustment allocate segment profit primarily comprise miscellaneous corporate profit operate profit relate thirdparty manufacture arrangement unallocate net include expense corporate manufacturing cost center intangible asset impairment charge gain loss sale business expense income relate change estimate fair value measurement liability contingent consideration miscellaneous income expense item table content equity income affiliate depreciation include segment profit follow pharmaceutical animal health total year end december include segment profit equity income affiliate depreciation year end december include segment profit equity income affiliate depreciation year end december include segment profit equity income affiliate depreciation property plant equipment net geographic area locate follow december united states europe middle east africa asia pacific china japan latin america china japan company disaggregate asset product service basis internal management report information present table content report independent register public accounting firm board director stockholders merck co inc opinion financial statement internal control financial reporting audit accompany consolidated balance sheet merck co inc subsidiary company december relate consolidated statement income comprehensive loss income equity cash flow year period end december include related note collectively refer consolidated financial statement audit company internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso opinion consolidated financial statement refer present fairly material respect financial position company december result operation cash flow year period end december conformity accounting principle generally accept united states america opinion company maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue coso basis opinion company management responsible consolidated financial statement maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include management report internal control financial reporting appear item responsibility express opinion company consolidate financial statement companys internal control financial reporting base audits public accounting firm register public company accounting oversight board united states pcaob require independent respect company accordance federal security law applicable rule regulations securities exchange commission pcaob conduct audits accordance standard pcaob standard require plan perform audits obtain reasonable assurance consolidated financial statement free material misstatement error fraud effective internal control financial reporting maintain material respect audits consolidated financial statement include perform procedure assess risk material misstatement consolidated financial statement error fraud perform procedure respond risk procedure include examine test basis evidence amount disclosure consolidated financial statement audits include evaluate accounting principle significant estimate management evaluate overall presentation consolidate financial statement audit internal control financial reporting include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk audits include perform procedure consider necessary circumstance believe audits provide reasonable basis opinion definition limitation internal control financial reporting company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition assets company ii provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company iii provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate table content critical audit matter critical audit matter communicate matter arise current period audit consolidated financial statement communicate require communicate audit committee relate account disclosure material consolidated financial statement ii involve especially challenge subjective complex judgment communication critical audit matter alter way opinion consolidated financial statement take communicate critical audit matter provide separate opinion critical audit matter account disclosure relate rebate accrual medicaid manage care medicare describe note consolidated financial statement company record certain variable consideration include discount estimate time sale generally expect value method amount accrue aggregate customer discount evaluate quarterly basis comparison information provide wholesaler health maintenance organization pharmacy benefit manager federal state agency customer amount accrue certain discount represent portion accrual form rebate amount owe base definitive contractual agreement legal requirement private sector manage care public sector medicaid medicare benefit provider final dispense product benefit plan participant provision rebate base expect patient usage inventory level distribution channel determine contractual obligation benefit provider management use historical customer segment utilization mix sale forecast change product mix price inventory level distribution channel government pricing calculation prior payment history order estimate expect provision accrue balance relative provision rebate include accrue current liability billion december majority relate rebate accrual medicaid manage care medicare principal consideration determination perform procedure relate rebate accrual medicaid manage care medicare critical audit matter significant judgment management significant measurement uncertainty involve develop rebate accrual accrual base assumption develop pricing information historical customer segment utilization mix high degree auditor judgment subjectivity effort perform procedure evaluate evidence relate assumption address matter involve perform procedure evaluate audit evidence connection form overall opinion consolidated financial statement procedure include testing effectiveness control relate rebate accrual medicaid manage care medicare include management control assumption estimate correspond rebate accrual procedure include develop independent estimate rebate accrual utilize party datum historical customer segment utilization mix pricing information term specific rebate program historical trend actual rebate claim pay ii compare independent estimate rebate accrual record management iii testing rebate claim pay include evaluate claim consistency contractual term company rebate agreement pricewaterhousecooper llp florham park new jersey february serve company auditor table content item change disagreement accountant account financial disclosure applicable item control procedure management company participation chief executive officer chief financial officer evaluate effectiveness company disclosure control procedure base evaluation end period cover company chief executive officer chief financial officer conclude company disclosure control procedure define rule ae de securities exchange act amend act effective fourth quarter change internal control financial reporting materially affect reasonably likely materially affect company internal control financial reporting management responsible establish maintain adequate internal control financial reporting term define rule f act management conduct evaluation effectiveness internal control financial reporting base framework internal control integrate framework issue committee sponsor organization treadway commission base evaluation management conclude internal control financial reporting effective december pricewaterhousecooper llp independent register public accounting firm perform assessment effectiveness company internal control financial reporting attestation report include filing management report management responsibility financial statement responsibility integrity objectivity company financial statement rest management financial statement report management stewardship company asset statement prepare conformity generally accept accounting principle accordingly include amount base management good estimate judgment nonfinancial information include annual report prepare management consistent financial statement assure financial information reliable asset safeguard management maintain effective system internal control procedure important element include careful selection training development operate financial manager organization provide appropriate division responsibility communication aim assure company policy procedure understand organization staff internal auditor regularly monitor adequacy application internal control worldwide basis ensure personnel continue understand system internal control procedure policy concern good prudent business practice annually employee company require complete code conduct training training reinforce importance understand internal control review key corporate policy procedure system addition company compliance program include ethical business practice program reinforce company longstanding commitment high ethical standard conduct business financial statement financial information include annual report fairly present material respect companys financial condition result operation cash flow formal certification security exchange commission include filing management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting term define rule f securities exchange act company internal control financial reporting design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle united states america management conduct evaluation effectiveness internal control financial reporting base framework internal control integrate framework issue committee sponsor organization treadway commission base evaluation management conclude internal control financial reporting effective december inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control table content inadequate change condition degree compliance policy procedure deteriorate effectiveness company internal control financial reporting december audit pricewaterhousecooper llp independent register public accounting firm state report appear robert davis caroline litchfield chairman chief executive officer president executive vice president chief financial officer item b information insider trading arrangement month end december company director executive officer adopt terminate rule b trading arrangement nonrule b trading arrangement item c disclosure foreign jurisdiction prevent inspection applicable table content iii item director executive officer corporate governance require information director nominee incorporate reference discussion proposal election director company proxy statement annual meeting shareholder hold information executive officer set forth document require information compliance section securities exchange act applicable incorporate reference discussion head stock ownership information company proxy statement annual meeting shareholder hold company code conduct value standard applicable employee include principal executive officer principal financial officer principal accounting officer controller code conduct available company website wwwmerckcomcompany overviewcultureandvaluescodeofconductvaluesandstandards company intend disclose future amendment certain provision code conduct waivers code conduct grant executive officer director website business day follow date amendment waiver merck employee responsible adhering business practice accordance law ethical principle reflect high standard corporate individual behavior require information identification audit committee audit committee financial expert incorporate reference discussion head board meeting committee companys proxy statement annual meeting shareholder hold item executive compensation information require executive compensation incorporate reference discussion heading compensation discussion analysis summary compensation table compensation table ceo pay ratio pay vs performance table grant planbase award table outstanding equity award table option exercise stock vest table pension benefit table nonqualifie defer compensation table potential payment termination change control include discussion subheading separation change control footnote information table company proxy statement annual meeting shareholder hold require information director compensation incorporate reference discussion head director compensation relate schedule director fee table director compensation table company proxy statement annual meeting shareholder hold require information heading compensation management development committee interlock insider participation compensation management development committee report incorporate reference company proxy statement annual meeting shareholder hold table content item security ownership certain beneficial owner management relate stockholder matter information respect security ownership certain beneficial owner management incorporate reference discussion head stock ownership information company proxy statement annual meeting shareholder hold equity compensation plan information follow table summarize information option warrant right equity compensation company equity compensation plan close business december table include information tax qualify plan merck saving plan number number security remain security available future issue weightedaverage issuance equity exercise exercise price compensation plan outstanding outstanding exclude option warrant option warrant security right right reflect column plan category b c equity compensation plan approve security holder equity compensation plan approve security holder total include option purchase share company common stock right follow shareholderapprove plan merck co inc incentive stock plan merck co inc nonemployee directors stock option plan exclude approximately share restrict stock unit performance share unit assume maximum payout merck sharp dohme incentive stock plan exclude share phantom stock defer msd employee deferral program share phantom stock defer merck co inc plan defer payment director compensation item certain relationship relate transaction director independence require information transaction relate person incorporate reference discussion head related person transaction company proxy statement annual meeting shareholder hold require information director independence incorporate reference discussion head independence director company proxy statement annual meeting shareholder hold item principal accountant fee service information require item incorporate reference discussion proposal ratification appointment independent register public accounting firm begin caption preapproval policy service independent register public accounting firm fee service provide independent register public accounting firm company proxy statement annual meeting shareholder hold table content iv item